Pfizer (PFE) 10-K 27 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data, unless otherwise specified	Dec. 31, 2014	Feb. 20, 2015	Jun. 27, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	PFE
Entity Registrant Name	PFIZER INC
Entity Central Index Key	78003
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		6,128,855,392
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$188

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Income Statement [Abstract]
Revenues	$49,605	[1]	$51,584	[1]	$54,657	[1]
Costs and expenses:
Cost of sales(a)	9,577	[1],[2]	9,586	[1],[2]	9,821	[1],[2]
Selling, informational and administrative expenses(a)	14,097	[1],[2]	14,355	[1],[2]	15,171	[1],[2]
Research and development expenses(a)	8,393	[1],[2]	6,678	[1],[2]	7,482	[1],[2]
Amortization of intangible assets	4,039	[1]	4,599	[1]	5,109	[1]
Restructuring charges and certain acquisition-related costs	250	[1]	1,182	[1]	1,810	[1]
Other (income)/deductions––net	1,009	[1]	-532	[1]	4,022	[1]
Income from continuing operations before provision for taxes on income	12,240	[1],[3]	15,716	[1],[3]	11,242	[1],[3]
Provision for taxes on income	3,120	[1]	4,306	[1]	2,221	[1]
Income from continuing operations	9,119	[1]	11,410	[1]	9,021	[1]
Discontinued operations:
Income from discontinued operations––net of tax	-6	[1],[4]	308	[1],[4]	794	[1],[4]
Gain on disposal of discontinued operations––net of tax	55	[1],[4],[5]	10,354	[1],[4],[5]	4,783	[1],[4],[5]
Discontinued operations––net of tax	48	[1],[4]	10,662	[1],[4]	5,577	[1],[4]
Net income before allocation to noncontrolling interests	9,168	[1]	22,072	[1]	14,598	[1]
Less: Net income attributable to noncontrolling interests	32	[1]	69	[1]	28	[1]
Net income attributable to Pfizer Inc.	$9,135	[1]	$22,003	[1]	$14,570	[1]
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	$1.43	[1]	$1.67	[1]	$1.21	[1]
Discontinued operations––net of tax (in dollars per share)	$0.01	[1]	$1.56	[1]	$0.75	[1]
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	$1.44	[1]	$3.23	[1]	$1.96	[1]
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders	$1.41	[1]	$1.65	[1]	$1.20	[1]
Discontinued operations––net of tax	$0.01	[1]	$1.54	[1]	$0.74	[1]
Net income attributable to Pfizer Inc. common shareholders	$1.42	[1]	$3.19	[1]	$1.94	[1]
Weighted-average shares––basic	6,346	[1]	6,813	[1]	7,442	[1]
Weighted-average shares––diluted	6,424	[1]	6,895	[1]	7,508	[1]
Cash dividends paid per common share (in dollars per share)	$1.04	[1]	$0.96	[1]	$0.88	[1]
[1]	Amounts may not add due to rounding.
[2]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.
[3]	Income from continuing operations before provision for taxes on income.
[4]	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.
[5]	Includes post-close adjustments for the periods subsequent to disposal.

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	$9,168	[1]	$22,072	[1]	$14,598	[1]
Other Comprehensive Income/(Loss)
Foreign currency translation adjustments	-1,992	[1]	-535	[1]	-811	[1]
Reclassification adjustments(a)	-62	[1],[2]	144	[1],[2]	-207	[1],[2]
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total	-2,054	[1]	-391	[1]	-1,018	[1]
Unrealized holding gains on derivative financial instruments, net	24	[1]	488	[1]	745	[1]
Reclassification adjustments for realized (gains)/losses(b)	477	[1],[3]	-94	[1],[3]	-616	[1],[3]
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	501	[1]	394	[1]	129	[1]
Unrealized holding gains/(losses) on available-for-sale securities, net	-640	[1]	151	[1]	74	[1]
Reclassification adjustments for realized (gains)/losses(b)	222	[1],[3]	-237	[1],[3]	356	[1],[3]
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total	-418	[1]	-86	[1]	430	[1]
Benefit plans: actuarial gains/(losses), net	-4,173	[1]	3,714	[1]	-2,136	[1]
Reclassification adjustments related to amortization(c)	195	[1],[4]	581	[1],[4]	473	[1],[4]
Reclassification adjustments related to settlements, net(c)	101	[1],[4]	175	[1],[4]	221	[1],[4]
Other	188	[1]	48	[1]	22	[1]
Defined benefit Plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	-3,690	[1]	4,518	[1]	-1,420	[1]
Benefit plans: prior service credits and other, net	746	[1]	151	[1]	25	[1]
Reclassification adjustments related to amortization(c)	-73	[1],[4]	-58	[1],[4]	-69	[1],[4]
Reclassification adjustments related to curtailments, net(c)	8	[1],[4]	1	[1],[4]	-130	[1],[4]
Other	-9	[1]	-8	[1]	-3	[1]
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	672	[1]	86	[1]	-177	[1]
Other comprehensive income/(loss), before tax	-4,988	[1]	4,521	[1]	-2,056	[1]
Tax provision/(benefit) on other comprehensive income/(loss)(d)	-946	[1],[5]	1,928	[1],[5]	-225	[1],[5]
Other comprehensive income/(loss) before allocation to noncontrolling interests	-4,042	[1]	2,593	[1]	-1,831	[1]
Comprehensive income before allocation to noncontrolling interests	5,126	[1]	24,665	[1]	12,767	[1]
Less: Comprehensive income attributable to noncontrolling interests	36	[1]	7	[1]	21	[1]
Comprehensive income attributable to Pfizer Inc.	$5,090	[1]	$24,658	[1]	$12,746	[1]
[1]	Amounts may not add due to rounding.
[2]	Reclassified into Gain on disposal of discontinued operations—net of tax in the consolidated statements of income.
[3]	Reclassified into Other (income)/deductions—net in the consolidated statements of income.
[4]	Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the consolidated statements of income. For additional information, see Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.
[5]	See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Assets
Cash and cash equivalents	$3,343	[1]	$2,183	[1]
Short-term investments	32,779	[1]	30,225	[1]
Accounts receivable, less allowance for doubtful accounts: 2014—$412; 2013—$478	8,669	[1]	9,357	[1]
Inventories	5,663	[1]	6,166	[1]
Current deferred tax assets and other current tax assets	4,498	[1]	4,624	[1]
Other current assets	2,750	[1]	3,689	[1]
Total current assets	57,702	[1]	56,244	[1]
Long-term investments	17,518	[1]	16,406	[1]
Property, plant and equipment, less accumulated depreciation	11,762	[1],[2]	12,397	[1],[2]
Identifiable intangible assets, less accumulated amortization	35,166	[1],[3]	39,385	[1],[3]
Goodwill	42,069	[1]	42,519	[1]
Noncurrent deferred tax assets and other noncurrent tax assets	1,544	[1]	1,554	[1]
Other noncurrent assets	3,513	[1]	3,596	[1]
Total assets	169,274	[1]	172,101	[1]
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2014—$3,011; 2013—$2,060	5,141	[1]	6,027	[1]
Accounts payable	3,440	[1]	3,234	[1]
Dividends payable	1,711	[1]	1,663	[1]
Income taxes payable	531	[1]	678	[1]
Accrued compensation and related items	1,784	[1]	1,792	[1]
Other current liabilities	9,024	[1]	9,972	[1]
Total current liabilities	21,631	[1]	23,366	[1]
Long-term debt	31,541	[1]	30,462	[1]
Pension benefit obligations, net	7,885	[1]	4,635	[1]
Postretirement benefit obligations, net	2,379	[1]	2,668	[1]
Noncurrent deferred tax liabilities	24,981	[1]	25,590	[1]
Other taxes payable	4,353	[1]	3,993	[1]
Other noncurrent liabilities	4,883	[1]	4,767	[1]
Total liabilities	97,652	[1]	95,481	[1]
Commitments and Contingencies		[1]		[1]
Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2014—717; 2013—829	29	[1]	33	[1]
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2014—9,110; 2013—9,051	455	[1]	453	[1]
Additional paid-in capital	78,977	[1]	77,283	[1]
Treasury stock, shares at cost: 2014—2,819; 2013—2,652	-73,021	[1]	-67,923	[1]
Retained earnings	72,176	[1]	69,732	[1]
Accumulated other comprehensive loss	-7,316	[1]	-3,271	[1]
Total Pfizer Inc. shareholders’ equity	71,301	[1]	76,307	[1]
Equity attributable to noncontrolling interests	321	[1]	313	[1]
Total equity	71,622	[1]	76,620	[1]
Total liabilities and equity	$169,274	[1]	$172,101	[1]
[1]	Amounts may not add due to rounding.
[2]	The decrease in total property, plant and equipment is primarily due to depreciation and, to a much lesser extent, disposals, impairments and the impact of foreign exchange, partially offset by capital additions.
[3]	The decrease in identifiable intangible assets, less accumulated amortization, is primarily due to amortization and, to a much lesser extent, asset impairment charges, partially offset by assets acquired as part of the InnoPharma acquisition,the Nexium OTC milestones and other asset acquisitions. For information about impairments of intangible assets, see Note 4. For information about the assets acquired from InnoPharma and the Nexium OTC milestones, see Note 2A and Note 2B, respectively.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$412	[1]	$478	[1]
Short term borrowings, current portion of long term debt	$3,011	[1]	$2,060	[1]
Preferred stock, shares authorized	27,000,000	[1]	27,000,000	[1]
Preferred stock, shares issued	717	[1]	829	[1]
Common stock, par value (in dollars per share)	$0.05	[1]	$0.05	[1]
Common stock, shares authorized	12,000,000,000	[1]	12,000,000,000	[1]
Common stock, shares issued	9,110,000,000	[1]	9,051,000,000	[1]
Treasury stock, shares at cost	2,819,000,000	[1]	2,652,000,000	[1]
[1]	Amounts may not add due to rounding.

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)		Total	Share - holders’ Equity	Preferred Stock	Common Stock	Add’l Paid-In Capital	Treasury Stock		Retained Earnings	Accum. Other Comp. Loss		Non-controlling Interests
In Millions, except Share data, unless otherwise specified
Beginning balance at Dec. 31, 2011	[1]	$82,621	$82,190	$45	$445	$71,423	($31,804)		$46,210	($4,129)		$431
Beginning balance (in shares) at Dec. 31, 2011	[1]			1,112,000,000	8,902,000,000		-1,327,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	14,598	14,570						14,570			28
Other comprehensive income/(loss), net of tax	[1]	-1,831	-1,824							-1,824	[2]	-7
Cash dividends declared:
Common stock	[1]	-6,537	-6,537						-6,537
Preferred stock	[1]	-3	-3						-3
Noncontrolling interests	[1]	-9										-9
Share-based payment transactions (in shares)	[1]				52,000,000		-4,000,000
Share-based payment transactions	[1]	1,056	1,056		3	1,150	-97
Purchases of common stock (in shares)		-349,000,000					-349,000,000	[1]
Purchases of common stock	[1]	-8,228	-8,228				-8,228
Preferred stock conversions and redemptions (in shares)	[1]			-145,000,000			0
Preferred stock conversions and redemptions	[1]	-8	-8	-6		-3	1
Other (in shares)	[1]				2,000,000		0
Other	[1]	19	44		0	38	6		0			-25
Ending balance at Dec. 31, 2012	[1]	81,678	81,260	39	448	72,608	-40,122		54,240	-5,953		418
Ending balance (in shares) at Dec. 31, 2012	[1]			967,000,000	8,956,000,000		-1,680,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	22,072	22,003						22,003			69
Other comprehensive income/(loss), net of tax	[1]	2,593	2,655							2,655	[2]	-62
Cash dividends declared:
Common stock	[1]	-6,509	-6,509						-6,509
Preferred stock	[1]	-2	-2						-2
Noncontrolling interests	[1]	-121										-121
Share-based payment transactions (in shares)	[1]				95,000,000		-4,000,000
Share-based payment transactions	[1]	2,296	2,296		5	2,390	-99
Purchases of common stock (in shares)		-563,000,000					-563,000,000	[1]
Purchases of common stock	[1]	-16,290	-16,290				-16,290
Preferred stock conversions and redemptions (in shares)	[1]			-138,000,000			0
Preferred stock conversions and redemptions	[1]	-11	-11	-6		-5	0
Sale of 19.8% of subsidiary through an IPO(a)	[1],[3]	2,479	2,324			2,297				27		155
Acquisition of common stock in exchange offer (in shares)	[1],[3]						-405,000,000
Acquisition of common stock in exchange offer(a)	[1],[3]	-11,408	-11,408				-11,408
Deconsolidation of subsidiary sold(a)	[1],[3]	-145										-145
Other (in shares)	[1]				0		0
Other	[1]	-12	-11		0	-7	-4		0			-1
Ending balance at Dec. 31, 2013	[1]	76,620	76,307	33	453	77,283	-67,923		69,732	-3,271		313
Ending balance (in shares) at Dec. 31, 2013	[1]			829,000,000	9,051,000,000		-2,652,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	9,168	9,135						9,135			32
Other comprehensive income/(loss), net of tax	[1]	-4,042	-4,045							-4,045	[2]	3
Cash dividends declared:
Common stock	[1]	-6,690	-6,690						-6,690
Preferred stock	[1]	-2	-2						-2
Noncontrolling interests	[1]	-6										-6
Share-based payment transactions (in shares)	[1]				59,000,000		-2,000,000
Share-based payment transactions	[1]	1,597	1,597		3	1,693	-100
Purchases of common stock (in shares)		-165,000,000					-165,000,000	[1]
Purchases of common stock	[1]	-5,000	-5,000				-5,000
Preferred stock conversions and redemptions (in shares)	[1]			-112,000,000			0
Preferred stock conversions and redemptions	[1]	-8	-8	-4		-4	1
Other (in shares)	[1]			0	0		0
Other	[1]	-17	5	0	-1	5	0		0	0		-22
Ending balance at Dec. 31, 2014	[1]	$71,622	$71,301	$29	$455	$78,977	($73,021)		$72,176	($7,316)		$321
Ending balance (in shares) at Dec. 31, 2014	[1]			717,424,152	9,110,000,000		-2,819,000,000
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $3 million gain in 2014, $62 million loss in 2013 and $7 million loss in 2012.
[3]	Relates to Zoetis (our former Animal Health subsidiary). See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.

Consolidated_Statements_of_Equ1

Consolidated Statements of Equity (Parenthetical) (Zoetis [Member])	0 Months Ended
	Feb. 06, 2013
Subsidiaries [Member] | IPO [Member]
Percentage offered in IPO	19.80%

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Operating Activities
Net income before allocation to noncontrolling interests	$9,168	[1]	$22,072	[1]	$14,598	[1]
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	5,537		6,410		7,655
Asset write-offs and impairments	531		1,145		1,299
Gain on disposal of discontinued operations	-51	[2],[3]	-10,446	[2],[3]	-7,123	[2],[3]
Gain associated with the transfer of certain product rights to an equity-method investment	0	[4]	-459	[4]	0	[4]
Deferred taxes from continuing operations	320		1,726		786
Deferred taxes from discontinued operations	-3		-23		1,412
Share-based compensation expense	586		523		481
Benefit plan contributions (in excess of)/less than expense	-199		296		135
Other adjustments, net	-430		-182		-130
Other changes in assets and liabilities, net of acquisitions and divestitures:
Accounts receivable	148		940		367
Inventories	175		-538		-631
Other assets	1,156		-822		-434
Accounts payable	297		382		579
Other liabilities	-844		-3,170		-2,738
Other tax accounts, net	491		-170		490
Net cash provided by operating activities	16,883		17,684		16,746
Investing Activities
Purchases of property, plant and equipment	-1,199		-1,206		-1,327
Purchases of short-term investments	-50,954		-42,761		-24,018
Proceeds from redemptions/sales of short-term investments	47,374		41,127		25,302
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of 90 days or less	3,930		-4,277		1,459
Purchases of long-term investments	-10,718		-11,020		-11,145
Proceeds from redemptions/sales of long-term investments	6,145		7,555		4,990
Acquisitions of businesses, net of cash acquired	-195		-15		-1,050
Acquisitions of intangible assets	-384		-259		-92
Proceeds from sale of businesses	0		0		11,850
Other investing activities, net	347		312		185
Net cash provided by/(used in) investing activities	-5,654		-10,544		6,154
Financing Activities
Proceeds from short-term borrowings	13		4,323		7,995
Principal payments on short-term borrowings	-10		-4,234		-8,177
Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less	-1,841		3,475		-30
Proceeds from issuance of long-term debt(a)	4,491	[5]	6,618	[5]	0	[5]
Principal payments on long-term debt	-2,104		-4,146		-1,513
Purchases of common stock	-5,000		-16,290		-8,228
Cash dividends paid	-6,609		-6,580		-6,534
Proceeds from exercise of stock options	1,002		1,750		568
Other financing activities, net	72		109		-80
Net cash used in financing activities	-9,986		-14,975		-15,999
Effect of exchange-rate changes on cash and cash equivalents	-83		-63		-2
Net increase/(decrease) in cash and cash equivalents	1,160		-7,898		6,899
Cash and cash equivalents, beginning	2,183	[1]	10,081		3,182
Cash and cash equivalents, end	3,343	[1]	2,183	[1]	10,081
Supplemental Cash Flow Information
Sale of subsidiary common stock (Zoetis) for Pfizer common stock(b)	0	[6]	11,408	[6]	0	[6]
Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013(b)	0	[6]	2,479	[6]	0	[6]
Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012(b)	0	[6]	992	[6]	0	[6]
Transfer of certain product rights to an equity-method investment (Hisun Pfizer)(c)	0	[7]	1,233	[7]	0	[7]
Contribution of an investment in connection with the resolution of a legal matter (Quigley)	0		447		0
Cash paid during the period for:
Income taxes	2,100		2,874		2,409
Interest	$1,550		$1,729		$1,873
[1]	Amounts may not add due to rounding.
[2]	Includes post-close adjustments for the periods subsequent to disposal.
[3]	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.
[4]	In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.
[5]	In 2013, includes $2.6 billion from the issuance of senior notes by Zoetis (our former Animal Health subsidiary), which is net of the $1.0 billion non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.
[6]	See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.
[7]	See Note 2E. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Equity-Method Investments.

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Proceeds from issuance of long-term debt(a)	$6,618	[1]
Non-cash exchange of subsidiary senior notes for the retirement of company commercial paper	992	[2]
Zoetis [Member]
Proceeds from issuance of long-term debt(a)	2,600
Non-cash exchange of subsidiary senior notes for the retirement of company commercial paper	$1,000
[1]	In 2013, includes $2.6 billion from the issuance of senior notes by Zoetis (our former Animal Health subsidiary), which is net of the $1.0 billion non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.
[2]	See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies
	A. Basis of Presentation
	The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the United States (U.S.), the financial information is included as of and for the year ended November 30 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Taxes paid on intercompany sales transactions are deferred until recognized upon sale of the asset to a third party.
	In the consolidated statements of cash flows, we have revised the presentation of certain items in prior periods, none of which had a significant impact.
	On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis), and recognized a gain of approximately $10.3 billion, net of tax, in Gain on disposal of discontinued operations––net of tax in the consolidated statement of income for the year ended December 31, 2013. The operating results of this business through June 24, 2013, the date of disposal, are reported as Income from discontinued operations––net of tax in the consolidated statements of income. For additional information, see Note 2D.
	On November 30, 2012, we completed the sale of our Nutrition business to Nestlé and recognized a gain of approximately $4.8 billion, net of tax, in Gain on disposal of discontinued operations––net of tax in the consolidated statement of income for the year ended December 31, 2012. The operating results of this business through November 30, 2012, the date of disposal, are reported as Income from discontinued operations––net of tax in the consolidated statements of income. For additional information, see Note 2D.
	Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
	B. Adoption of New Accounting Standards
	We adopted the following new accounting and disclosure standards as of January 1, 2014 and there were no impacts to our consolidated financial statements:
	•	A new standard that clarified the accounting for cumulative translation adjustment (CTA) upon derecognition of a group of assets that is a business or an equity-method investment within a foreign entity.
	•	A new standard regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings.
	C. Estimates and Assumptions
	In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired in-process research & development (IPR&D) assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income.
	Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.
	As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our financial statements on a prospective basis, unless they are required to be treated retrospectively under relevant accounting standards. It is possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.
	D. Acquisitions
	Our consolidated financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed.
	Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net.
	Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
	E. Fair Value
	We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.
	When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:
	•	Income approach, which is based on the present value of a future stream of net cash flows.
	•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
	•	Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.
	Our fair value methodologies depend on the following types of inputs:
	•	Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
	•	Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
	•	Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
	A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
	F. Foreign Currency Translation
	For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss). The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.
	G. Revenues and Accounts Receivable
	Revenue Recognition—We record revenues from product sales when the goods are shipped and title passes to the customer. At the time of sale, we also record estimates for a variety of revenue deductions, such as rebates, chargebacks, sales allowances and sales returns. When we cannot reasonably estimate the amount of future sales returns and/or other revenue deductions, we record revenues when the risk of product return and/or additional revenue deductions has been substantially eliminated.
	Deductions from Revenues––Our gross product revenues are subject to a variety of deductions, that generally are estimated and recorded in the same period that the revenues are recognized, and primarily represent rebates, chargebacks and sales allowances to government agencies, wholesalers/distributors and managed care organizations with respect to our pharmaceutical products. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period.
	Specifically:
	•	In the U.S., we record provisions for pharmaceutical Medicare, Medicaid, and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.
	•	Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds, and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.
	•	Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability.
	•	Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.
	•	We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.
	Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, and sales returns and cash discounts totaled $3.4 billion as of December 31, 2014, of which approximately $2.0 billion is included in Other current liabilities, $300 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, and sales returns and cash discounts totaled $3.3 billion as of December 31, 2013, of which approximately $2.1 billion is included in Other current liabilities, $234 million is included in Other noncurrent liabilities and approximately $1.0 billion is included against Accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet.
	Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
	Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues.
	Collaborative Arrangements—Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded when our collaboration partners ship the product and title passes to their customer. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when our collaboration partners sell the product and title passes to their customers. All royalty payments to collaboration partners are included in Cost of sales.
	Accounts Receivable—Accounts receivable are stated at their net realizable value. The allowance against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
	H. Cost of Sales and Inventories
	We carry inventories at the lower of cost or market. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.
	I. Selling, Informational and Administrative Expenses
	Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.
	Advertising expenses totaled approximately $3.1 billion in 2014, $3.0 billion in 2013 and $2.8 billion in 2012. Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs.
	J. Research and Development Expenses
	Research and development (R&D) costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
	R&D expenses related to upfront and milestone payments for intellectual property rights totaled $1.4 billion in 2014, $203 million in 2013 and $371 million in 2012. For additional information, see Note 2B and Note 2C.
	K. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets
	Long-lived assets include:
	•	Property, plant and equipment, less accumulated depreciation—These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
	•	Identifiable intangible assets, less accumulated amortization—These acquired assets are recorded at cost. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the European Union (EU), or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.
	•	Goodwill—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.
	Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
	We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
	Specifically:
	•	For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate.
	•	For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.
•	For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.
Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
L. Restructuring Charges and Certain Acquisition-Related Costs
We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. (If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate). Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other costs incurred in connection with a business acquisition are expensed as incurred.
Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
M. Cash Equivalents and Statement of Cash Flows
Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments.
Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.
N. Investments and Derivative Financial Instruments
Our investments are comprised of the following: trading securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and ability to hold the investment to maturity) and private equity investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.
•	Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.
•	Available-for-sale debt and equity securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.
•	Held-to-maturity debt securities are carried at amortized cost.
•	Private equity securities are carried at equity-method or cost. For equity investments where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity method, we record our share of the investee's income and expenses in Other (income)/deductions—net. The excess of the cost of the investment over our share of the equity of the investee as of the acquisition date is allocated to the identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not include amounts of contingent consideration.
Realized gains or losses on sales of investments are determined by using the specific identification cost method.
We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Derivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E).
A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
O. Deferred Tax Assets and Liabilities and Income Tax Contingencies
Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All current deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount and all noncurrent deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount.
We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.
Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to more-likely-than-not; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision for taxes on income and are classified on our consolidated balance sheet with the related tax liability.
Amounts recorded for valuation allowances and income tax contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
P. Pension and Postretirement Benefit Plans
The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both qualified and supplemental (non-qualified) defined benefit and defined contribution plans, as well as other postretirement benefit plans consisting primarily of healthcare and life insurance for retirees. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic benefit costs are recognized, as required, into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
Q. Legal and Environmental Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
R. Share-Based Payments
Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

Acquisitions_Licensing_Agreeme

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments	12 Months Ended
	Dec. 31, 2014
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures And Equity-Method Investments	Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments
	A. Acquisitions
	InnoPharma, Inc. (InnoPharma)
	On September 24, 2014, we completed our acquisition of InnoPharma, a privately-held pharmaceutical development company, for an upfront cash payment of $225 million and contingent consideration with an estimated acquisition-date fair value of approximately $67 million. The contingent consideration consists of up to $135 million in additional milestone payments based on application filing with and acceptance by the U.S. Food and Drug Administration (FDA), or approval of marketing applications related to certain pipeline products by the FDA. We believe this acquisition represents a potential innovative growth opportunity for our sterile injectables portfolio in areas such as oncology and central nervous disorders. In connection with this acquisition, we recorded $247 million in Identifiable intangible assets, consisting of $212 million in IPR&D and $35 million in Developed technology rights; $81 million in net deferred tax liabilities; and $125 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized.
	NextWave Pharmaceuticals Incorporated (NextWave)
	On November 27, 2012, we completed our acquisition of NextWave, a privately-held, specialty pharmaceutical company. As a result of this acquisition, we hold exclusive North American rights to Quillivant XR™ (methylphenidate hydrochloride), the first once-daily liquid medication approved in the U.S. for the treatment of attention deficit hyperactivity disorder. The total consideration for the acquisition was approximately $442 million, which consisted of upfront payments to NextWave's shareholders of approximately $278 million and contingent consideration with an estimated acquisition-date fair value of approximately $164 million. The contingent consideration consisted of up to $425 million in additional payments that are contingent upon attainment of certain revenue milestones. In connection with this acquisition, we recorded $519 million in Identifiable intangible assets, consisting of $474 million in Developed technology rights and $45 million in IPR&D; $166 million in net deferred tax liabilities; and $89 million in Goodwill. In 2014 and 2013, as a result of lowered commercial forecasts, the fair value of the contingent consideration decreased and we recognized pre-tax income of approximately $43 million and $114 million, respectively, in Other (income)/deductions––net.
	Alacer Corp. (Alacer)
	On February 26, 2012, we completed our acquisition of Alacer, a company that manufactured, marketed and distributed Emergen-C, a line of effervescent, powdered drink mix vitamin supplements. In connection with this Consumer Healthcare acquisition, we recorded $181 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand; $69 million in net deferred tax liabilities; and $192 million in Goodwill.
	Ferrosan Holding A/S (Ferrosan)
	On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan, a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. This acquisition is reflected in our consolidated financial statements beginning in the first fiscal quarter of 2012. Our acquisition of Ferrosan’s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believed that the acquisition would allow us to expand the marketing of Ferrosan's brands through Pfizer's global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan's key markets. In connection with this Consumer Healthcare acquisition, we recorded $362 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands; $94 million in net deferred tax liabilities; and $322 million in Goodwill.
	B. Licensing Agreements
	Cellectis SA (Cellectis)
	On June 18, 2014, we entered into a global arrangement with Cellectis to develop Chimeric Antigen Receptor T-cell immunotherapies in the field of oncology directed at select cellular surface antigen targets. In August 2014, in connection with this licensing agreement, we made an upfront payment of $80 million to Cellectis, which was recorded in Research and development expenses. We will also fund research and development costs associated with 15 Pfizer-selected targets and, for the benefit of Cellectis, a portion of the research and development costs associated with four Cellectis-selected targets within the arrangement. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per product that results from the Pfizer-selected targets. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer. In addition, in August 2014, we acquired approximately 10% of the capital of Cellectis through the purchase of newly issued shares, for a total investment of approximately $35 million.
	Nexium Over-the-Counter Rights
	In August 2012, we entered into an agreement with AstraZeneca PLC (AstraZeneca) for the exclusive, global, over-the-counter (OTC) rights for Nexium, a leading prescription drug approved to treat the symptoms of gastroesophageal reflux disease. In connection with this Consumer Healthcare licensing agreement, we made an upfront payment of $250 million to AstraZeneca, which was recorded in Research and development expenses in our consolidated statement of income for the year ended December 31, 2012. On May 27, 2014, we launched Nexium 24HR in the U.S., and on July 11, 2014, we paid AstraZeneca a related $200 million product launch milestone payment; and on August 1, 2014, we launched Nexium Control in Europe, and on September 15, 2014, we paid AstraZeneca a related $50 million product launch milestone payment. These post-approval milestone payments were recorded in Identifiable intangible assets in the consolidated balance sheet and are being amortized over the estimated useful life of the Nexium brand. AstraZeneca is eligible to receive additional milestone payments of up to $300 million, based on product launches outside the U.S. and level of worldwide sales as well as royalty payments, based on worldwide sales.
	C. Collaborative Arrangements
	In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.
	The following table provides the amounts and classification of payments (income/(expense)), between us and our collaboration partners:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Revenues—Revenues(a)		$	786		$	1,153		$	1,640
	Revenues—Alliance revenues(b)		957			2,628			3,492
	Total revenues from collaborative arrangements		1,743			3,781			5,132
	Cost of sales(c)		(280		)	(333		)	(362		)
	Selling, informational and administrative expenses(d)		(268		)	(279		)	(290		)
	Research and development expenses(e)		(1,210		)	(73		)	(74		)
	Other income/(deductions)—net(f)		518			103			(15		)
	(a)	Represents sales to our partners of products manufactured by us.
	(b)	Substantially all relates to amounts earned from our partners under co-promotion agreements. The decline in 2014 and 2013 reflects declines in alliance revenues from Enbrel (as a result of the expiration of the co-promotion term of the collaboration agreement on October 31, 2013 in the U.S. and Canada) and Spiriva (as a result of the expiration of the co-promotion collaboration in the U.S. and certain European countries during 2014, combined with the expiration of the collaboration in Australia, Canada and certain other European countries during 2013).
	(c)	Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners.
	(d)	Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
	(e)	Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $1.2 billion in 2014 (related to collaboration with Merck KGaA, see below), $67 million in 2013 and $44 million in 2012.
	(f)	In 2014 and 2013, includes royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and we became entitled to royalties for a 36-month period thereafter.
	The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated with the products under the collaborative arrangements.
	In addition, in connection with our collaborative arrangements, we paid post-approval milestones to collaboration partners of $80 million in 2014, $175 million in 2013 and $29 million in 2012. These payments were recorded in Identifiable intangible assets––Developed technology rights. We also received upfront and milestone payments from our collaboration partners of $128 million in 2013. These amounts were recorded in our consolidated balance sheets as deferred revenue and are being recognized into Other (income)/deductions––net over a multi-year period.
	Collaboration with Merck KGaA
	On November 17, 2014, we entered into a collaborative arrangement with Merck KGaA, to jointly develop and commercialize avelumab, an investigational anti-PD-L1 antibody currently in development as a potential treatment for multiple types of cancer. We and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent, as well as in various combinations with our and Merck KGaA’s broad portfolio of approved and investigational oncology therapies. Both companies will collaborate on up to 20 high priority immuno-oncology clinical development programs expected to commence in 2015. These clinical development programs include up to six trials (Phase 2 or 3) that could be pivotal for potential product registrations. We and Merck KGaA will also combine resources and expertise to advance our anti-PD-1 antibody into Phase 1 trials. Under the terms of the agreement, we made an upfront cash payment of $850 million to Merck KGaA and Merck KGaA is eligible to receive regulatory and commercial milestone payments of up to approximately $2.0 billion. Both companies will jointly fund all development and commercialization costs, and split equally any profits generated from selling any anti-PD-L1 or anti-PD-1 products from this collaboration. Also, as part of the agreement, we gave Merck KGaA certain co-promotion rights for Xalkori in the U.S. and several other key markets. In 2014, we recorded $1.2 billion of Research and development expenses associated with this collaborative arrangement, composed of the $850 million upfront cash payment as well as an additional amount of $309 million, reflecting the estimated fair value of the co-promotion rights given to Merck KGaA.
	D. Divestitures
	Animal Health Business—Zoetis Inc.
	On June 24, 2013, we completed the full disposition of our Animal Health business. The full disposition was completed through a series of steps, including, in the first quarter of 2013, the formation of Zoetis and an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and, in the second quarter of 2013, an exchange offer for the remaining 80.2% interest.
	With respect to the formation and disposition of Zoetis, in 2013:
	•	Formation of Zoetis—On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.
	•	Initial Public Offering (19.8% Interest)—On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital.
	•	Exchange Offer (80.2% Interest)—On June 24, 2013, we exchanged all of our remaining interest in Zoetis, 400.985 million shares of Class A common stock of Zoetis (after converting all of our Class B common stock into Class A common stock, representing approximately 80.2% of the total outstanding Zoetis shares), for approximately 405.117 million outstanding shares of Pfizer common stock on a tax-free basis pursuant to an exchange offer made to Pfizer shareholders. The $11.4 billion of Pfizer common stock received in the exchange transaction was recorded in Treasury stock and was valued using the opening price of Pfizer common stock on June 24, 2013, the date we accepted the Zoetis shares for exchange. The gain on the sale of the remaining interest in Zoetis was approximately $10.3 billion, net of income taxes resulting from certain legal entity reorganizations, and was recorded in Gain on disposal of discontinued operations––net of tax in the consolidated statement of income for the year ended December 31, 2013.
	In summary, as a result of the above transactions, we received cash and were relieved of debt obligations in the aggregate amount of approximately $6.1 billion and received shares of Pfizer common stock (held in Treasury stock) valued at approximately $11.4 billion.
	The operating results of the animal health business through June 24, 2013, the date of disposal, are reported as Income from discontinued operations––net of tax in the consolidated statements of income.
	In connection with the above transactions, we entered into a transitional services agreement (TSA) and manufacturing and supply agreements (MSAs) with Zoetis that are designed to facilitate the orderly transfer of business operations to the standalone Zoetis entity. The TSA relates primarily to administrative services, which are generally to be provided within 24 months. Under the MSAs, we will manufacture and supply certain animal health products to Zoetis for a transitional period of up to five years, with an ability to extend, if necessary, upon mutual agreement of both parties. These agreements are not material and none confers upon us the ability to influence the operating and/or financial policies of Zoetis subsequent to June 24, 2013, the date of disposal.
	Nutrition Business
	On November 30, 2012, we completed the sale of our Nutrition business to Nestlé for $11.85 billion in cash, and recognized a gain of approximately $4.8 billion, net of tax, in Gain on disposal of discontinued operations––net of tax. The operating results of this business through November 30, 2012, the date of disposal, are reported as Income from discontinued operations––net of tax in the consolidated statements of income.
	The divested business includes:
	•	our former Nutrition operating segment and certain prenatal vitamins previously commercialized by our Consumer Healthcare business; and
	•	other associated amounts, such as direct manufacturing costs, enabling support functions and other costs not charged to the business, purchase-accounting impacts, acquisition-related costs, impairment charges, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives, all of which are reported outside our operating segment results.
	While the full purchase price of $11.85 billion was received on November 30, 2012, the sale of the business was not completed in certain non-U.S. jurisdictions at that date as regulatory review of the transaction was not yet complete. In these jurisdictions, which represented a relatively small portion of the Nutrition business, we continued to operate the business on an interim basis pending regulatory approval or divestiture to a third-party buyer. Pursuant to these interim arrangements, Pfizer operated the business for the net economic benefit of Nestlé and was indemnified by Nestlé against any risk associated with such operations during the interim period. These agreements concluded with the sale of these operations in those jurisdictions in 2013. As Pfizer operated the business in those jurisdictions for the net economic benefit of Nestlé, we had already received all of the expected proceeds from the sale, and as Nestlé was contractually obligated to complete the transaction (or permit us to divest the delayed businesses to a third-party buyer on its behalf) regardless of the outcome of any pending regulatory reviews, we treated these delayed-close businesses as sold for accounting purposes on November 30, 2012.
	In connection with the sale transaction, we also entered into certain transitional agreements designed to ensure and facilitate the orderly transfer of business operations to the buyer. These agreements primarily relate to administrative services, which were generally being provided for a period of 2 to 18 months. We are also manufacturing and supplying certain prenatal vitamin products for a transitional period. These agreements were not material and none conferred upon us the ability to influence the operating and/or financial policies of the Nutrition business subsequent to November 30, 2012, the date of disposal.
	Total Discontinued Operations
	The following table provides the components of Discontinued operations—net of tax:
			Year Ended December 31,(a)
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Revenues		$	—		$	2,201		$	6,587
	Pre-tax income from discontinued operations(a), (b)		(9		)	408			1,253
	Provision for taxes on income(b), (c)		(3		)	100			459
	Income from discontinued operations––net of tax		(6		)	308			794
	Pre-tax gain on disposal of discontinued operations(b)		51			10,446			7,123
	Provision for taxes on income(b), (d)		(4		)	92			2,340
Gain on disposal of discontinued operations––net of tax(b)		55			10,354			4,783
Discontinued operations––net of tax		$	48		$	10,662		$	5,577
(a)	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.
(b)	Includes post-close adjustments for the periods subsequent to disposal.
(c)	Includes a deferred tax benefit of $3 million for 2014, $23 million for 2013 and $23 million for 2012, which is net of a deferred tax expense of $42 million in 2012 related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries indefinitely.
(d)	For 2013, primarily reflects income tax expense of $122 million resulting from certain legal entity reorganizations. For 2012, includes a deferred tax expense of $1.4 billion, which includes a deferred tax expense of $2.2 billion on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas. For 2012, also includes a deferred tax benefit reflecting the reversal of net deferred tax liabilities associated with the divested Nutrition assets.
The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for any period presented, except that (i) financing activities in 2013 include the cash proceeds from the issuance of senior notes by Zoetis and (ii) investing activities in 2012 include the cash proceeds from the sale of our Nutrition business.
E. Equity-Method Investments
Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)
On September 6, 2012, we and Zhejiang Hisun Pharmaceuticals Co., Ltd., a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of $250 million, of which our portion was $122.5 million. On January 1, 2013, both parties transferred selected employees to Hisun Pfizer and contributed, among other things, certain rights to commercialized products and products in development, intellectual property rights, and facilities, equipment and distribution/customer contracts. Our contributions in 2013 constituted a business, as defined by U.S. GAAP, and included, among other things, the China rights to certain commercialized products and other products not yet commercialized and all associated intellectual property rights. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health and other therapeutic areas. We hold a 49% equity interest in Hisun Pfizer.
We also entered into certain transition agreements designed to ensure and facilitate the orderly transfer of the business operations to Hisun Pfizer, primarily the Pfizer Products Transition Period Agreement and a related supply and promotional services agreement. These agreements provide for a profit margin on the manufacturing services provided by Pfizer to Hisun Pfizer and govern the supply, promotion and distribution of Pfizer products until Hisun Pfizer begins its own manufacturing and distribution. While intended to be transitional, these agreements may be extended by mutual agreement of the parties for several years and, possibly, indefinitely. These agreements are not material to Pfizer, and none confers upon us any additional ability to influence the operating and/or financial policies of Hisun Pfizer.
In connection with our contributions in the first quarter of 2013, we recognized a pre-tax gain of approximately $459 million in Other (income)/deductions––net, reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our former Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we had an indirect retained interest in the contributed assets. As such, 49% of the gain, or $225 million, represents the portion of the gain associated with that indirect retained interest.
In valuing our investment in Hisun Pfizer (which includes the indirect retained interest in the contributed assets), we used discounted cash flow techniques, utilizing a 11.5% discount rate, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.
We are accounting for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we have over the operations of Hisun Pfizer through our board representation, minority veto rights and 49% voting interest. Our investment in Hisun Pfizer is reported in Long-term investments, and our share of Hisun Pfizer's net income is recorded in Other (income)/deductions––net. As of December 31, 2014, the carrying value of our investment in Hisun Pfizer was approximately $1.4 billion, and the amount of our underlying equity in the net assets of Hisun Pfizer was approximately $780 million. As of December 31, 2013, the carrying value of our investment in Hisun Pfizer was approximately $1.4 billion, and the amount of our underlying equity in the net assets of Hisun Pfizer was approximately $770 million. The excess of the carrying value of our investment over our underlying equity in the net assets of Hisun Pfizer has been allocated, within the investment account, to goodwill and other intangible assets. The amount allocated to other intangible assets is being amortized into Other (income)/deductions––net over an average estimated useful life of 25 years.
Investment in ViiV Healthcare Limited (ViiV)
Our minority ownership interest in ViiV, a company formed in 2009 by Pfizer and GlaxoSmithKline plc to focus solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines, was impacted by the following events:
•	The January 21, 2014 European Commission approval of Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV. This approval triggered a reduction in our equity interest in ViiV from 12.6% to 11.7%, effective April 1, 2014. As a result, in 2014, we recognized a loss of approximately $30 million in Other (income)/deductions––net;
•	The August 12, 2013 FDA approval of Tivicay (dolutegravir). This approval triggered a reduction in our interest in ViiV from 13.5% to 12.6% effective October 1, 2013. As a result, in 2013, we recognized a loss of approximately $32 million in Other (income)/ deductions––net; and
•	The October 31, 2012 acquisition by ViiV of the remaining 50% of Shionogi-ViiV Healthcare LLC, its equity-method investee, from Shionogi & Co., Ltd. in consideration for a 10% interest in ViiV (newly issued shares) and contingent consideration in the form of future royalties. As a result of this transaction, ViiV recorded a gain associated with the step-up on the 50% interest previously held by ViiV. Also, our equity interest in ViiV was reduced from 15.0% to 13.5%. As a result of the above, in 2012 we recognized a gain of $44 million, which was recorded in Other (income)/deductions––net.
Investment in Laboratório Teuto Brasileiro S.A. (Teuto)
We have an option to acquire the remaining 60% of Teuto, a 40%-owned generics company in Brazil, through 2015, and Teuto’s shareholders have an option to sell their 60% stake to us beginning in 2015. Our investment in Teuto is accounted for under the equity method due to the significant influence we have over the operations of Teuto through our board representation, minority veto rights and 40% voting interest.
•	In 2014, we recorded income of approximately $55 million in Other (income)/deductions––net, resulting from a decline in the estimated loss from the net call/put option recorded in 2013 and an impairment loss of $56 million in Other (income)/deductions––net related to our equity method investment.
•	In 2013, we recorded a loss of $223 million in Other (income)/deductions––net related to the net call/put option and an impairment loss of $32 million in Other (income)/deductions––net related to our equity-method investment.
•	In 2012, we made a performance-based milestone payment to Teuto of $91.5 million, which was recorded as an additional investment in Teuto.

Restructuring_Charges_and_Othe

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
	We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:
	•	In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
	•	In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.
	All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as groups such as information technology, shared services and corporate operations.
	At the end of 2013, we had substantially completed many of the initiatives launched in prior periods. In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives.
	We have the following initiatives underway:
	•	Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of seven sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $300 million associated with prior acquisition activity and costs of approximately $1.5 billion associated with new non-acquisition-related cost-reduction initiatives. Through December 31, 2014, we incurred approximately $182 million and $292 million, respectively, associated with these initiatives.
	•	New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting
	requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $300 million. Through December 31, 2014, we incurred approximately $153 million associated with this initiative.
	•	Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $850 million. Through December 31, 2014, we incurred approximately $154 million associated with this initiative.
	The costs expected to be incurred during 2014-2016, of approximately $2.9 billion in total, include restructuring charges, integration costs, implementation costs and additional depreciation––asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.
	Current-Period Key Activities
	In 2014, we incurred approximately $781 million in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the aforementioned programs, primarily associated with our manufacturing and sales operations.
	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Restructuring charges(a):
	Employee terminations		$	68		$	805		$	953
	Asset impairments		45			165			325
	Exit costs		58			68			150
	Total restructuring charges		170			1,038			1,428
	Transaction costs(b)		—			—			1
	Integration costs(c)		80			144			381
	Restructuring charges and certain acquisition-related costs		250			1,182			1,810
	Additional depreciation––asset restructuring recorded in our
	consolidated statements of income as follows(d):
	Cost of sales		228			178			257
	Selling, informational and administrative expenses		1			19			20
	Research and development expenses		31			94			296
	Total additional depreciation––asset restructuring		261			291			573
	Implementation costs recorded in our consolidated statements of income as follows(e):
	Cost of sales		78			53			31
	Selling, informational and administrative expenses		140			145			130
	Research and development expenses		52			33			231
	Other (income)/deductions––net		1			—			—
	Total implementation costs		270			231			392
	Total costs associated with acquisitions and cost-reduction/productivity initiatives		$	781		$	1,704		$	2,775
	(a)	In 2014, Employee terminations represent the expected reduction of the workforce by approximately 1,700 employees, mainly in manufacturing and sales.
	The restructuring charges in 2014 are associated with the following:
	•	Global Innovative Pharmaceutical segment (GIP) ($35 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($28 million); the Global Established Pharmaceutical segment (GEP) ($57 million); Worldwide Research and Development and Medical ($37 million); manufacturing operations ($97 million); and Corporate ($65 million), as well as $149 million of income related to the partial reversal of prior-period restructuring charges, that we are unable to directly associate with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.
	The restructuring charges in 2013 are associated with the following:
	•	Total operating segments ($496 million); Worldwide Research and Development and Medical ($13 million); manufacturing operations ($356 million); and Corporate ($173 million).
	At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
	The restructuring charges in 2012 are associated with the following:
	•	Total operating segments ($640 million); Worldwide Research and Development and Medical ($6 million income); manufacturing operations ($281 million); and Corporate ($513 million).
	At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
	(b)	Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.
	(c)	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
	(d)	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
	(e)	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
	The following table provides the components of and changes in our restructuring accruals:
	(MILLIONS OF DOLLARS)		Employee			Asset			Exit Costs			Accrual
			Termination			Impairment
			Costs			Charges
	Balance, January 1, 2013		$	1,734		$	—		$	152		$	1,886
	Provision		805			165			68			1,038
	Utilization and other(a)		(854		)	(165		)	(126		)	(1,145		)
	Balance, December 31, 2013(b)		1,685			—			94			1,779
	Provision		68			45			58			170
	Utilization and other(a)		(639		)	(45		)	(100		)	(783		)
	Balance, December 31, 2014(c)		$	1,114		$	—		$	52		$	1,166
	(a)	Includes adjustments for foreign currency translation.
	(b)	Included in Other current liabilities ($1.0 billion) and Other noncurrent liabilities ($767 million).
(c)	Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).

Other_IncomeDeductions_Net

Other (Income)/Deductions - Net	12 Months Ended
	Dec. 31, 2014
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net
	Note 4. Other (Income)/Deductions—Net
	The following table provides components of Other (income)/deductions––net:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Interest income(a)		$	(425	)	$	(403	)	$	(382	)
	Interest expense(a)		1,360			1,414			1,522
	Net interest expense		935			1,011			1,140
	Royalty-related income(b)		(1,002		)	(523		)	(451		)
	Patent litigation settlement income(c)		—			(1,342		)	—
	Other legal matters, net(d)		993			35			2,220
	Gain associated with the transfer of certain product rights(e)		—			(459		)	—
	Net gains on asset disposals(f)		(288		)	(320		)	(52		)
	Certain asset impairments(g)		469			878			890
	Business and legal entity alignment costs(h)		168			—			—
	Costs associated with the Zoetis IPO(i)		—			18			125
	Other, net(j)		(265		)	170			150
	Other (income)/deductions––net		$	1,009		$	(532	)	$	4,022
	(a)	2014 v. 2013––Interest income increased due to higher cash equivalents and investment balances. Interest expense decreased, primarily due to the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. 2013 v. 2012––Interest income increased due to higher investment balances. Interest expense decreased due to lower outstanding debt, refinancings at lower rates, and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. Capitalized interest expense totaled $41 million in 2014, $32 million in 2013 and $41 million in 2012.
	(b)	Royalty-related income increased in 2014 and 2013 primarily due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and Pfizer became entitled to royalties for a 36-month period thereafter.
	(c)	In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.
	(d)	In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million for an agreement in principle to resolve a securities class action pending against Pfizer in New York federal court, which is subject to court approval, and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable. For additional information, see Note 17A. In 2012, primarily includes a $491 million charge relating to the resolution of an investigation by the U.S. Department of Justice into Wyeth's historical promotional practices in connection with Rapamune, a $450 million settlement of a lawsuit by Brigham Young University related to Celebrex, and charges related to hormone-replacement therapy litigation and Chantix litigation.
	(e)	In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.
	(f)	In 2014, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $76 million; (ii) gross realized gains on sales of available-for-sale debt securities of $138 million; (iii) gross realized losses on sales of available-for-sale debt securities of $436 million; (iv) net gain of $323 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of approximately $135 million; and (vi) gains on sales of investments in private equity securities of approximately $39 million. Proceeds from the sale of available-for-sale securities were $10.2 billion in 2014.
	In 2013, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $87 million; (ii) gross realized gains on sales of available-for-sale debt securities of $442 million; (iii) gross realized losses on sales of available-for-sale debt securities of $310 million; (iv) net loss of $137 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; and (v) a gain of $170 million on the sale of various product rights, including a portion of our in-licensed generic sterile injectables portfolio. Proceeds from the sale of available-for-sale securities were $15.2 billion in 2013.
	In 2012, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $2 million; (ii) gross realized gains on sales of available-for-sale debt securities of $212 million; (iii) gross realized losses on sales of available-for-sale debt securities of $535 million; and (iv) net gain of $351 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale securities. Proceeds primarily from the sale of available-for-sale securities were $19.0 billion in 2012.
	(g)	In 2014, includes intangible asset impairment charges of $396 million, reflecting (i) $190 million for an IPR&D compound for the treatment of skin fibrosis (full write-off); (ii) $159 million for developed technology rights, primarily related to Quillivant XR; and (iii) $47 million for indefinite-lived brands. The intangible asset impairment charges for 2014 are associated with the following: the Global Innovative Pharmaceutical segment ($12 million); Global Established Pharmaceutical segment ($166 million); Worldwide Research and Development ($190 million); and Consumer Healthcare ($28 million). In addition, 2014 includes an impairment charge of approximately $56 million related to our investment in Teuto.
	The intangible asset impairment charges for 2014 reflect, among other things, updated commercial forecasts; and with regard to IPR&D, the impact of changes to the development program and new scientific findings.
	In 2013, includes intangible asset impairment charges of $803 million, reflecting (i) $394 million of developed technology rights (for use in the development of bone and cartilage) acquired in connection with our acquisition of Wyeth; (ii) $227 million related to IPR&D compounds; (iii) $109 million of indefinite-lived brands, primarily related to our biopharmaceutical indefinite-lived brand Xanax/Xanax XR; and (iv) $73 million of other finite-lived intangible assets, related to platform technology, that no longer have an alternative future use. The intangible asset impairment charges for 2013 are associated with the following: the Global Innovative Pharmaceutical segment ($448 million); the Global Established Pharmaceutical segment ($201 million); Worldwide Research and Development ($140 million); and Consumer Healthcare ($14 million). In addition, 2013 includes an impairment charge of approximately $43 million for certain private company investments and an impairment charge of $32 million related to our investment in Teuto.
	The intangible asset impairment charges for 2013 reflect, among other things, updated commercial forecasts and, with regard to IPR&D, also reflect the impact of new scientific findings and delayed launch dates.
	In 2012, includes intangible asset impairment charges of $835 million, reflecting (i) $393 million of IPR&D assets, primarily related to compounds that targeted autoimmune and inflammatory diseases (full write-off) and, to a lesser extent, compounds related to pain treatment; (ii) $175 million related to our Consumer Healthcare indefinite-lived brand assets, primarily Robitussin, a cough suppressant; (iii) $242 million related to developed technology rights, a charge composed of impairments of various products, none of which individually exceeded $45 million; and (iv) $25 million of finite-lived brands. The impairment charges in 2012 are associated with the following: Worldwide Research and Development ($303 million); Consumer Healthcare ($200 million); the Global Innovative Pharmaceutical segment ($173 million); and the Global Established Pharmaceutical segment ($159 million). In addition, in 2012, also includes charges of approximately $55 million for certain investments. These investment impairment charges reflect the difficult global economic environment.
	The intangible asset impairment charges for 2012 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, an increased competitive environment and litigation uncertainties regarding intellectual property.
	(h)	Represents expenses for planning and implementing changes to our infrastructure to operate our new business segments.
	(i)	Represents costs incurred in connection with the IPO of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. For additional information, see Note 2D.
	(j)	Includes the following: (i) in 2014, the gain of approximately $43 million reflecting the change in the fair value of the contingent consideration associated with our acquisition of NextWave and the gain of approximately $89 million reflecting the change in the fair value of the contingent consideration associated with our acquisition of Excaliard Pharmaceuticals, Inc., and in 2013, the gain of approximately $114 million, reflecting the change in the fair value of the contingent consideration associated with our acquisition of NextWave; (ii) in 2013, an estimated loss of $223 million related to an option to acquire the remaining interest in Teuto, and in 2014, income of $55 million resulting from a decline in the estimated loss from the aforementioned option; and (iii) in 2014, a loss of $30 million due to a change in our ownership interest in ViiV, in 2013, a loss of $32 million due to a change in our ownership interest in ViiV and in 2012, a gain of $44 million as a result of ViiV's transaction with Shionogi & Co., Ltd and the resulting change in ownership. For additional information concerning NextWave, see Note 2A. For additional information concerning Teuto and ViiV, see Note 2E.
	The asset impairment charges included in Other (income)/deductions––net in 2014 virtually all relate to identifiable intangible assets and are based on estimates of fair value.
	The following table provides additional information about the intangible assets that were impaired during 2014 in Other (income)/deductions––net :
														Year Ended December 31,
			Fair Value(a)											2014
	(MILLIONS OF DOLLARS)		Amount			Level 1			Level 2			Level 3		Impairment
	Intangible assets––IPR&D(b)		$	—		$	—		$	—		$	—	$	190
	Intangible assets––Developed technology rights(b)		233			—			—			233		159
	Intangible assets––Indefinite-lived Brands(b)		293			—			—			293		47
	Total		$	526		$	—		$	—		$	526	$	396
	(a)	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
	(b)	Reflects intangible assets written down to fair value in 2014. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then we applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax_Matters

Tax Matters	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters
	A. Taxes on Income from Continuing Operations
	The following table provides the components of Income from continuing operations before provision for taxes on income:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	United States		$	(4,744	)		$	(1,678	)		$	(5,148	)
	International		16,984				17,394				16,390
	Income from continuing operations before provision for taxes on income(a), (b)		$	12,240			$	15,716			$	11,242
	(a)	2014 v. 2013––The increase in the domestic loss was primarily due to lower revenues, the non-recurrence of income from a litigation settlement in 2013 with Teva and Sun for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S., higher charges related to other legal matters, a non-tax deductible charge in the third quarter of 2014 to account for an additional year of the Branded Prescription Drug Fee in accordance with final regulations issued by the U.S. Internal Revenue Service (IRS), higher research and development expenses, and higher charges for business and legal entity alignment costs, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, and lower asset impairments. The decrease in international income is primarily related to lower revenues, the non-recurrence of the gain associated with the transfer of certain product rights to Pfizer’s equity-method investment in China (Hisun Pfizer) in 2013, and higher research and development expenses, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives and the non-recurrence of certain charges.
	(b)	2013 v. 2012––The decrease in the domestic loss was primarily due to income from a litigation settlement in the second quarter of 2013 with Teva and Sun for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S., lower charges related to other legal matters, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, partially offset by lower revenues. The increase in international income is primarily related to the gain associated with the transfer of certain product rights to Hisun Pfizer in 2013, lower charges related to other legal matters, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives and lower amortization of intangible assets, partially offset by lower revenues and higher asset impairments and other charges.
	The following table provides the components of Provision for taxes on income based on the location of the taxing authorities:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	United States
	Current income taxes:
	Federal		$	393			$	142			$	(941	)
	State and local		85				(106		)		(54		)
	Deferred income taxes:
	Federal		725				2,124				869
	State and local		(256		)		(33		)		(339		)
	Total U.S. tax provision/(benefit)		948				2,127				(465		)
	International
	Current income taxes		2,321				2,544				2,430
	Deferred income taxes		(149		)		(365		)		256
	Total international tax provision		2,172				2,179				2,686
	Provision for taxes on income		$	3,120			$	4,306			$	2,221
	In 2014, the Provision for taxes on income was impacted by the following:
	•	U.S. tax expense of approximately $2.2 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year (see Note 5C);
	•	Tax benefits of approximately $350 million, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations;
	•	The favorable impact of the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely;
	•	The extension of the U.S. R&D tax credit, which was signed into law in December 2014; and
	•	The non-deductibility of a $362 million fee payable to the federal government as a result of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (U.S. Healthcare Legislation).
	In 2013, the Provision for taxes on income was impacted by the following:
	•	U.S. tax expense of approximately $2.3 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year (see Note 5C);
	•	U.S. tax benefits of approximately $430 million, representing tax and interest, resulting from a multi-year settlement with the IRS with respect to audits of the Wyeth tax returns for the years 2006 through date of acquisition, and international tax benefits of approximately $470 million, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years with various foreign tax authorities, and from the expiration of certain statutes of limitations;
	•	The unfavorable tax rate associated with the $1.3 billion of patent litigation settlement income;
	•	The non-deductibility of the $292 million of goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer;
	•	The non-deductibility of the $223 million loss on an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely, and the non-deductibility of a $32 million impairment charge related to our equity-method investment in Teuto;
	•	The extension of the U.S. R&D tax credit (resulting in the full-year benefit of the 2012 and 2013 U.S. R&D tax credit being recorded in 2013); and
	•	The non-deductibility of a $280 million fee payable to the federal government as a result of the U.S. Healthcare Legislation.
	In 2012, the Provision for taxes on income was impacted by the following:
	•	U.S. tax expense of approximately $2.2 billion as a result of providing U.S. deferred income taxes on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas (see Note 5C);
	•	U.S. tax benefits of approximately $1.1 billion, representing tax and interest, resulting from a multi-year settlement with the IRS with respect to audits of the Pfizer Inc. tax returns for the years 2006 through 2008, and international tax benefits of approximately $310 million, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years with various foreign tax authorities, and from the expiration of certain statutes of limitations;
	•	The non-deductibility of a $336 million fee payable to the federal government as a result of the U.S. Healthcare Legislation;
	•	The non-deductibility of the $491 million legal charge associated with Rapamune litigation (see also Note 4); and
	•	The expiration of the U.S. R&D tax credit on December 31, 2011.
	In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision for taxes on income (see Note 2A).
	B. Tax Rate Reconciliation
	The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows:
			Year Ended December 31,
			2014			2013			2012
	U.S. statutory income tax rate		35	%		35	%		35	%
	Taxation of non-U.S. operations(a), (b), (c)		(7.4	)		(2.5	)		(3.5	)
	Tax settlements and resolution of certain tax positions(d)		(2.9	)		(5.7	)		(12.8	)
	U.S. Healthcare Legislation(d)		1			0.6			1
	U.S. R&D tax credit and manufacturing deduction(d)		(0.9	)		(0.8	)		(0.3	)
	Certain legal settlements and charges(d)		—			(0.2	)		1.5
	All other, net		0.5			1			(1.1	)
	Effective tax rate for income from continuing operations		25.5	%		27.4	%		19.8	%
	(a)	For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision for taxes on income.
	(b)	In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations.
	(c)	The favorable rate impact in 2014 also includes the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely. The rate impact in 2013 also includes the non-deductibility of the goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer, and the non-deductibility of the loss on an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely, and the non-deductibility of an impairment charge related to our equity-method investment in Teuto. For additional information, see Note 2E.
	(d)	For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and the impact of certain legal settlements and charges, see Note 5A. The extension of the U.S. R&D tax credit in January 2013 resulted in the full-year benefit of the 2012 and 2013 U.S. R&D tax credit being recorded in 2013.
	C. Deferred Taxes
Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts.
The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:
		2014 Deferred Tax								2013 Deferred Tax
(MILLIONS OF DOLLARS)		Assets				(Liabilities)				Assets			(Liabilities)
Prepaid/deferred items		$	1,995			$	(53	)		$	1,913		$	(134	)
Inventories		219				(56		)		277			(217		)
Intangible assets		969				(9,224		)		892			(10,331		)
Property, plant and equipment		174				(1,242		)		376			(1,390		)
Employee benefits		3,950				(154		)		3,154			(77		)
Restructurings and other charges		114				(28		)		453			(237		)
Legal and product liability reserves		1,010				—				904			—
Net operating loss/tax credit carryforwards(a)		2,918				—				2,043			—
Unremitted earnings(b)		—				(21,174		)		—			(19,399		)
State and local tax adjustments		295				—				297			—
All other		283				(783		)		249			(448		)
		11,927				(32,714		)		10,558			(32,233		)
Valuation allowances		(1,615		)		—				(1,288		)	—
Total deferred taxes		$	10,312			$	(32,714	)		$	9,270		$	(32,233	)
Net deferred tax liability(c), (d)						$	(22,402	)					$	(22,963	)
(a)	The amounts in 2014 and 2013 are reduced for unrecognized tax benefits of $2.6 billion and $2.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
(b)	The increase in 2014 reflects additional accruals for certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year. For additional information, see Note 5A.
(c)	The net deferred tax liability position decreased, reflecting an increase in noncurrent deferred tax assets related to net operating loss and tax credit carryforwards, an increase in current deferred tax assets related to product liability reserves due to settlements, an increase in noncurrent deferred tax assets related to employee benefits, and a decrease in noncurrent deferred tax liabilities resulting from the amortization of identifiable intangible assets, partially offset by the increase in noncurrent deferred tax liabilities related to unremitted earnings.
(d)	In 2014, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($515 million), Other current liabilities ($43 million) and Noncurrent deferred tax liabilities ($25.0 billion). In 2013, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($569 million), Other current liabilities ($52 million) and Noncurrent deferred tax liabilities ($25.6 billion).
We have carryforwards, primarily related to foreign tax credits, net operating and capital losses and charitable contributions, which are available to reduce future U.S. federal and state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2015 to 2034. Certain of our U.S. net operating losses are subject to limitations under Internal Revenue Code Section 382.
Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets.
As of December 31, 2014, we have not made a U.S. tax provision on approximately $74.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2014, is not practicable.
D. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.
For a description of our accounting policies associated with accounting for income tax contingencies, see Note 1O. For a description of the risks associated with estimates and assumptions, see Note 1C.
Uncertain Tax Positions
As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2014 and 2013, we had approximately $4.7 billion and $4.4 billion, respectively, in net unrecognized tax benefits, excluding associated interest.
•	Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process and from foreign tax credits that would be generated upon settlement of an uncertain tax position. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2014 and 2013, we had approximately $1.5 billion and $1.7 billion, respectively, in assets associated with uncertain tax positions. In 2014, these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ($966 million) and Noncurrent deferred tax liabilities ($527 million). In 2013, these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ($926 million) and Noncurrent deferred tax liabilities ($766 million).
•	Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.
The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:
(MILLIONS OF DOLLARS)		2014				2013				2012
Balance, beginning		$	(6,087	)		$	(6,315	)		$	(7,309	)
Divestitures(a)		—				29				85
Increases based on tax positions taken during a prior period(b)		(110		)		(205		)		(139		)
Decreases based on tax positions taken during a prior period(b), (c)		473				876				1,442
Decreases based on settlements for a prior period(d)		70				571				647
Increases based on tax positions taken during the current period(b)		(795		)		(1,178		)		(1,125		)
Impact of foreign exchange		161				38				78
Other, net(b), (e)		106				97				6
Balance, ending(f)		$	(6,182	)		$	(6,087	)		$	(6,315	)
(a)	Primarily relates to the sales of our Nutrition and Animal Health (Zoetis) businesses. See also Note 2D.
(b)	Primarily included in Provision for taxes on income.
(c)	Primarily related to effectively settling certain tax positions with the U.S. and foreign tax authorities. See also Note 5A.
(d)	Primarily related to cash payments.
(e)	Includes decreases as a result of a lapse of applicable statutes of limitations.
(f)	In 2014, included in Income taxes payable ($13 million), Current deferred tax assets and other current tax assets ($59 million), Noncurrent deferred tax assets and other noncurrent tax assets ($165 million), Current deferred tax liabilities ($13 million), Noncurrent deferred tax liabilities ($2.4 billion) and Other taxes payable ($3.5 billion). In 2013, included in Income taxes payable ($51 million), Current deferred tax assets and other current tax assets ($63 million), Noncurrent deferred tax assets and other noncurrent tax assets ($241 million), Noncurrent deferred tax liabilities ($2.3 billion) and Other taxes payable ($3.4 billion).
•	Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded in Provision for taxes on income in our consolidated statements of income. In 2014, we recorded net interest expense of $40 million. In 2013, we recorded net interest income of $16 million primarily as a result of settling certain tax positions with the U.S. and various foreign tax authorities; and in 2012, we recorded net interest income of $120 million primarily as a result of settling certain tax positions with the U.S. and various foreign tax authorities. Gross accrued interest totaled $643 million as of December 31, 2014 (reflecting a decrease of approximately $18 million as a result of cash payments) and gross accrued interest totaled $621 million as of December 31, 2013 (reflecting a decrease of approximately $120 million as a result of cash payments). In 2014, these amounts were included in Current deferred tax assets and other current tax assets ($15 million) and Other taxes payable ($628 million). In 2013, these amounts were included in Income taxes payable ($14 million) and Current deferred tax assets and other current tax assets ($12 million) and Other taxes payable ($595 million). Accrued penalties are not significant. See also Note 5A.
Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:
•	With respect to Pfizer Inc., tax years 2009-2013 are currently under audit. Tax year 2014 is open, but not under audit. All other tax years are closed.
In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2004-2014), Japan (2013-2014), Europe (2007-2014, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2014, primarily reflecting Brazil) and Puerto Rico (2009-2014).
Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next twelve months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $100 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.
E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
The following table provides the components of the tax provision/(benefit) on Other comprehensive income/(loss):
		Year Ended December 31,
(MILLIONS OF DOLLARS)		2014				2013				2012
Foreign currency translation adjustments(a)		$	42			$	111			$	110
Unrealized holding gains on derivative financial instruments, net		(199		)		217				251
Reclassification adjustments for realized (gains)/losses		262				(63		)		(144		)
		63				154				107
Unrealized holding gains/(losses) on available-for-sale securities, net		(56		)		57				15
Reclassification adjustments for realized (gains)/losses		10				(57		)		47
		(46		)		—				62
Benefit plans: actuarial gains/(losses), net		(1,416		)		1,422				(721		)
Reclassification adjustments related to amortization		61				205				171
Reclassification adjustments related to settlements, net		35				2				105
Other		61				2				15
		(1,258		)		1,631				(430		)
Benefit plans: prior service credits and other, net		281				56				7
Reclassification adjustments related to amortization		(28		)		(23		)		(27		)
Reclassification adjustments related to curtailments, net		—				(1		)		(51		)
Other		(1		)		—				(3		)
		253				32				(74		)
Tax provision/(benefit) on other comprehensive income/(loss)		$	(946	)		$	1,928			$	(225	)
(a)	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
	The following table provides the changes, net of tax, in Accumulated other comprehensive income/(loss):
			Net Unrealized Gain/(Losses)									Benefit Plans
	(MILLIONS OF DOLLARS)		Foreign Currency Translation Adjustments			Derivative Financial Instruments			Available-For-Sale Securities			Actuarial Gains/(Losses)			Prior Service (Costs)/ Credits and Other			Accumulated Other Comprehensive Income/(Loss)
	Balance, January 1, 2012		$	944		$	(183	)	$	(132	)	$	(5,120	)	$	362		$	(4,129	)
	Other comprehensive income/(loss)(a)		(1,121		)	22			368			(990		)	(103		)	(1,824		)
	Balance, December 31, 2012		(177		)	(161		)	236			(6,110		)	259			(5,953		)
	Other comprehensive income/(loss)(a)		(440		)	240			(86		)	2,887			54			2,655
	Sale of 19.8% of subsidiary through an IPO(b)		27			—			—			—			—			27
	Balance, December 31, 2013		(590		)	79			150			(3,223		)	313			(3,271		)
	Other comprehensive income/(loss)(a)		(2,099		)	438			(372		)	(2,432		)	419			(4,045		)
	Balance, December 31, 2014		$	(2,689	)	$	517		$	(222	)	$	(5,654	)	$	733		$	(7,316	)
	(a)	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $3 million gain in 2014, $62 million loss in 2013 and $7 million loss in 2012.
	(b)	Relates to Zoetis (our former Animal Health subsidiary). See Note 2D.
	As of December 31, 2014, we estimate that we will reclassify into 2015 income the following pre-tax amounts currently held in Accumulated other comprehensive loss: $419 million of unrealized holding gains on derivative financial instruments (expected to be offset by losses resulting from reclassification adjustments related to available-for-sale securities); $549 million of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and $138 million of prior service credits, primarily related to benefit plan amendments.

Financial_Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2014
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments
	A. Selected Financial Assets and Liabilities
	The following table provides additional information about certain of our financial assets and liabilities:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014				2013
	Selected financial assets measured at fair value on a recurring basis(a)
	Trading securities(b)		$	105			$	126
	Available-for-sale debt securities(c)		39,762				34,899
	Available-for-sale money market funds		2,174				945
	Available-for-sale equity securities, excluding money market funds(c)		397				356
	Derivative financial instruments in a receivable position(d):
	Interest rate swaps		801				468
	Foreign currency swaps		593				871
	Foreign currency forward-exchange contracts		547				172
			44,379				37,837
	Other selected financial assets
	Held-to-maturity debt securities, carried at amortized cost(c), (e)		7,255				9,139
	Private equity securities, carried at equity-method or at cost(e), (f)		1,993				2,270
			9,248				11,409
	Total selected financial assets		$	53,627			$	49,246
	Selected financial liabilities measured at fair value on a recurring basis(a)
	Derivative financial instruments in a liability position(g):
	Interest rate swaps		$	17			$	301
	Foreign currency swaps		594				110
	Foreign currency forward-exchange contracts		78				219
			689				630
	Other selected financial liabilities(h)
	Short-term borrowings, carried at historical proceeds, as adjusted(e)		5,141				6,027
	Long-term debt, carried at historical proceeds, as adjusted(i), (j)		31,541				30,462
			36,682				36,489
	Total selected financial liabilities		$	37,371			$	37,119
	(a)	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 1% that use Level 1 inputs.
	(b)	Trading securities are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
	(c)	Gross unrealized gains and losses are not significant.
	(d)	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $159 million as of December 31, 2014; and interest rate swaps with fair values of $38 million, foreign currency swaps with fair values of $30 million and foreign currency forward-exchange contracts with fair values of $66 million as of December 31, 2013.
	(e)	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2014 or December 31, 2013. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs.
	(f)	Our private equity securities represent investments in the life sciences sector.
	(g)	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $121 million and foreign currency forward-exchange contracts with fair values of $54 million as of December 31, 2014; and foreign currency swaps with fair values of $76 million and foreign currency forward-exchange contracts with fair values of $77 million as of December 31, 2013.
	(h)	Some carrying amounts may include adjustments for discount or premium amortization or for the effect of hedging the interest rate fair value risk associated with certain financial liabilities by interest rate swaps.
	(i)	Includes foreign currency debt with fair values of $560 million as of December 31, 2014 and $651 million as of December 31, 2013, which are used as hedging instruments.
	(j)	The fair value of our long-term debt (not including the current portion of long-term debt) was $36.6 billion as of December 31, 2014 and $35.1 billion as of December 31, 2013. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance.
	A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C.
	The following methods and assumptions were used to estimate the fair value of our financial assets and liabilities:
	•	Trading equity securities—quoted market prices.
	•	Trading debt securities—observable market interest rates.
	•	Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. Loan-backed, receivable-backed, and mortgage-backed securities are valued by third-party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates.
	•	Available-for-sale money market funds—observable Net Asset Value prices.
	•	Available-for-sale equity securities, excluding money market funds—third-party pricing services that principally use a composite of observable prices.
	•	Derivative financial instruments (assets and liabilities)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.
	•	Held-to-maturity debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves.
	•	Private equity securities, excluding equity-method investments—application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio.
	•	Short-term borrowings and long-term debt—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and our own credit rating.
	We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.
	The following table provides the classification of these selected financial assets and liabilities in our consolidated balance sheets:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014				2013
	Assets
	Cash and cash equivalents		$	1,389			$	1,104
	Short-term investments		32,779				30,225
	Long-term investments		17,518				16,406
	Other current assets(a)		1,059				286
	Other noncurrent assets(b)		881				1,225
			$	53,627			$	49,246
	Liabilities
Short-term borrowings, including current portion of long-term debt		$	5,141			$	6,027
Other current liabilities(c)		93				303
Long-term debt		31,541				30,462
Other noncurrent liabilities(d)		596				327
		$	37,371			$	37,119
(a)	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($34 million), foreign currency swaps ($494 million) and foreign currency forward-exchange contracts ($531 million) and, as of December 31, 2013, include interest rate swaps ($90 million), foreign currency swaps ($24 million) and foreign currency forward-exchange contracts ($172 million).
(b)	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($767 million) and foreign currency swaps ($99 million) and foreign currency forward-exchange contracts ($15 million) and, as of December 31, 2013, include interest rate swaps ($378 million) and foreign currency swaps ($847 million).
(c)	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($13 million) and foreign currency forward-exchange contracts ($78 million) and, as of December 31, 2013, include foreign currency swaps ($84 million) and foreign currency forward-exchange contracts ($219 million).
(d)	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($16 million) and foreign currency swaps ($581 million) and, as of December 31, 2013, include interest rate swaps ($301 million) and foreign currency swaps ($26 million).
In addition, as of December 31, 2014, we had long-term receivables where the determination of fair value employs discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. As of December 31, 2014, the differences between the estimated fair values and carrying values of these receivables were not significant.
There were no significant impairments of financial assets recognized in any period presented.
B. Investments in Debt Securities
The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:
		Years														December 31,
																2014
(MILLIONS OF DOLLARS)		Within 1				Over 1				Over 5			Over 10			Total
						to 5				to 10
Available-for-sale debt securities
Western European, Scandinavian and other government debt(a)		$	13,281			$	2,281			$	—		$	—		$	15,561
Corporate debt(b)		2,756				3,847				1,370			46			8,019
U.S. government debt		2,246				2,277				21			—			4,543
Western European, Scandinavian and other government agency debt(a)		2,417				435				—			—			2,853
Supranational debt(a)		1,293				905				—			—			2,198
Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities		16				1,850				72			—			1,938
Reverse repurchase agreements(c)		1,589				—				—			—			1,589
Government National Mortgage Association and other U.S. government guaranteed asset-backed securities		198				793				27			—			1,017
Other asset-backed debt(d)		960				1,077				9			—			2,046
Held-to-maturity debt securities
Western European, Asian and other government debt(a)		3,893				—				—			—			3,893
Time deposits, corporate debt and other(b)		3,346				12				3			—			3,361
Total debt securities		$	31,994			$	13,476			$	1,501		$	46		$	47,017
(a)	Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade.
(b)	Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade.
(c)	Involving U.S. securities.
(d)	Includes loan-backed, receivable-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and receivable-backed securities are collateralized by credit cards receivables. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
C. Short-Term Borrowings
Short-term borrowings include amounts for commercial paper of $570 million as of December 31, 2014 and $3.0 billion December 31, 2013. The weighted-average effective interest rate on short-term borrowings outstanding was 2.5% as of December 31, 2014 and 1.7% as of December 31, 2013.
As of December 31, 2014, we had access to $8.4 billion of lines of credit, of which $822 million expire within one year. Of these lines of credit, $8.1 billion are unused, of which our lenders have committed to loan us $7.1 billion at our request. Also, $7.0 billion of our unused lines of credit, all of which expire in 2019, may be used to support our commercial paper borrowings.
D. Long-Term Debt
On May 15, 2014, we completed a public offering of $4.5 billion aggregate principal amount of senior unsecured notes.
On June 3, 2013, we completed a public offering of $4.0 billion aggregate principal amount of senior unsecured notes. In addition, we repaid at maturity our 3.625% senior unsecured notes that were due June 2013, which had a balance of approximately $2.4 billion at December 31, 2012, and in December 2013, we redeemed the aggregate principal amount of $1.8 billion of our 5.50% senior unsecured notes that were due in February 2014.
The following table provides the components of our senior unsecured long-term debt:
				As of December 31,
(MILLIONS OF DOLLARS)		Maturity Date		2014				2013
6.20%(a)		March 2019		$	3,264			$	3,234
7.20%(a)		Mar-39		2,902				2,603
4.75% euro(b)		Jun-16		2,424				2,752
5.75% euro(b)		Jun-21		2,419				2,748
6.50% U.K. pound(b)		Jun-38		2,316				2,459
5.95%(c)		Apr-37		2,083				2,085
2.10%(c)		May-19		1,507				—
4.55% euro(d)		May-17		1,201				1,390
5.50%(b)		Feb-16		1,018				1,033
5.35%(e)		Mar-15		—				3,037
Notes and other debt with a weighted-average interest rate of 5.11%(f)		2021–2044		6,698				4,810
Notes and other debt with a weighted-average interest rate of 3.19%(g)		2017–2018		5,161				3,683
Foreign currency notes and other foreign currency debt with a weighted-		2015-2016		547				628
average interest rate of 2.84%(h)
Long-term debt				$	31,541			$	30,462
Current portion of long-term debt (not included above)				$	3,011			$	2,060
(a)	Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.50%, plus, in each case, accrued and unpaid interest.
(b)	Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at a comparable government bond rate plus 0.20%. plus, in each case, accrued and unpaid interest.
(c)	The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.25% for the 5.95% notes and 0.07% for the 2.10% notes, plus, in each case, accrued and unpaid interest.
(d)	The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the price at which the gross redemption yield on the notes would be equal to the gross redemption yield of a comparable European government bond (selected at the discretion of the Trustee) on the basis of the middle market price of such European government bond.
(e)	At December 31, 2014, the note has been reclassified to Current portion of long-term debt.
(f)	Contains debt issuances with a weighted-average maturity of approximately 22 years, and the majority of which are redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average 0.22%, plus, in each case, accrued and unpaid interest.
(g)	Contains debt issuances with a weighted-average maturity of approximately 3 years, and the majority of which are redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average 0.14%, plus, in each case, accrued and unpaid interest.
(h)	Contains debt issuances with a weighted-average maturity of approximately 1 year.
The following table provides the maturity schedule of our Long-term debt outstanding as of December 31, 2014:
(MILLIONS OF DOLLARS)		2016				2017				2018			2019			After 2019			TOTAL
Maturities		$	3,990			$	3,963			$	2,399		$	4,771		$	16,418		$	31,541
E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk
A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income and net investments against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions.
As of December 31, 2014, the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was $36.6 billion. The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen, U.K. pound and Swiss franc. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $2.3 billion U.K. pound debt maturing in 2038.
All derivative contracts used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings or in Other comprehensive income/(loss), depending on the nature and purpose of the financial instrument (offset or hedge relationship) and the effectiveness of the hedge relationships, as follows:
•	We record in Other comprehensive income/(loss) the effective portion of the gains or losses on foreign currency forward-exchange contracts and foreign currency swaps that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings.
•	We recognize the gains and losses on foreign currency forward-exchange contracts and foreign currency swaps that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.
•	We recognize the gain and loss impact on foreign currency swaps and foreign currency forward-exchange contracts designated as hedges of our net investments in earnings in three ways: over time—for the periodic net swap payments; immediately—to the extent of any change in the difference between the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net investments—to the extent of change in the foreign exchange spot rates.
•	We record in Other comprehensive income/(loss) the foreign exchange gains and losses related to foreign exchange-denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments.
Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented.
Interest Rate Risk
Our interest-bearing investments and borrowings are subject to interest rate risk. We strive to invest and borrow primarily on a floating-rate basis; however, in light of current market conditions, we currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps.
We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. As of December 31, 2014, the aggregate notional amount of interest rate derivative financial instruments was $17.5 billion. The derivative financial instruments primarily hedge U.S. dollar and euro fixed-rate debt.
All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows:
•	We recognize the gains and losses on interest rate swaps that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk also in earnings.
Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented.
The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:
		Amount of								Amount of Gains/(Losses)						Amount of Gains/(Losses)
		Gains/(Losses)								Recognized in OCI						Reclassified from
		Recognized in OID(a), (b), (c)								(Effective Portion)(a), (d)						OCI into OID
																(Effective Portion)(a), (d)
(MILLIONS OF DOLLARS)		Dec 31,				Dec 31,				Dec 31,			Dec 31,			Dec 31,			Dec 31,
		2014				2013				2014			2013			2014			2013
Derivative Financial Instruments in Cash Flow Hedge Relationships:
Foreign currency swaps		$	—			$	—			$	(799	)	$	554		$	(808	)	$	220
Foreign currency forward-exchange contracts		—				—				823			(66		)	332			(126		)
Derivative Financial Instruments in Net Investment Hedge Relationships:
Foreign currency swaps		—				(3		)		78			156			—			—
Foreign currency forward-exchange contracts		—				(3		)		—			(1		)	—			—
Derivative Financial Instruments Not Designated as Hedges:
Foreign currency forward-exchange contracts		164				56				—			—			—			—
Foreign currency swaps		(2		)		(18		)		—			—			—			—
Non-Derivative Financial Instruments in Net Investment Hedge Relationships:
Foreign currency long-term debt		—				—				33			133			—			—
All other net		(3		)		(1		)		—			—			—			—
		$	160			$	31			$	135		$	776		$	(477	)	$	94
(a)	OID =ther (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income. OCI =ther comprehensive income/(loss), included in the consolidated statements of comprehensive income.
(b)	Also includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.
(c)	There was no significant ineffectiveness for any period presented.
(d)	For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments.
For information about the fair value of our derivative financial instruments, and the impact on our consolidated balance sheets, see Note 7A above. Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. As of December 31, 2014, the aggregate fair value of these derivative instruments that are in a net liability position was $233 million, for which we have posted collateral of $231 million in the normal course of business. These features include the requirement to pay additional collateral in the event of a downgrade in our debt ratings. If there had been a downgrade to below an A rating by Standard and Poor's (S&P) or the equivalent rating by Moody’s Investors Service, on December 31, 2014, we would have been required to post an additional $5 million of collateral to our counterparties. The collateral advanced receivables are reported in Short-term investments.
F. Credit Risk
On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. As of December 31, 2014, we had $3.5 billion due from a well-diversified, highly rated group (S&P ratings of mostly A or better) of bank counterparties around the world. For details about our investments, see Note 7B above.
In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under master netting agreements with financial institutions and these agreements contain provisions that provide for the ability for collateral payments, depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of December 31, 2014, we received cash collateral of $1.6 billion from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, which is included in Cash and cash equivalents, the obligations are reported in Short-term borrowings, including current portion of long-term debt.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories
	The following table provides the components of Inventories:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014		2013
	Finished goods		$	1,905	$	2,216
	Work-in-process		3,248		3,445
	Raw materials and supplies		510		505
	Inventories		$	5,663	$	6,166
	Noncurrent inventories not included above(a)		$	425	$	463
	(a)	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment
	The following table provides the components of Property, plant and equipment:
			Useful Lives	As of December 31,
	(MILLIONS OF DOLLARS)		(Years)	2014		2013
	Land		—	$	529	$	557
	Buildings		33-50	9,355		10,055
	Machinery and equipment		8-20	9,671		10,050
	Furniture, fixtures and other		3-12 1/2	4,162		3,914
	Construction in progress		—	1,271		1,102
				24,988		25,678
	Less: Accumulated depreciation			13,226		13,281
	Property, plant and equipment(a)			$	11,762	$	12,397
	(a)	The decrease in total property, plant and equipment is primarily due to depreciation and, to a much lesser extent, disposals, impairments and the impact of foreign exchange, partially offset by capital additions.

Identifiable_Intangible_Assets

Identifiable Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill
	A. Identifiable Intangible Assets
	Balance Sheet Information
	The following table provides the components of Identifiable intangible assets:
			31-Dec-14											December 31, 2013
	(MILLIONS OF DOLLARS)		Gross				Accumulated				Identifiable			Gross			Accumulated			Identifiable
			Carrying				Amortization				Intangible			Carrying			Amortization			Intangible
			Amount								Assets, less			Amount						Assets, less
											Accumulated									Accumulated
											Amortization									Amortization
	Finite-lived intangible assets
	Developed technology rights		$	70,946			$	(44,694	)		$	26,252		$	72,038		$	(41,541	)	$	30,497
	Brands		1,951				(855		)		1,096			1,743			(773		)	970
	Licensing agreements and other		991				(832		)		159			896			(805		)	91
			73,887				(46,381		)		27,506			74,677			(43,119		)	31,558
	Indefinite-lived intangible assets
	Brands and other		7,273								7,273			7,384						7,384
	In-process research and development		387								387			443						443
			7,660								7,660			7,827						7,827
	Identifiable intangible assets(a)		$	81,547			$	(46,381	)		$	35,166		$	82,504		$	(43,119	)	$	39,385
	(a)	The decrease in identifiable intangible assets, less accumulated amortization, is primarily due to amortization and, to a much lesser extent, asset impairment charges, partially offset by assets acquired as part of the InnoPharma acquisition,the Nexium OTC milestones and other asset acquisitions. For information about impairments of intangible assets, see Note 4. For information about the assets acquired from InnoPharma and the Nexium OTC milestones, see Note 2A and Note 2B, respectively.
	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
			December 31, 2014
			GIP			VOC			GEP
	Developed technology rights		33	%		34	%		33	%
	Brands, finite-lived		—	%		80	%		20	%
	Brands, indefinite-lived		—	%		69	%		31	%
	In-process research and development		7	%		31	%		62	%
	Developed Technology Rights
	Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Prevnar 13/Prevenar 13 Infant and Enbrel and, to a lesser extent, Premarin, Prevnar 13/Prevenar 13 Adult, Effexor, Pristiq, Tygacil, Refacto AF and Benefix. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products.
	Brands
	Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. Most of these assets are associated with our Consumer Healthcare business unit. The more significant components of indefinite-lived brands are the following (in order of significance): Advil, Xanax/Xanax XR, Centrum, Medrol and Caltrate. The more significant components of finite-lived brands are the following (in order of significance): Nexium, Depo-Provera and, to a lesser extent, Advil Cold and Sinus and Idoform Bifiform.
	In-Process Research and Development
	IPR&D assets represent research and development assets that have not yet received regulatory approval in a major market. The more significant components of IPR&D are the programs for the treatment of staph aureus infections, as well as the sterile injectables IPR&D portfolio acquired as part of the InnoPharma acquisition.
	IPR&D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated research and development effort. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of in-process research and development and begin amortization. If the associated research and development effort is abandoned, the related IPR&D assets will likely be written-off, and we will record an impairment charge.
	For IPR&D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&D assets will become impaired and be written off at some time in the future.
	Amortization
	The weighted-average life of both our total finite-lived intangible assets and the largest component, developed technology rights, is approximately ten years. Total amortization expense for finite-lived intangible assets was $4.1 billion in 2014, $4.8 billion in 2013 and $5.3 billion in 2012.
	The following table provides the annual amortization expense expected for the years 2015 through 2019:
	(MILLIONS OF DOLLARS)		2015				2016				2017			2018			2019
	Amortization expense		$	3,665			$	3,413			$	3,311		$	3,203		$	2,888
	B. Goodwill
	Our businesses were previously managed through four operating segments (Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets and Consumer Healthcare) and are now managed through three different operating segments: the Global Innovative Pharmaceutical segment (GIP) ; the Global Vaccines, Oncology and Consumer Healthcare segment (VOC); and the Global Established Pharmaceutical segment (GEP). For additional information, see Note 18. As a result of this change, our goodwill was required to be reallocated to the new reporting units based on the relative fair value of the components transferred into the new reporting units. We have retrospectively presented goodwill according to the new operating segment structure.
	The following table provides the components of and changes in the carrying amount of Goodwill:
	(MILLIONS OF DOLLARS)		GIP				VOC				GEP			Total
	Balance, January 1, 2013		$	13,482			$	11,766			$	18,413		$	43,661
	Derecognition(a)		—				—				(292		)	(292		)
	Other(b)		(272		)		(207		)		(371		)	(850		)
	Balance, December 31, 2013		13,210				11,559				17,750			42,519
	Additions(c)		—				—				125			125
	Other(b)		(178		)		(161		)		(236		)	(575		)
	Balance, December 31, 2014		$	13,032			$	11,398			$	17,639		$	42,069
	(a)	Reflects the goodwill derecognized as part of the transfer of certain product rights, which constituted a business, to our equity-method investment in China. For additional information, see Note 2E.
	(b)	Primarily reflects the impact of foreign exchange.
	(c)	Reflects the acquisition of InnoPharma. For additional information, see Note 2A.

Pension_and_Postretirement_Ben

Pension and Postretirement Benefit Plans and Defined Contribution Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Postretirement Benefit Plans and Defined Contribution Plans	Pension and Postretirement Benefit Plans and Defined Contribution Plans
	The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both Internal Revenue Code-qualified and supplemental (non-qualified) defined benefit plans and contribution plans. A qualified plan meets the requirements of certain sections of the Internal Revenue Code, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans.
	A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)
	The following table provides the annual cost (including, for 2013 and 2012, costs reported as part of discontinued operations) and changes in Other comprehensive income/(loss) for our benefit plans:
			Year Ended December 31,
			Pension Plans
			U.S.											U.S.									International(c)									Postretirement
			Qualified(a)											Supplemental																		Plans(d)
														(Non-Qualified)(b)
	(MILLIONS OF DOLLARS)		2014				2013				2012			2014			2013			2012			2014			2013			2012			2014			2013			2012
	Service cost		$	253			$	301			$	357		$	20		$	26		$	35		$	199		$	216		$	215		$	55		$	61		$	68
	Interest cost		697				666				697			57			67			62			394			378			406			169			166			182
	Expected return on plan assets		(1,043		)		(999		)		(983		)	—			—			—			(459		)	(407		)	(424		)	(63		)	(55		)	(46		)
	Amortization of:
	Actuarial losses		63				355				306			29			51			41			97			129			93			6			46			33
	Prior service credits		(7		)		(7		)		(10		)	(2		)	(2		)	(3		)	(7		)	(5		)	(7		)	(57		)	(44		)	(49		)
	Curtailments		2				—				(62		)	—			—			(9		)	—			(20		)	(16		)	(7		)	(11		)	(65		)
	Settlements		52				113				145			28			40			33			22			22			7			—			—			—
	Special termination benefits		—				—				8			—			—			30			8			4			5			—			—			6
	Net periodic benefit costs reported in Income		16				429				458			132			182			189			254			317			279			102			163			129
	(Income)/cost reported in Other comprehensive income/(loss)(e)		2,768				(3,044		)		461			163			(255		)	110			260			(569		)	759			(174		)	(736		)	267
	(Income)/cost recognized in Comprehensive income		$	2,784			$	(2,615	)		$	919		$	294		$	(73	)	$	299		$	514		$	(252	)	$	1,038		$	(72	)	$	(573	)	$	396
	(a)	2014 v. 2013––The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses), (ii) lower service cost resulting from cost-reduction initiatives, (iii) lower settlement activity and (iv) greater expected return on plan assets resulting from an increased plan asset base, partially offset by higher interest costs resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation. 2013 v. 2012––The decrease in net periodic benefit cost for our U.S. qualified plans was primarily driven by (i) lower service cost resulting from cost reduction initiatives, (ii) lower settlements and (iii) higher expected return on plan assets resulting from an increased plan asset base, partially offset by the curtailment gain in 2012 resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico. Also, the decrease in the discount rate resulted in lower interest costs, as well as an increase in the amounts amortized for actuarial losses.
	(b)	2014 v. 2013––The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation, (ii) lower settlement activity and (iii) lower interest costs. 2013 v. 2012––The decrease in net periodic benefit cost for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) a decrease in special termination benefits, partially offset by (ii) an increase in the amounts amortized for actuarial losses resulting from a decrease in discount rates, and (iii) the curtailment gain in 2012 resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico.
	(c)	2014 v. 2013––The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) greater expected return on plan assets resulting from an increased plan asset base, (ii) the decrease in the amounts amortized for actuarial losses resulting from increases, in 2013, in the discount rates used to determine the benefit obligations, partially offset by (iii) increased curtailment losses primarily due to a loss relating to a U.K. pension plan freeze in the current year and (iv) changes in curtailments related to restructuring initiatives. 2013 v. 2012––The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from changes in assumptions, (ii) lower expected return on plan assets driven by lower expected rate of return in certain significant plans, (iii) higher settlements and (iv) 2012 curtailment gains, partially offset by (v) lower interest costs resulting from the decrease in discount rates.
	(d)	2014 v. 2013––The decrease in net periodic benefit costs for our postretirement plans was primarily driven by the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses). 2013 v. 2012––The increase in net periodic benefit cost for our postretirement plans was primarily driven by (i) 2012 curtailment gains, partially offset by (ii) higher expected return on plan assets and (iii) a decrease in special termination benefits. Also, the decrease in the discount rate resulted in (iv) lower interest costs, as well as (v) an increase in the amounts amortized for actuarial losses.
	(e)	For details of the changes in Other comprehensive income/(loss), see the benefit plan activity in the consolidated statements of comprehensive income.
	The following table provides the amounts in Accumulated other comprehensive loss expected to be amortized into 2015 net periodic benefit costs:
			Pension Plans
	(MILLIONS OF DOLLARS)		U.S.				U.S.				International			Postretirement
			Qualified				Supplemental							Plans
							(Non-Qualified)
	Actuarial losses		$	(330	)		$	(46	)		$	(133	)	$	(40	)
	Prior service credits and other		7				2				7			123
	Total		$	(324	)		$	(44	)		$	(126	)	$	84
	B. Actuarial Assumptions
	The following table provides the weighted-average actuarial assumptions of our benefit plans:
	(PERCENTAGES)		2014			2013			2012
	Weighted-average assumptions used to determine benefit obligations
	Discount rate:
	U.S. qualified pension plans		4.2	%		5.2	%		4.3	%
	U.S. non-qualified pension plans		4	%		4.8	%		3.9	%
	International pension plans		3	%		3.9	%		3.8	%
	Postretirement plans		4.2	%		5.1	%		4.1	%
	Rate of compensation increase:
	U.S. qualified pension plans		2.8	%		2.8	%		2.8	%
	U.S. non-qualified pension plans		2.8	%		2.8	%		2.8	%
	International pension plans		2.7	%		2.9	%		3.1	%
	Weighted-average assumptions used to determine net periodic benefit cost
	Discount rate:
	U.S. qualified pension plans		5.2	%		4.3	%		5.1	%
	U.S. non-qualified pension plans		4.8	%		3.9	%		5	%
	International pension plans		3.9	%		3.8	%		4.7	%
	Postretirement plans		5.1	%		4.1	%		4.8	%
	Expected return on plan assets:
	U.S. qualified pension plans		8.5	%		8.5	%		8.5	%
	International pension plans		5.8	%		5.6	%		5.9	%
	Postretirement plans		8.5	%		8.5	%		8.5	%
	Rate of compensation increase:
	U.S. qualified pension plans		2.8	%		2.8	%		3.5	%
	U.S. non-qualified pension plans		2.8	%		2.8	%		3.5	%
	International pension plans		2.9	%		3.1	%		3.3	%
	The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit obligations are established at each fiscal year-end.
	The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits.
The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at
which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to determine the discount rates at year-end 2014 exhibited lower interest rates as compared to the prior year.
The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:
		2014			2013
Healthcare cost trend rate assumed for next year		7	%		7.3	%
Rate to which the cost trend rate is assumed to decline		4.5	%		4.5	%
Year that the rate reaches the ultimate trend rate		2027			2027
The following table provides the effects as of December 31, 2014 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:
(MILLIONS OF DOLLARS)		Increase				Decrease
Effect on total service and interest cost components		$	15			$	(14	)
Effect on postretirement benefit obligation		228				(217		)
Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see Note 1C.
C. Obligations and Funded Status
The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans (including, for 2013, those reported as part of discontinued operations):
		Year Ended December 31,
		Pension Plans
		U.S. Qualified(a)								U.S. Supplemental						International(c)						Postretirement
										(Non-Qualified)(b)												Plans(d)
(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
Change in benefit obligation(e)
Benefit obligation, beginning		$	13,976			$	16,268			$	1,341		$	1,549		$	10,316		$	10,227		$	3,438		$	4,165
Service cost		253				301				20			26			197			216			55			61
Interest cost		697				666				57			67			393			378			169			166
Employee contributions		—				—				—			—			8			10			75			69
Plan amendments		—				—				—			—			(54		)	1			(692		)	(152		)
Changes in actuarial assumptions and other		2,653				(2,257		)		218			(165		)	1,346			229			447			(540		)
Foreign exchange impact		—				—				—			—			(794		)	(66		)	(10		)	(9		)
Acquisitions/divestitures, net		—				—				—			37			(55		)	(63		)	—			—
Curtailments		2				(8		)		—			(1		)	(127		)	(64		)	(4		)	(8		)
Settlements		(308		)		(444		)		(96		)	(105		)	(32		)	(156		)	—			—
Special termination benefits		—				—				—			—			8			4			—			—
Benefits paid		(697		)		(550		)		(58		)	(67		)	(408		)	(400		)	(309		)	(314		)
Benefit obligation, ending(e)		16,575				13,976				1,481			1,341			10,796			10,316			3,168			3,438
Change in plan assets
Fair value of plan assets, beginning		12,869				12,540				—			—			8,250			7,589			741			644
Actual gain on plan assets		819				1,318				—			—			1,046			976			45			98
Company contributions		23				5				154			172			316			380			210			244
Employee contributions		—				—				—			—			8			10			75			69
Foreign exchange impact		—				—				—			—			(594		)	(95		)	—			—
Acquisitions/divestitures, net		—				—				—			—			3			(54		)	—			—
Settlements		(308		)		(444		)		(96		)	(105		)	(32		)	(156		)	—			—
Benefits paid		(697		)		(550		)		(58		)	(67		)	(408		)	(400		)	(309		)	(314		)
Fair value of plan assets, ending		12,706				12,869				—			—			8,588			8,250			762			741
Funded status—Plan assets less than benefit obligation		$	(3,869	)		$	(1,107	)		$	(1,481	)	$	(1,341	)	$	(2,208	)	$	(2,066	)	$	(2,406	)	$	(2,697	)
(a)	The unfavorable change in the funded status of our U.S. qualified plans is primarily due to (i) a decrease in the discount rate (reflecting lower interest rates) and (ii) a change in mortality assumptions (reflecting a longer life expectancy for plan participants), which more than offset (iii) a gain on plan assets.
(b)	Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations.
(c)	The unfavorable change in the international plans' funded status was primarily due to (i) a decrease in the discount rate (reflecting lower interest rates), partially offset by (ii) the strengthening U.S. dollar and (iii) a gain on plan assets.
(d)	The favorable change in the funded status of our postretirement plans is due to (i) a plan amendment that decreased the benefit obligation by transferring certain plan participants to a retiree drug coverage program eligible for a Medicare Part D plan subsidy, partially offset by (ii) a decrease in the discount rate (reflecting lower interest rates).
(e)	For the U.S. and international pension plans, the benefit obligation is the projected benefit obligation. For the postretirement plans, the benefit obligation is the accumulated postretirement benefit obligation (ABO). The ABO for all of our U.S. qualified pension plans was $16.3 billion in 2014 and $13.7 billion in 2013. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2014 and $1.3 billion 2013. The ABO for our international pension plans was $10.3 billion in 2014 and $9.7 billion in 2013.
The following table provides information as to how the funded status is recognized in our consolidated balance sheets:
		As of December 31,
		Pension Plans
		U.S. Qualified								U.S. Supplemental						International						Postretirement
										(Non-Qualified)												Plans
(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
Noncurrent assets(a)		$	—			$	—			$	—		$	—		$	509		$	318		$	—		$	—
Current liabilities(b)		—				—				(136		)	(151		)	(45		)	(46		)	(27		)	(29		)
Noncurrent liabilities(c)		(3,869		)		(1,107		)		(1,345		)	(1,190		)	(2,671		)	(2,338		)	(2,379		)	(2,668		)
Funded status		$	(3,869	)		$	(1,107	)		$	(1,481	)	$	(1,341	)	$	(2,208	)	$	(2,066	)	$	(2,406	)	$	(2,697	)
(a)	Included primarily in Other noncurrent assets.
(b)	Included in Accrued compensation and related items.
(c)	Included in Pension benefit obligations, net and Postretirement benefit obligations, net, as appropriate.
The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
		As of December 31,
		Pension Plans
		U.S. Qualified								U.S. Supplemental						International						Postretirement
										(Non-Qualified)												Plans
(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
Actuarial losses(a)		$	(4,735	)		$	(1,974	)		$	(567	)	$	(406	)	$	(2,527	)	$	(2,213	)	$	(745	)	$	(292	)
Prior service (costs)/credits		35				42				10			11			36			(18		)	1,098			470
Total		$	(4,700	)		$	(1,932	)		$	(557	)	$	(395	)	$	(2,492	)	$	(2,231	)	$	352		$	178
(a)	The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants, using the corridor approach. The average amortization periods utilized are 9.5 years for our U.S. qualified plans, 9.4 years for our U.S. supplemental (non-qualified) plans, 17.4 years for our international plans, and 10.6 years for our postretirement plans.
The following table provides information related to the funded status of selected benefit plans:
		As of December 31,
		Pension Plans
		U.S. Qualified								U.S. Supplemental (Non-Qualified)						International
(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013
Pension plans with an accumulated benefit obligation in excess of plan assets:
Fair value of plan assets		$	12,706			$	12,869			$	—		$	—		$	1,718		$	1,309
Accumulated benefit obligation		16,323				13,704				1,447			1,294			4,021			3,348
Pension plans with a projected benefit obligation in excess of plan assets:
Fair value of plan assets		12,706				12,869				—			—			1,999			2,499
Projected benefit obligation		16,575				13,976				1,481			1,341			4,715			4,883
All of our U.S. plans and many of our international plans were underfunded as of December 31, 2014.
D. Plan Assets
The following table provides the components of plan assets:
						Fair Value(a)													Fair Value(a)
(MILLIONS OF DOLLARS)		As of December 31, 2014				Level 1				Level 2			Level 3			As of December 31, 2013			Level 1			Level 2			Level 3
U.S. qualified pension plans
Cash and cash equivalents		$	756			$	84			$	672		$	—		$	360		$	—		$	360		$	—
Equity securities:
Global equity securities		3,394				3,391				2			1			4,335			4,328			7			—
Equity commingled funds		1,845				—				1,698			147			2,294			—			2,294			—
Fixed Income securities:
Corporate debt securities		3,013				—				3,008			5			2,042			—			2,042			—
Government and agency obligations		1,124				—				1,124			—			1,235			—			1,235			—
Fixed income commingled funds		242				—				242			—			675			—			675			—
Other investments:
Partnership investments(c)		958				—				—			958			932			—			—			932
Insurance contracts		278				—				278			—			281			—			281			—
Other commingled funds(d)		1,096				—				—			1,096			715			—			—			715
Total		12,706				3,475				7,024			2,207			12,869			4,328			6,894			1,647
International pension plans
Cash and cash equivalents		331				25				306			—			229			—			229			—
Equity securities:
Global equity securities		1,781				1,674				107			—			1,833			1,832			1			—
Equity commingled funds		1,851				19				1,832			—			2,446			—			2,446			—
Fixed Income securities:
Corporate debt securities		773				183				590			—			614			—			614			—
Government and agency obligations		1,213				140				1,073			—			812			—			812			—
Fixed income commingled funds		1,037				44				969			24			968			—			968			—
Other investments:
Partnership investments(c)		61				—				6			55			69			—			5			64
Insurance contracts		425				1				150			274			421			—			121			300
Other(d)		1,116				46				326			744			858			—			358			500
Total		8,588				2,132				5,359			1,097			8,250			1,832			5,554			864
U.S. postretirement plans(b)
Cash and cash equivalents		18				1				17			—			29			—			29			—
Equity securities:
Global equity securities		89				89				—			—			105			105			—			—
Equity commingled funds		49				—				45			4			56			—			56			—
Fixed Income securities:
Corporate debt securities		79				—				79			—			50			—			50			—
Government and agency obligations		30				—				30			—			30			—			30			—
Fixed income commingled funds		6				—				6			—			16			—			16			—
Other investments:
Partnership investments(c)		25				—				—			25			23			—			23			—
Insurance contracts		437				—				437			—			415			—			415			—
Other commingled funds(d)		29				—				—			29			17			—			17			—
Total		$	762			$	90			$	614		$	58		$	741		$	105		$	636		$	—
(a)	Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E).
(b)	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
(c)	Primarily includes investments in private equity, private debt and, to a lesser extent, real estate and venture capital.
(d)	Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:
		Year Ended December 31,
		U.S. Qualified Pension Plans														International Pension Plans
		Partnership investments								Other commingled funds						Insurance contracts						Other
(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
Fair value, beginning		$	932			$	950			$	715		$	673		$	300		$	346		$	500		$	389
Actual return on plan assets:
Assets held, ending		104				86				47			18			23			15			47			13
Assets sold during the period		—				—				(7		)	(6		)	—			—			8			—
Purchases, sales and settlements, net		(78		)		(105		)		341			31			(20		)	(40		)	254			69
Transfer into/(out of) Level 3		—				—				—			—			—			(16		)	(19		)	27
Exchange rate changes		—				—				—			—			(29		)	(5		)	(46		)	2
Fair value, ending		$	958			$	932			$	1,096		$	715		$	274		$	300		$	744		$	500
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C.
Specifically, the following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:
•	Cash and cash equivalents, Equity commingled funds, Fixed-income commingled funds––observable prices.
•	Global equity securities—quoted market prices.
•	Government and agency obligations, Corporate debt securities—observable market prices.
•	Other investments—principally unobservable inputs that are significant to the estimation of fair value. These unobservable inputs could include, for example, the investment managers’ assumptions about earnings multiples and future cash flows.
We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness.
The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:
		As of December 31,
		Target			Percentage of Plan Assets
		Allocation Percentage
(PERCENTAGES)		2014			2014			2013
U.S. qualified pension plans
Cash and cash equivalents		0-10%			5.9	%		2.8	%
Equity securities		35-55%			41.2	%		51.5	%
Fixed Income securities		28-53%			34.5	%		30.7	%
Other investments		5-20%			18.4	%		15	%
Total		100	%		100	%		100	%
International pension plans
Cash and cash equivalents		0-10%			3.9	%		2.8	%
Equity securities		35-55%			42.3	%		51.9	%
Fixed Income securities		28-53%			35.2	%		29	%
Other investments		5-20%			18.6	%		16.3	%
Total		100	%		100	%		100	%
U.S. postretirement plans
Cash and cash equivalents		0-5%			2.4	%		4	%
Equity securities		10-35%			18.1	%		21.7	%
Fixed Income securities		5-30%			15.1	%		13	%
Other investments		55-70%			64.4	%		61.3	%
Total		100	%		100	%		100	%
Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to minimize net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.
Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans’ long-term benefit obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset classes and our liability profile.
The investment managers of certain commingled funds and private equity funds may be permitted to use derivative securities as described in each respective investment management, subscription, partnership or other governing agreement.
E. Cash Flows
It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.
The following table provides the expected future cash flow information related to our benefit plans:
		Pension Plans
(MILLIONS OF DOLLARS)		U.S. Qualified				U.S. Supplemental				International			Postretirement Plans
						(Non-Qualified)
Expected employer contributions:
2015(a)		$	1,000			$	136			$	227		$	91
Expected benefit payments:
2015		$	904			$	136			$	368		$	261
2016		870				118				376			211
2017		932				124				383			216
2018		1,021				129				390			220
2019		949				114				399			222
2020–2024		4,874				547				2,125			1,146
(a)	For the U.S. Qualified plan, the $1.0 billion voluntary contribution was paid in January 2015.
The table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation and, therefore, actual benefit payments may differ from projected benefit payments.
F. Defined Contribution Plans
We have defined contribution plans in the U.S. and several other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. Beginning on January 1, 2011, for new non-union employees in the U.S. or Puerto Rico, we no longer offer a defined benefit pension plan and, instead, offer an enhanced benefit under our defined contribution plans. The enhanced benefit consists of a non-contributory employer contribution determined based on each employee’s eligible compensation, age and years of service. We recorded charges related to the employer contributions to global defined contribution plans of $278 million in 2014, $266 million in 2013 and $297 million in 2012.

Equity

Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Equity	Equity
	A. Common Stock
	We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. Our December 2011 $10 billion share-purchase plan was exhausted in the first quarter of 2013. Our November 2012 $10 billion share-purchase plan was exhausted in the fourth quarter of 2013. On June 27, 2013, we announced that the Board of Directors had authorized an additional $10 billion share-purchase plan, and share purchases commenced thereunder in October 2013. On October 23, 2014, we announced that the Board of Directors had authorized an additional $11 billion share-purchase plan (the October 2014 Stock Purchase Plan). After giving effect to share purchases through year-end 2014, our remaining share-purchase authorization was approximately $11.5 billion at December 31, 2014.
	•	In 2014, we purchased approximately 165 million shares of our common stock for approximately $5.0 billion under our publicly announced share-purchase plans.
	•	In 2013, we purchased approximately 563 million shares of our common stock for approximately $16.3 billion under our publicly announced share-purchase plans. In addition, we exchanged all of our remaining interest in Zoetis for approximately 405.117 million shares of our common stock, valued at $11.4 billion. The common stock received in the exchange transaction was recorded in Treasury stock. For additional information, see Note 2D.
	•	In 2012, we purchased approximately 349 million shares of our common stock for approximately $8.2 billion under our publicly announced share-purchase plans.
	B. Preferred Stock
	The Series A convertible perpetual preferred stock is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of 6.25%, which are accumulated and paid quarterly. The per-share stated value is $40,300 and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder’s option, into 2,574.87 shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of $40,300 per share.
	C. Employee Stock Ownership Plans
	We have two employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP).
	Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for the earnings per share (EPS) calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of December 31, 2014, the Preferred ESOP held preferred shares convertible into approximately 2 million shares of our common stock, and the Common ESOP held approximately 61 million shares of our common stock. As of December 31, 2014, all shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. and certain Puerto Rico defined contribution plan participants. The compensation cost related to the common ESOPs was $136 million in 2014, $133 million in 2013 and $139 million in 2012.

ShareBased_Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments
	Our compensation programs can include share-based payments, in the form of Restricted Stock Units (RSUs), stock options, Portfolio Performance Shares (PPSs), Total Shareholder Return Units (TSRUs), Performance Share Awards (PSAs) and restricted stock grants.
	The 2014 Stock Plan (2014 Plan) replaced and superseded the 2004 Stock Plan (2004 Plan), as amended and restated. The 2014 Plan provides for 520 million shares to be authorized for grants, plus any shares remaining available for grant under the 2004 Plan as of April 24, 2014 (the carryforward shares). In addition, the 2014 Plan provides that the number of stock options, Stock Appreciation Rights (SARs) (known as TSRUs), RSUs, restricted stock awards or other performance-based awards that may be granted to any one individual during any 36-month period is limited to 20 million shares, and that RSUs, PPSs, PSAs and restricted stock grants count as 3 shares, while stock options and TSRUs count as 1 share, toward the maximum shares available under the 2014 plan. The 2004 Plan provided that the number of stock options, TSRUs or other performance-based awards granted to any one individual during any 36-month period was limited to 8 million shares, and that RSUs, PPSs, PSAs and restricted stock grants counted against the maximum available shares as 2 shares, while stock options and TSRUs counted as 1 share. As of December 31, 2014, 595 million shares were available for award.
	Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.
	A. Impact on Net Income
	The following table provides the components of share-based compensation expense and the associated tax benefit (including those reported as part of discontinued operations in 2013 and 2012):
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	Restricted Stock Units		$	270			$	249			$	235
	Stock Options		150				140				157
	Portfolio Performance Shares		96				56				14
	Total Shareholder Return Units		37				37				35
	Performance Share Awards		30				34				35
	Directors’ compensation		3				7				5
	Share-based payment expense		586				523				481
	Tax benefit for share-based compensation expense		(179		)		(173		)		(149		)
	Share-based payment expense, net of tax		$	407			$	350			$	332
	Amounts capitalized as part of inventory cost and the impact of modifications under our cost-reduction and productivity initiatives to share-based awards were not significant for any period presented. Generally, the modifications resulted in an acceleration of vesting, either in accordance with plan terms or at management’s discretion.
	B. Restricted Stock Units (RSUs)
	RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after three years of continuous service from the grant date.
	We measure the value of RSU grants as of the grant date using the closing price of Pfizer common stock. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
	The following table summarizes all RSU activity during 2014:
			Shares				Weighted-
			(Thousands)				Average
							Grant Date
							Fair Value
							Per Share
	Nonvested, December 31, 2013		32,751				$	22.5
	Granted		10,188				32.11
	Vested		(12,613		)		19.74
	Reinvested dividend equivalents		1,071				29.69
	Forfeited		(1,461		)		26.66
	Nonvested, December 31, 2014		$	29,936			$	26.99
	The following table provides data related to all RSU activity:
	(MILLIONS OF DOLLARS)		Year Ended December 31,
			2014				2013				2012
	Total fair value of shares vested		$	401			$	379			$	348
	Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax		$	255			$	239			$	258
	Weighted-average period over which RSU cost is expected to be recognized (years)		1.8				1.8				1.8
	C. Stock Options
	Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of Pfizer common stock at a price per share equal to the closing market price of Pfizer common stock on the date of grant.
	All eligible employees may receive stock option grants. No stock options were awarded to senior and other key management in any period presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted since 2005 vest after three years of continuous service from the grant date and have a contractual term of 10 years. In most cases, stock options must be held for at least one year from the grant date before any vesting may occur. In the event of a sale or restructuring, options held by employees are immediately vested and are exercisable for a period from three months to their remaining term, depending on various conditions.
	We measure the value of stock option grants as of the grant date using, for virtually all grants, the Black-Scholes-Merton option-pricing model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
	The following table provides the weighted-average assumptions used in the valuation of stock options:
			Year Ended December 31,
			2014			2013			2012
	Expected dividend yield(a)		3.18	%		3.45	%		4.1	%
	Risk-free interest rate(b)		1.94	%		1.16	%		1.28	%
	Expected stock price volatility(c)		19.76	%		19.68	%		23.78	%
	Expected term (years)(d)		6.5			6.5			6.5
	(a)	Determined using a constant dividend yield during the expected term of the option.
	(b)	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
	(c)	Determined using implied volatility, after consideration of historical volatility.
	(d)	Determined using historical exercise and post-vesting termination patterns.
	The following table summarizes all stock option activity during 2014:
			Shares			Weighted-Average				Weighted-Average		Aggregate
			(Thousands)			Exercise Price				Remaining		Intrinsic
						Per Share				Contractual		Value(a)
										Term		(Millions)
										(Years)
	December 31, 2013(b)		299,653			$	24.33
	Granted		44,599			32.23
	Exercised		(46,960	)		21.44
	Forfeited		(4,396	)		26.36
Expired		(43,784	)		36.85
Outstanding, December 31, 2014		249,112			24.05				5.9		$	1,815
Vested and expected to vest, December 31, 2014(c)		243,297			23.91				5.9		1,805
Exercisable, December 31, 2014		122,618			$	21.19			3.6		$	1,222
(a)	Market price of underlying Pfizer common stock less exercise price.
(b)	Includes approximately 42 million stock options which expired on February 25, 2014 at a grant price of $37.15, which were granted under the 2001 Stock Plan. These stock options were not added into the amount of carry forward shares remaining available for grants under the 2004 Stock Plan.
(c)	The number of options expected to vest takes into account an estimate of expected forfeitures.
The following table summarizes data related to all stock option activity:
		Year Ended December 31,
(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)		2014				2013				2012
Weighted-average grant date fair value per stock option		$	4.4			$	3.13			$	2.79
Aggregate intrinsic value on exercise		$	458			$	578			$	263
Cash received upon exercise		$	1,002			$	1,750			$	568
Tax benefits realized related to exercise		$	131			$	160			$	81
Total compensation cost related to nonvested stock options not yet recognized, pre-tax		$	147			$	120			$	148
Weighted-average period over which stock option compensation cost is expected to be recognized (years)		1.8				1.7				1.7
D. Portfolio Performance Shares (PPSs)
PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible range of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards vest after three years of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer's long-term product portfolio during a five-year performance period from the year of the grant date. The target number of shares is determined by reference to competitive survey data. The number of shares that may be earned over the performance period ranges from 0% to 200% of the initial award.
We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of Pfizer common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer's common stock, changes in the number of shares that are probable of being earned and changes in management's assessment of the probability that the specified performance criteria will be achieved and/or changes in management's
assessment of the probable vesting term.
The following table summarizes all PPS activity during 2014, with the shares representing the maximum award that could be achieved:
		Shares			Weighted-
		(Thousands)			Average
					Intrinsic Value
					Per Share
Nonvested, December 31, 2013		11,324			$	30.63
Granted		8,377			32.23
Vested(a)		(7	)		30.18
Forfeited		(817	)		30.1
Nonvested, December 31, 2014(a)		18,877			$	31.15
(a)Vested and non-vested shares outstanding, but not paid as of December 31, 2014 were 18,877.
The following table provides data related to all PPS activity:
(MILLIONS OF DOLLARS)		Year Ended December 31,
		2014				2013			2012
Total fair value of shares vested		$	—			$	—		$	—
Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax		$	139			$	107		$	33
Weighted-average period over which PPS cost is expected to be recognized (years)		1.8				2			2.2
E. Total Shareholder Return Units (TSRUs)
TSRUs are awarded to senior and other key management. TSRUs entitle the holders to receive a number of shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the five-year or seven-year term, if and to the extent the total value is positive. The settlement price is the average closing price of Pfizer common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of Pfizer common stock on the date of the grant.
The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture. The target number of shares is determined by reference to the fair value of share-based awards to similar employees in the industry peer group.
We measure the value of TSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.
The following table provides the weighted-average assumptions used in the valuation of TSRUs:
		Year Ended December 31,
		2014			2013			2012
Expected dividend yield(a)		3.18	%		3.45	%		4.1	%
Risk-free interest rate(b)		1.78	%		1.03	%		1.15	%
Expected stock price volatility(c)		19.76	%		19.68	%		23.8	%
Contractual term (years)		5.97			5.98			5.97
(a)	Determined using a constant dividend yield during the expected term of the TSRU.
(b)	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
(c)	Determined using implied volatility, after consideration of historical volatility.
The following table summarizes all TSRU activity during 2014:
		Share Units			Weighted-				Weighted-Average
		(Thousands)			Average				Grant Price Per Share Unit
					Grant Date
					Fair Value
					Per Share Unit
Nonvested, December 31, 2013		24,195			$	4.77			$	22.3
Granted		6,288			6.51				32.23
Vested		(8,727	)		4.74				19.38
Forfeited		(821	)		5.1				25.87
Nonvested, December 31, 2014		20,935			$	5.29			$	26.4
The following table summarizes all outstanding TSRU activity as of December 31, 2014(a):
		Share Units			Weighted-				Weighted-		Aggregate Intrinsic Value (Millions)
		(Thousands)			Average				Average
					Grant Price				Remaining Contractual Term (Years)
					Per Share Unit
Outstanding		34,842			$	23.41			3.1		$	360
Vested		13,907			18.92				1.6		220
Expected to vest		20,935			26.4				4.1		140
(a)	In 2014, we settled 5,124,197 share units with a weighted-average grant price of $14.67 per share unit.
The following table provides data related to all TSRU activity:
		Year Ended December 31,
(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)		2014				2013				2012
Weighted-average grant date fair value per TSRU		$	6.51			$	5.14			$	4.48
Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax		$	30			$	31			$	31
Weighted-average period over which TSRU cost is expected to be recognized (years)		1.8				1.6				1.7
F. Performance Share Awards (PSAs)
PSAs are awarded to senior and other key management. PSAs vest after three years of continuous service from the grant date. The number of shares paid, if any, including shares resulting from dividend equivalents, depends upon the achievement of predetermined goals related to Pfizer's total shareholder return as compared to an industry peer group, for the three-year performance period from the year of the grant date. The target number of shares is determined by reference to the value of share-based awards to similar employees in the industry peer group. The number of shares that are earned over the performance period ranges from 0% to 200% of the initial award.
We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of Pfizer common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer's common stock, changes in the number of shares that are probable of being earned and changes in management's assessment of the probability that the specified performance criteria will be achieved.
The following table summarizes all PSA activity during 2014, with the shares granted representing the maximum award that could be achieved:
		Shares			Weighted-Average
		(Thousands)			Intrinsic Value
					Per Share
Nonvested, December 31, 2013		5,039			$	30.63
Granted		1,202			32.17
Vested		(1,231	)		31.99
Forfeited		(920	)		31.74
Nonvested, December 31, 2014		4,090			$	31.15
The following table provides data related to all PSA activity:
		Year Ended December 31,
(MILLIONS OF DOLLARS)		2014				2013				2012
Total fair value of shares vested		$	39			$	40			$	13
Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax		$	21			$	25			$	27
Weighted-average period over which PSA cost is expected to be recognized (years)		1.7				1.7				1.7

Earnings_Per_Common_Share_Attr

Earnings Per Common Share Attributable to Common Shareholders	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share Attributable to Common Shareholders	Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
	The following table provides the detailed calculation of Earnings per common share (EPS):
			Year Ended December 31,
	(IN MILLIONS)		2014		2013		2012
	EPS Numerator––Basic
	Income from continuing operations		$	9,119	$	11,410	$	9,021
	Less: Net income attributable to noncontrolling interests		32		30		28
	Income from continuing operations attributable to Pfizer Inc.		9,087		11,380		8,993
	Less: Preferred stock dividends––net of tax		1		2		2
	Income from continuing operations attributable to Pfizer Inc. common shareholders		9,086		11,378		8,991
	Discontinued operations––net of tax		48		10,662		5,577
	Less: Discontinued operations––net of tax, attributable to noncontrolling interests		—		39		—
	Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders		48		10,623		5,577
	Net income attributable to Pfizer Inc. common shareholders		$	9,134	$	22,001	$	14,568
	EPS Numerator––Diluted
	Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		$	9,087	$	11,380	$	8,993
	Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		48		10,623		5,577
	Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$	9,135	$	22,003	$	14,570
	EPS Denominator
	Weighted-average number of common shares outstanding––Basic		6,346		6,813		7,442
	Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock		78		82		66
	Weighted-average number of common shares outstanding––Diluted		6,424		6,895		7,508
	Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(a)		44		43		177
	`
	(a)	These common stock equivalents were outstanding for the years ended December 31, 2014, 2013 and 2012, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease_Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Lease Commitments	Lease Commitments
	We lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay directly for taxes, insurance, maintenance and other operating expenses or to pay higher rent when operating expenses increase. Rental expense, net of sublease income, was $216 million in 2014, $233 million in 2013 and $301 million in 2012.
	The future minimum rental commitments under non-cancelable operating leases follow:
	(MILLIONS OF DOLLARS)	2015		2016		2017		2018		2019		After 2019
	Lease commitments	$	183	$	159	$	151	$	112	$	88	$	774

Insurance

Insurance	12 Months Ended
	Dec. 31, 2014
Insurance Coverage [Abstract]
Insurance	Insurance
	Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued (see Note 17).

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 5D.
	A. Legal Proceedings
	Our non-tax contingencies include, but are not limited to, the following:
	•	Patent litigation, which typically involves challenges to the coverage and/or validity of our patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in a loss of patent protection for the drug at issue, a significant loss of revenues from that drug and impairments of any associated assets.
	•	Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities-law, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.
	•	Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.
	•	Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries.
	Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.
	We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.
	We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
	Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
	The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the Company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.
	A1. Legal Proceedings––Patent Litigation
	Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed claiming that our assertions of, or attempts to enforce, our patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, we note that the patent rights to certain of our products are being challenged in various other countries. Also, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products.
	Actions In Which We Are The Plaintiff
	Viagra (sildenafil)
	In October 2010, we filed a patent-infringement action with respect to Viagra in the U.S. District Court for the Southern District of New York against Apotex Inc. and Apotex Corp., Mylan Pharmaceuticals Inc. (Mylan) and Mylan Inc. and Actavis, Inc. These generic drug manufacturers have filed abbreviated new drug applications with the FDA seeking approval to market their generic versions of Viagra. They assert the invalidity and non-infringement of the Viagra method-of-use patent, which expires in 2020 (including the six-month pediatric exclusivity period resulting from the Company’s conduct of clinical studies to evaluate Revatio in the treatment of pediatric patients with pulmonary arterial hypertension; Viagra and Revatio have the same active ingredient, sildenafil).
	In May and June 2011, Watson Laboratories Inc. (Watson) and Hetero Labs Limited (Hetero), respectively, notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market their generic versions of Viagra. Each asserts the invalidity and non-infringement of the Viagra method-of-use patent. In June and July 2011, we filed actions against Watson and Hetero, respectively, in the U.S. District Court for the Southern District of New York asserting the validity and infringement of the Viagra method-of-use patent.
	Sutent (sunitinib malate)
	In May 2010, Mylan notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Sutent and challenging on various grounds the Sutent basic patent, which expires in 2021, and two other patents that expire in 2020 and 2021, respectively. In June 2010, we filed suit against Mylan in the U.S. District Court for the District of Delaware asserting the infringement of those three patents. The patent expiring in 2020 was dismissed from the case prior to trial. In October 2014, the court held that the two patents expiring in 2021 were valid and infringed. In October 2014, Mylan appealed the decision to the U.S. Court of Appeals for the Federal Circuit.
	Lyrica (pregabalin)
	In May and June 2011, Apotex Inc. notified us that it had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Lyrica oral solution and Lyrica capsules, respectively. Apotex Inc. asserts the invalidity and non-infringement of the basic patent, as well as the seizure patent that expired in October 2013. In July 2011, we filed an action against Apotex Inc. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the challenged patents in connection with both abbreviated new drug applications. In January 2015, the District Court entered a stipulated dismissal, and as a result, Apotex Inc. cannot obtain FDA approval for, or market in the U.S., its generic versions of Lyrica prior to the expiration of the basic patent in December 2018.
	EpiPen
	In July 2010, King Pharmaceuticals, Inc. (King), which we acquired in 2011 and is a wholly owned subsidiary, brought a patent-infringement action against Sandoz, Inc., a division of Novartis AG (Sandoz), in the U.S. District Court for the District of New Jersey in connection with Sandoz's abbreviated new drug application with the FDA that seeks approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.
	Celebrex (celecoxib)
	In March 2013, the U.S. Patent and Trademark Office granted us a reissue patent covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex. The reissue patent, including the six-month pediatric exclusivity period, expires in December 2015. On the date that the reissue patent was granted, we filed suit against Teva Pharmaceuticals USA, Inc. (Teva USA), Mylan, Watson (as predecessor to Actavis plc), Lupin Pharmaceuticals USA, Inc. (Lupin), Apotex Corp. and Apotex Inc. in the U.S. District Court for the Eastern District of Virginia, asserting the infringement of the reissue patent. Each of the defendant generic drug companies had previously filed an abbreviated new drug application with the FDA seeking approval to market a generic version of celecoxib beginning in May 2014, upon the expiration of the basic patent (including the six-month pediatric exclusivity period) for celecoxib. In March 2014, the court granted the defendants’ motion for summary judgment, invalidating the reissue patent. In May 2014, we appealed the District Court's decision to the U.S. Court of Appeals for the Federal Circuit.
	In April 2014, we entered into settlement agreements with two of the defendants, Teva USA and Watson, pursuant to which we granted licenses to the reissue patent permitting Teva USA and Watson to launch generic versions of celecoxib in the U.S. beginning in December 2014. In June 2014 and October 2014, we entered into settlement agreements with Mylan and Lupin, respectively, pursuant to which we granted licenses to the reissue patent permitting Mylan and Lupin to launch generic versions of celecoxib in the U.S. beginning in December 2014. In December 2014, Teva USA, Watson, Mylan and Lupin commenced marketing of generic versions of celecoxib.
	Toviaz (fesoterodine)
	We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH, which owns the patents relating to Toviaz.
	Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019; and a patent covering salts of fesoterodine that expires in 2022.
	Tygacil (tigecycline)
	In September 2013, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Tygacil. Apotex Inc. asserts the non-infringement of the polymorph patent for Tygacil that expires in 2030, but has not challenged the basic patent, which expires in 2016. In September 2013, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware asserting the infringement of the polymorph patent.
	In May 2014, CFT Pharmaceuticals LLC (CFT) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Tygacil. CFT asserts the invalidity and non-infringement of (i) the polymorph patent for Tygacil and (ii) the formulation patent for Tygacil that expires in 2029, but has not challenged the basic patent. In June 2014, we filed suit against CFT in the U.S. District Court for the District of Delaware asserting the validity and infringement of the polymorph patent and the formulation patent for Tygacil.
	In May 2014, Aurobindo Pharma Limited (Aurobindo) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Tygacil. Aurobindo asserts the invalidity and non-infringement of (i) the polymorph patent for Tygacil, and (ii) the formulation patent for Tygacil, but has not challenged the basic patent. In July 2014, we filed suit against Aurobindo in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the polymorph patent and the formulation patent for Tygacil.
	Action In Which Our Licensing Partner Is The Plaintiff
	Nexium 24HR (esomeprazole)
	We have an exclusive license to market in the U.S. the over-the-counter version of Nexium from AstraZeneca (Nexium 24HR). Beginning in October 2014, Actavis Laboratories FL, Inc., and then subsequently Andrx Labs, LLC (Andrx), and Perrigo Company plc (Perrigo), notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca’s patents listed in the FDA Orange Book for Nexium 24HR. In November 2014, December 2014 and February 2015, AstraZeneca filed actions against Actavis Laboratories FL, Inc., Andrx and Perrigo, respectively, in the U.S. District Court for the District of New Jersey asserting the infringement of the challenged patents. We are not a party to AstraZeneca’s patent-infringement action.
	Action In Which We Are The Defendant
	Effexor XR (venlafaxine HCI)
	In 2006, Wyeth and Wyeth Canada Limited (the Wyeth companies) filed an action in the Federal Court in Canada against Ratiopharm Inc. (Ratiopharm) seeking to prevent Ratiopharm from obtaining approval in Canada for its generic version of Effexor XR prior to the expiration of one of the Wyeth companies’ patents. As a result of that action, Ratiopharm was enjoined from obtaining regulatory approval for its generic product. However, in August 2007, the Federal Court of Appeal in Canada ruled that the patent at issue could not be asserted against Ratiopharm under the applicable Canadian regulations governing approvals, and it dismissed the Wyeth companies’ action.
	Following the dismissal, in 2007, Ratiopharm filed an action in the Federal Court in Canada seeking damages from the Wyeth companies for preventing Ratiopharm from marketing its generic version of Effexor XR in Canada from January 2006 through August 2007. The Federal Court dismissed Ratiopharm’s action in 2011, but the Federal Court of Appeal reinstated it in 2012. In 2011 and 2012, Pfizer made payments to Teva Canada Limited, which had acquired Ratiopharm, totaling Canadian dollars 52.5 million in partial settlement of this action.
	The trial in this action was held in January 2014, and the court issued various findings in March 2014. On June 30, 2014, the Federal Court in Canada issued a judgment based on those findings, awarding Teva Canada Limited damages of approximately Canadian dollars 125 million, consisting of compensatory damages, pre-judgment interest and legal costs. This judgment was satisfied by Pfizer Canada Inc., as successor to the Wyeth companies, in July 2014. In September 2014, Pfizer Canada Inc. appealed the judgment.
	A2. Legal Proceedings––Product Litigation
	Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.
	Asbestos
	Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of December 31, 2014, approximately 61,000 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is now a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.
	Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products containing asbestos and other allegedly hazardous materials sold by Gibsonburg Lime Products Company (Gibsonburg). Gibsonburg was acquired by Pfizer in the 1960s and sold products containing small amounts of asbestos until the early 1970s.
	There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.
	Celebrex and Bextra
	Beginning in late 2004, several purported class actions were filed in federal and state courts alleging that Pfizer and certain of our current and former officers violated federal securities laws by misrepresenting the safety of Celebrex and Bextra. In June 2005, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Pfizer Inc. Securities, Derivative and “ERISA” Litigation MDL-1688) in the U.S. District Court for the Southern District of New York. In March 2012, the court in the Multi-District Litigation certified a class consisting of all persons who purchased or acquired Pfizer stock between October 31, 2000 and October 19, 2005. In May 2014, the court in the Multi-District Litigation granted Pfizer’s motion to exclude the testimony of the plaintiffs’ loss causation and damages expert. We subsequently filed a motion for summary judgment seeking dismissal of the litigation, and the plaintiffs filed a motion for leave to submit an amended report by their expert. In July 2014, the court denied the plaintiffs’ motion for leave to submit an amended report, and granted our motion for summary judgment, dismissing the plaintiffs’ claims in their entirety. In August 2014, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Second Circuit.
	Various Drugs: Off-Label Promotion Action
	In May 2010, a purported class action was filed in the U.S. District Court for the Southern District of New York against Pfizer and several of our current and former officers. The complaint alleges that the defendants violated federal securities laws by making or causing Pfizer to make false statements, and by failing to disclose or causing Pfizer to fail to disclose material information concerning the alleged off-label promotion of certain pharmaceutical products, alleged payments to physicians to promote the sale of those products and government investigations related thereto. Plaintiffs seek damages in an unspecified amount. In March 2012, the court certified a class consisting of all persons who purchased Pfizer common stock in the U.S. or on U.S. stock exchanges between January 19, 2006 and January 23, 2009 and were damaged as a result of the decline in the price of Pfizer common stock allegedly attributable to the claimed violations. In January 2015, the parties reached an agreement in principle to resolve the matter for $400 million. The agreement is subject to court approval and other conditions.
	Various Drugs: Foreign Corrupt Practices Act Compliance
	In February 2013, a shareholder derivative action was filed in the Supreme Court of the State of New York, County of New York, against certain current and former officers and directors of Pfizer. Pfizer is named as a nominal defendant. The complaint alleged that the individual defendants breached their fiduciary duties to the Company as the result of, among other things, inadequate oversight of compliance by Pfizer subsidiaries in various countries outside the U.S. with the U.S. Foreign Corrupt Practices Act. The plaintiff sought damages in unspecified amounts and other unspecified relief on behalf of Pfizer. In November 2014, the court granted defendants’ motions to dismiss the complaint in its entirety.
	Effexor
	•	Personal Injury Actions
	A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Effexor (Venlafaxine Hydrochloride) Products Liability Litigation MDL-2458) in the U.S. District Court for the Eastern District of Pennsylvania.
	•	Antitrust Actions
	Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR, enforcing certain patents for Effexor XR, and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey.
	In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs have appealed to the United States Court of Appeals for the Third Circuit. Motions to dismiss remain pending as to the end-payer plaintiffs' remaining claims.
	Zoloft
	A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Zoloft Products Liability Litigation MDL-2342) in the U.S. District Court for the Eastern District of Pennsylvania.
	Neurontin
A number of lawsuits, including purported class actions, have been filed against us in various federal and state courts alleging claims arising from the promotion and sale of Neurontin. The plaintiffs in the purported class actions seek to represent nationwide and certain statewide classes consisting of persons, including individuals, health insurers, employee benefit plans and other third-party payers, who purchased or reimbursed patients for the purchase of Neurontin that allegedly was used for indications other than those included in the product labeling approved by the FDA. In 2004, many of the suits pending in federal courts, including individual actions as well as purported class actions, were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Neurontin Marketing, Sales Practices and Product Liability Litigation MDL-1629) in the U.S. District Court for the District of Massachusetts.
In the Multi-District Litigation, the District Court (i) denied the plaintiffs’ motion for certification of a nationwide class of all individual consumers and third-party payers who allegedly purchased or reimbursed patients for the purchase of Neurontin for off-label uses from 1994 through 2004, and (ii) dismissed actions by certain proposed class representatives for third-party payers and for individual consumers. In April 2013, the U.S. Court of Appeals for the First Circuit reversed the decision of the District Court dismissing the action by the third-party payer proposed class representatives and remanded that action to the District Court for further consideration, including reconsideration of class certification.
In December 2013, the U.S. Supreme Court denied our petition for certiorari seeking review of the First Circuit's decision reversing the dismissal of the third-party payer purported class action. In April 2014, we and the attorneys for the proposed class representatives and for the plaintiffs in various individual actions entered into an agreement-in-principle to settle the third-party payer purported class action, subject to court approval, as well as the pending individual actions by third-party payers, for an aggregate of $325 million. In November 2014, the District Court granted final approval of the settlement. Plaintiffs’ counsel have agreed to dismiss with prejudice all Neurontin marketing lawsuits by consumers, including the purported statewide consumer class actions in California and Illinois. Some counsel have advised that certain plaintiffs can no longer be located.
Lipitor
•	Whistleblower Action
In 2004, a former employee filed a “whistleblower” action against us in the U.S. District Court for the Eastern District of New York. The complaint remained under seal until September 2007, at which time the U.S. Attorney for the Eastern District of New York declined to intervene in the case. We were served with the complaint in December 2007. Plaintiff alleges off-label promotion of Lipitor in violation of the Federal Civil False Claims Act and the false claims acts of certain states, and he seeks treble damages and civil penalties on behalf of the federal government and the specified states as the result of their purchase, or reimbursement of patients for the purchase, of Lipitor allegedly for such off-label uses. Plaintiff also seeks compensation as a whistleblower under those federal and state statutes. In addition, plaintiff alleges that he was wrongfully terminated, in violation of the anti-retaliation provisions of applicable federal and New York law, and he seeks damages and the reinstatement of his employment. In 2009, the District Court dismissed without prejudice the off-label promotion claims and, in 2010, plaintiff filed an amended complaint containing off-label promotion allegations that are substantially similar to the allegations in the original complaint. In November 2012, the District Court dismissed the amended complaint. In December 2012, plaintiff appealed the District Court's decision to the U.S. Court of Appeals for the Second Circuit. In August 2014, the U.S. Court of Appeals for the Second Circuit dismissed the appeal for lack of jurisdiction, and sent the case back to the District Court for clarification of its ruling regarding the plaintiff's employment claims. In November 2014, the District Court granted plaintiff’s motion for a partial final judgment certifying the dismissal of the false claims counts, and plaintiff appealed the order dismissing those claims to the U.S. Court of Appeals for the Second Circuit.
•	Antitrust Actions
Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (In re Lipitor Antitrust Litigation MDL-2332) in the U.S. District Court for the District of New Jersey.
In September 2013 and 2014, the District Court dismissed the claims by direct purchasers. In October 2014, the direct purchaser plaintiffs: (i) filed a motion to amend the judgment and for leave to amend their complaint and (ii) appealed the District Court’s decision to the United States Court of Appeals for the Third Circuit. In October and November 2014, the District Court dismissed the claims of all other MDL plaintiffs, who subsequently appealed in November and December 2014 the District Court’s decision to the United States Court of Appeals for the Third Circuit.
Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.
•	Personal Injury Actions
A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502) in the U.S. District Court for the District of South Carolina.
Chantix/Champix
Beginning in December 2008, purported class actions were filed against us in the Ontario Superior Court of Justice (Toronto Region), the Superior Court of Quebec (District of Montreal), the Court of Queen’s Bench of Alberta, Judicial District of Calgary, and the Superior Court of British Columbia (Vancouver Registry) on behalf of all individuals and third-party payers in Canada who have purchased and ingested Champix or reimbursed patients for the purchase of Champix. Each of these actions asserts claims under Canadian product liability law, including with respect to the safety and efficacy of Champix, and, on behalf of the putative class, seeks monetary relief, including punitive damages. In June 2012, the Ontario Superior Court of Justice certified the Ontario proceeding as a class action, defining the class as consisting of the following: (i) all persons in Canada who ingested Champix during the period from April 2, 2007 to May 31, 2010 and who experienced at least one of a number of specified neuropsychiatric adverse events; (ii) all persons who are entitled to assert claims in respect of Champix pursuant to Canadian legislation as the result of their relationship with a class member; and (iii) all health insurers who are entitled to assert claims in respect of Champix pursuant to Canadian legislation. The Ontario Superior Court of Justice certified the class against Pfizer Canada Inc. only and ruled that the action against Pfizer should be stayed until after the trial of the issues that are common to the class members. The actions in Quebec, Alberta and British Columbia have been stayed in favor of the Ontario action, which is proceeding on a national basis.
Celebrex
Beginning in July 2014, purported class actions were filed in the United States District Court for the Eastern District of Virginia against Pfizer and certain subsidiaries of Pfizer relating to Celebrex. The plaintiffs seek to represent U.S. nationwide or multi-state classes consisting of persons or entities who directly purchased from the defendants, or indirectly purchased or reimbursed patients for some or all of the purchase price of, Celebrex or generic Celebrex from May 31, 2014 until the cessation of the defendants’ allegedly unlawful conduct. The plaintiffs allege delay in the launch of generic Celebrex in violation of federal antitrust laws or certain state antitrust, consumer protection and various other laws as a result of Pfizer fraudulently obtaining and improperly listing a patent on Celebrex, engaging in sham litigation, and prolonging the impact of sham litigation through settlement activity that further delayed generic entry. Each of the actions seeks treble damages on behalf of the putative class for alleged price overcharges for Celebrex since May 31, 2014. In December 2014, the District Court granted the parties’ joint motions to consolidate the direct purchaser and end-payor cases, and consolidation will be sought for cases in accordance with that order.
Reglan
Reglan is a pro-motility medicine for the treatment of gastroesophageal reflux disease and diabetic gastroparesis that was marketed by Wyeth and a predecessor company from 1979 until the end of 2001, when Wyeth sold the product and transferred the new drug application to another pharmaceutical company. Generic versions of Reglan have been sold by other companies since 1985. Pfizer, as Wyeth’s parent company, and certain wholly owned subsidiaries and limited liability companies, including Wyeth, along with several other pharmaceutical manufacturers, have been named as defendants in numerous actions in various federal and state courts alleging personal injury resulting from the use of Reglan and/or generic equivalents thereof. Plaintiffs in these actions seek to hold the defendants, including Pfizer and its affiliated companies, liable for a variety of personal injuries, including movement disorders such as Tardive Dyskinesia, allegedly resulting from the ingestion of Wyeth’s product and/or products sold by other companies. A substantial majority of the claims involve the ingestion of generic versions of Reglan produced and sold by other companies. Claims against Pfizer and its affiliated companies are largely based on the novel theory of innovator liability under which plaintiffs allege that an innovator pharmaceutical company can be liable for injuries caused by the ingestion of generic forms of the product produced and sold by other companies. This theory of liability has been rejected by more than 100 federal and state courts, applying the laws of 30 states. However, a small number of courts have adopted the theory, including the Alabama Supreme Court in August 2014. Actions have been filed under the laws of those jurisdictions, including Alabama, and additional actions may be filed in the future.
A3. Legal Proceedings––Commercial and Other Matters
Average Wholesale Price Litigation
Pfizer, certain of its subsidiaries and other pharmaceutical manufacturers were sued in various state courts by a number of states alleging that the defendants provided average wholesale price (AWP) information for certain of their products that was higher than the actual average prices at which those products were sold. The AWP is used to determine reimbursement levels under Medicare Part B and Medicaid and in many private-sector insurance policies and medical plans. All but two of those actions have been resolved through settlement, dismissal or final judgment. The plaintiff states in the two remaining actions claim that the alleged spread between the AWPs at which purchasers were reimbursed and the actual sale prices was promoted by the defendants as an incentive to purchase certain of their products. In addition to suing on their own behalf, the two states seek to recover on behalf of individuals, private-sector insurance companies and medical plans in their states. These actions allege, among other things, fraud, unfair competition, unfair trade practices and the violation of consumer protection statutes, and seek monetary and other relief, including civil penalties and treble damages.
Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia Corporation (Pharmacia). Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is now a wholly owned subsidiary of Pfizer.
In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto is defending and indemnifying Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business.
In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto's chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto's chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia's and New Monsanto's assumption of, and agreement to, indemnify Pharmacia for these liabilities apply to pending actions and any future actions related to Former Monsanto's chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and New Monsanto are defending and indemnifying Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses.
Trade Secrets Action in California
In 2004, Ischemia Research and Education Foundation (IREF) and its chief executive officer brought an action in California Superior Court, Santa Clara County, against a former IREF employee and Pfizer. Plaintiffs allege that defendants conspired to misappropriate certain information from IREF’s allegedly proprietary database in order to assist Pfizer in designing and executing a clinical study of a Pfizer drug. In 2008, the jury returned a verdict for compensatory damages of approximately $38.7 million. In March 2009, the court awarded prejudgment interest, but declined to award punitive damages. In July 2009, the court granted our motion for a new trial and vacated the jury verdict. In February 2013, the trial court's decision was affirmed by the California Court of Appeal, Sixth Appellate District. In May 2013, the action was remanded for further proceedings to the California Superior Court, Santa Clara County. We do not expect this litigation to have a material adverse effect on our financial position.
Environmental Matters
In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia Corporation's discontinued industrial chemical facility in North Haven, Connecticut and a revised site-wide feasibility study with regard to Wyeth Holdings Corporation's discontinued industrial chemical facility in Bound Brook, New Jersey. In September 2010, our corrective measures study report with regard to the North Haven facility was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility's main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. The estimated costs of the site remedy for the North Haven facility and the site remediation for the Bound Brook facility are covered by accruals previously taken by us.
We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.
A4. Legal Proceedings––Government Investigations
Like other pharmaceutical companies, we are subject to extensive regulation by national, state and local government agencies in the U.S. and in the other countries in which we operate. As a result, we have interactions with government agencies on an ongoing basis. It is possible that criminal charges and substantial fines and/or civil penalties could result from government investigations. Among the investigations by government agencies is the matter discussed below.
In 2009, the U.S. Department of Justice (DOJ) filed a civil complaint in intervention in two qui tam actions that had been filed under seal in the U.S. District Court for the District of Massachusetts. The complaint alleges that Wyeth’s practices relating to the pricing for Protonix for Medicaid rebate purposes between 2001 and 2006, prior to Wyeth's acquisition by Pfizer, violated the Federal Civil False Claims Act and federal common law. The two qui tam actions have been unsealed and the complaints include substantially similar allegations. In addition, in 2009, several states and the District of Columbia filed a complaint under the same docket number asserting violations of various state laws based on allegations substantially similar to those set forth in the civil complaint filed by the DOJ.
A5. Legal Proceedings––Certain Matters Resolved During 2014
As previously reported, during 2014, certain matters, including the matters discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.
Neurontin Antitrust Actions
In January 2011, in a Multi-District Litigation (In re Neurontin Antitrust Litigation MDL-1479) that consolidated four actions, the U.S. District Court for the District of New Jersey certified a nationwide class consisting of wholesalers and other entities who purchased Neurontin directly from Pfizer and Warner-Lambert during the period from December 11, 2002 to August 31, 2008 or who purchased generic gabapentin after it became available. The complaints alleged that Pfizer and Warner-Lambert engaged in anticompetitive conduct in violation of the Sherman Act. In April 2014, the parties entered into an agreement to settle this action for $190 million. In addition, in July 2014, Pfizer, Warner-Lambert and certain direct purchasers who opted out of the certified class entered into an agreement-in-principle to settle two actions pending in the District Court of New Jersey, that assert allegations substantially similar to those in the class, on terms not material to Pfizer.
Lyrica (pregabalin)
Beginning in March 2009, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Lyrica capsules and, in the case of one generic drug manufacturer, Lyrica oral solution. Each of the generic drug manufacturers challenged one or more of three patents for Lyrica: the basic patent, which expires in 2018, and two other patents, one of which expired in October 2013 and the other of which expires in 2018. Each of the generic drug manufacturers asserted the invalidity and/or the non-infringement of the patents subject to challenge. Beginning in April 2009, we filed actions against these generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement and validity of our patents for Lyrica, and all of these cases were consolidated in the District of Delaware. In July 2012, the court held that all three patents were valid and infringed. In August 2012, the generic drug manufacturers appealed the decision to the U.S. Court of Appeals for the Federal Circuit. In February 2014, the Federal Circuit affirmed the decision of the District Court with respect to the validity and enforcement of one claim of the basic patent and determined, on the ground of mootness, that it did not have to render a decision on any other issues raised on appeal, including with respect to the other patent that expires in 2018. The generic drug manufacturers' time to file a petition for certiorari requesting a review by the U.S. Supreme Court expired in May 2014. As a result, the generic drug manufacturers cannot obtain FDA approval for their generic versions of Lyrica or market those products in the U.S. prior to the expiration of the basic patent in 2018.
In November 2010 and December 2012, Novel Laboratories, Inc. (Novel) and Wockhardt Limited (Wockhardt), respectively, notified us that they had each filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Lyrica oral solution. Novel asserted the invalidity and/or non-infringement of our three patents for Lyrica referred to in the paragraph above. Wockhardt asserted the invalidity and non-infringement of the basic patent. In October 2011, Alembic Pharmaceuticals Limited (Alembic) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Lyrica capsules and asserting the invalidity of the basic patent. In December 2011, January 2011 and January 2013, we filed actions against each of Alembic, Novel and Wockhardt, respectively, in the U.S. District Court for the District of Delaware, asserting the validity and infringement of our patents. Each of Novel, Alembic and Wockhardt agreed to a stay of the respective actions described above and to be bound by any final judgment of infringement and validity of the patents at issue in the consolidated action discussed in the paragraph above. In late May and early June 2014, the District Court entered consent judgments against Novel, Alembic and Wockhardt, and, as a result, these generic drug manufacturers cannot obtain FDA approval for their generic versions of Lyrica or market their products in the U.S. prior to the expiration of the basic patent in December 2018.
Bapineuzumab
In June 2010, a purported class action was filed in the U.S. District Court for the District of New Jersey against Pfizer, as successor to Wyeth, and several former officers of Wyeth. The complaint alleged that Wyeth and the individual defendants violated federal securities laws by making or causing Wyeth to make false and misleading statements, and by failing to disclose or causing Wyeth to fail to disclose material information, concerning the results of a clinical trial involving bapineuzumab, a product in development for the treatment of Alzheimer’s disease. The plaintiff sought to represent a class consisting of all persons who purchased Wyeth securities from May 21, 2007 through July 2008 and sought damages in an unspecified amount on behalf of the putative class. In February 2012, the court granted the defendants’ motion to dismiss the complaint. In December 2012, the court granted the plaintiff's motion to file an amended complaint. In April 2013, the court granted the defendants' motion to dismiss the amended complaint. In May 2013, the plaintiff appealed the District Court's decision to the U.S. Court of Appeals for the Third Circuit. In June 2014, the U.S. Court of Appeals for the Third Circuit affirmed the District Court's decision to dismiss the complaint. The plaintiff’s time to file a petition for certiorari requesting a review by the U.S. Supreme Court expired in September 2014.
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2014, recorded amounts for the estimated fair value of these indemnifications were not significant.
Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.
C. Purchase Commitments
As of December 31, 2014, we had agreements totaling $4.1 billion to purchase goods and services that are enforceable and legally binding and include amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur.

Segment_Geographic_and_Other_R

Segment, Geographic and Other Revenue Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information
	A. Segment Information
	We manage our commercial operations through a global commercial structure consisting of two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operating segments, each of which is led by a single manager––the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP), which is led by a single manager. Each operating segment has responsibility for its commercial activities and for certain in-process research and development (IPR&D) projects for new investigational products and additional indications for in-line products that generally have achieved proof of concept. Each business has a geographic footprint across developed and emerging markets. We have restated prior-period information (Revenues and Earnings, as defined by management, and Depreciation and Amortization) to conform to the current management structure. As our operations were not managed under the new structure until the beginning of fiscal 2014, certain costs and expenses could not be directly attributed to one of the new operating segments. As a result, our operating segment results for 2013 include allocations. The amounts subject to allocation methods in 2013 were approximately $2.1 billion of selling, informational and administrative expenses and approximately $800 million of research and development expenses. The amounts subject to allocation methods in 2012 were approximately $2.3 billion of selling, informational and administrative expenses and approximately $990 million of research and development expenses:
	•	The selling, informational and administrative expenses were allocated using proportional allocation methods based on associated selling costs, revenues or product-specific costs, as applicable.
	•	The research and development expenses were allocated based on product-specific R&D costs or revenue metrics, as applicable.
	Management believes that the allocations are reasonable.
	We regularly review our segments and the approach used by management to evaluate performance and allocate resources.
	Operating Segments
	Some additional information about each segment follows:
	•	Global Innovative Pharmaceutical segment––GIP is focused on developing, registering and commercializing novel, value-creating medicines that significantly improve patients’ lives. These therapeutic areas include inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health and include leading brands, such as Xeljanz, Eliquis and Lyrica (U.S., Japan). GIP has a pipeline of medicines in inflammation, cardiovascular/metabolic disease, neuroscience and pain, and rare diseases.
	•	Global Vaccines, Oncology and Consumer Healthcare segment––VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets several well known, OTC products. Each of the three businesses in VOC operates as a separate, global business with distinct specialization in terms of the science and market approach necessary to deliver value to consumers and patients.
	•	Global Established Pharmaceutical segment––GEP includes the brands that have lost market exclusivity and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets and, to a much smaller extent, generic pharmaceuticals. Additionally, GEP includes our sterile injectable products and biosimilar development portfolio.
	Our chief operating decision maker uses the revenues and earnings of the three operating segments, among other factors, for performance evaluation and resource allocation.
	Other Costs and Business Activities
	Certain costs are not allocated to our operating segment results, such as costs associated with the following:
	•	Worldwide Research and Development (WRD), which is generally responsible for research projects until proof-of-concept is achieved and then for transitioning those projects to the appropriate operating segment for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. This organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.
	•	Pfizer Medical, which is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, partnerships with global public health and medical associations, regulatory inspection readiness reviews, internal audits of Pfizer-sponsored clinical trials and internal regulatory compliance processes.
	•	Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments.
	•	Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.
	•	Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, which include non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.
	Segment Assets
	We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $169 billion as of December 31, 2014 and approximately $172 billion as of December 31, 2013.
	Selected Income Statement Information
	The following table provides selected income statement information by reportable segment:
			Revenues									Earnings(a)									Depreciation and Amortization(b)
			Year Ended December 31,									Year Ended December 31,									Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012			2014			2013			2012			2014		2013		2012
	Reportable Segments:
	Global Innovative Pharmaceutical (GIP)		$	13,861		$	14,317		$	13,756		$	7,780		$	8,549		$	8,325		$	255	$	238	$	250
	Global Vaccines, Oncology and Consumer Healthcare (VOC)		10,144			9,285			8,991			4,692			4,216			3,597			263		231		270
	Global Established Pharmaceutical (GEP)		25,149			27,619			31,678			16,199			17,552			19,910			475		478		595
	Total reportable segments		49,154			51,221			54,426			28,671			30,318			31,832			993		947		1,115
	Other business activities(c)		253			232			231			(3,092		)	(2,828		)	(2,888		)	91		105		117
	Reconciling Items:
	Corporate(d)		—			—			—			(5,200		)	(5,689		)	(6,059		)	384		432		546
	Purchase accounting adjustments(d)		—			—			—			(3,641		)	(4,344		)	(4,905		)	3,782		4,487		4,988
	Acquisition-related costs(d)		—			—			—			(183		)	(376		)	(946		)	53		124		273
	Certain significant items(e)		198			132			—			(3,749		)	(692		)	(5,039		)	207		167		300
	Other unallocated		—			—			—			(567		)	(671		)	(751		)	27		44		55
			$	49,605		$	51,584		$	54,657		$	12,240		$	15,716		$	11,242		$	5,537	$	6,306	$	7,394
	(a)	Income from continuing operations before provision for taxes on income.
	(b)	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
	(c)	Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
	(d)	For a description, see the "Other Costs and Business Activities" section above.
	(e)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
	For Revenues in 2014, certain significant items primarily represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $32 million, (ii) charges for certain legal matters of $999 million, (iii) certain asset impairments of $440 million, (iv) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (v) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (vi) upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vii) charges for business and legal entity alignment of $168 million and (viii) other charges of $197 million. For additional information, see Note 2C, Note 3 and Note 4.
	For Revenues in 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2013, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $16 million, (ii) patent litigation settlement income of $1.3 billion, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iv) net charges for certain legal matters of $21 million, (v) certain asset impairments of $836 million, (vi) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vii) costs associated with the separation of Zoetis of $18 million and (viii) other charges of $306 million. For additional information, see Note 3 and Note 4.
	For Earnings in 2012, certain significant items includes: (i) net charges for certain legal matters of $2.2 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.8 billion, (iii) certain asset impairment charges of $875 million, (iv) costs associated with the separation of Zoetis of $125 million and (v) other charges of $19 million. For additional information, see Note 3 and     Note 4.
	Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments.
	B. Geographic Information
	Revenues exceeded $500 million in each of 13, 12 and 14 countries outside the U.S. in 2014, 2013 and 2012, respectively. The U.S. is the only country to contribute more than 10% of total revenue in 2014. The U.S. and Japan were the only countries to contribute more than 10% of total revenue in 2013 and 2012.
	The following table provides revenues by geographic area:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	United States		$	19,073		$	20,274		$	21,313
	Developed Europe(a)		11,719			11,739			12,545
	Developed Rest of World(b)		7,314			8,346			9,956
	Emerging Markets(c)		11,499			11,225			10,843
	Revenues		$	49,605		$	51,584		$	54,657
	(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $9.0 billion in 2014, $8.9 billion in 2013 and $9.4 billion in 2012.
	(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
	(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.
Long-lived assets by geographic region follow:
		As of December 31,
(MILLIONS OF DOLLARS)		2014			2013			2012
Property, plant and equipment, net
United States		$	5,575		$	5,885		$	6,485
Developed Europe(a)		4,606			4,845			4,895
Developed Rest of World(b)		617			696			816
Emerging Markets(c)		963			971			1,017
Property, plant and equipment, net		$	11,762		$	12,397		$	13,213
(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.
(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.
C. Other Revenue Information
Significant Customers
We sell our biopharmaceutical products primarily to customers in the wholesale sector. In 2014, sales to our three largest U.S. wholesaler customers represented approximately 13%, 10% and 9% of total revenues, respectively, and, collectively, represented approximately 24% of total accounts receivable as of December 31, 2014. In 2013, sales to our three largest U.S. wholesaler customers represented approximately 12%, 9% and 8% of total revenues, respectively, and, collectively, represented approximately 20% of total accounts receivable as of December 31, 2013. For both years, these sales and related accounts receivable were concentrated in our biopharmaceutical businesses.
Significant Product Revenues
The following table provides detailed revenue information:
			Year Ended December 31,
(MILLIONS OF DOLLARS)	Business(a)		2014			2013			2012
Biopharmaceutical revenues:
Lyrica(b)	GEP/GIP		$	5,168		$	4,595		$	4,158
Prevnar family	V		4,464			3,974			4,117
Enbrel (Outside the U.S. and Canada)	GIP		3,850			3,774			3,737
Celebrex	GEP		2,699			2,918			2,719
Lipitor	GEP		2,061			2,315			3,948
Viagra(c)	GEP/GIP		1,685			1,881			2,051
Zyvox	GEP		1,352			1,353			1,345
Sutent	O		1,174			1,204			1,236
Norvasc	GEP		1,112			1,229			1,349
Premarin family	GEP		1,076			1,092			1,073
BeneFIX	GIP		856			832			775
Vfend	GEP		756			775			754
Pristiq	GEP		737			698			630
Genotropin	GIP		723			772			832
Chantix/Champix	GIP		647			648			670
Refacto AF/Xyntha	GIP		631			602			584
Xalatan/Xalacom	GEP		495			589			806
Medrol	GEP		443			464			523
Xalkori	O		438			282			123
Zoloft	GEP		423			469			541
Inlyta	O		410			319			100
Relpax	GEP		382			359			368
Fragmin	GEP		364			359			381
Sulperazon	GEP		354			309			262
Effexor	GEP		344			440			425
Rapamune	GIP		339			350			346
Tygacil	GEP		323			358			335
Zithromax/Zmax	GEP		314			387			435
Xeljanz	GIP		308			114			6
Zosyn/Tazocin	GEP		303			395			484
EpiPen	GEP		294			273			263
Toviaz	GIP		288			236			207
Revatio	GEP		276			307			534
Cardura	GEP		263			296			338
Xanax/Xanax XR	GEP		253			276			274
Inspra	GEP		233			233			214
Somavert	GIP		229			217			197
BMP2	GIP		228			209			263
Diflucan	GEP		220			242			259
Neurontin	GEP		210			216			235
Unasyn	GEP		207			212			228
Detrol/Detrol LA	GEP		201			562			761
Depo-Provera	GEP		201			191			148
Protonix/Pantoprazole	GEP		198			185			188
Dalacin/Cleocin	GEP		184			199			232
Caduet	GEP		180			223			258
Alliance revenues(d)	GEP/GIP		957			2,628			3,492
All other GIP	GIP		469			540			332
All other GEP	GEP		6,175			6,614			7,442
All other V/O	V/O		211			164			236
Total biopharmaceutical revenues	GEP/GIP/V/O		45,708			47,878			51,214
Other revenues:
Consumer Healthcare	C		3,446			3,342			3,212
Other(e)			451			364			231
Revenues			$	49,605		$	51,584		$	54,657
(a)	Indicates the business to which the revenues relate. GIP =he Global Innovative Pharmaceutical segment; V=he Global Vaccines
business; O=he Global Oncology business; C =he global Consumer Healthcare business; and GEP =he Global Established Pharmaceutical segment.
(b)	Lyrica revenues from all of Europe are included in GEP. All other Lyrica revenues are included in GIP.
(c)	Viagra revenues from the U.S. and Canada are included in GIP. All other Viagra revenues are included in GEP.
(d)	Includes Enbrel (GIP, in the U.S. and Canada through October 31, 2013), Spiriva (GEP), Rebif (GIP), Aricept (GEP) and Eliquis (GIP).
(e)	Other primarily includes revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and also includes the revenues related to our transitional manufacturing and supply agreements with Zoetis.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events
	A. Agreement to Acquire Hospira, Inc. (Hospira)
	On February 5, 2015, we announced that we have entered into a definitive merger agreement under which we agreed to acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 per share in cash, for a total enterprise value of approximately $17 billion. We expect to finance the transaction through a combination of existing cash and new debt, with approximately two-thirds of the value financed from cash and one-third from debt. The transaction is subject to customary closing conditions, including regulatory approvals in several jurisdictions and the approval of Hospira's shareholders, and is expected to close in the second half of 2015.
	B. Acquisition of Marketed Vaccines Business of Baxter International Inc. (Baxter)
	On December 1, 2014 (which falls in the first fiscal quarter of 2015 for our international operations), we completed the acquisition of Baxter's portfolio of marketed vaccines for $635 million. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. We also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been completed.
	C. Collaboration with OPKO Health, Inc. (OPKO)
	On December 13, 2014, we entered into a collaborative agreement with OPKO to develop and commercialize OPKO’s long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. The transaction closed on January 28, 2015, upon termination of the Hart-Scott-Rodino waiting period. In February 2015, we made an upfront payment of $295 million to OPKO and OPKO is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. We have received the exclusive license to commercialize hGH-CTP worldwide. In addition, OPKO is eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for Adult GHD, which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalties will transition to tiered gross profit sharing for both hGH-CTP and our product, Genotropin. OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which includes Adult and Pediatric GHD and Pediatric SGA. We will be responsible for all development costs for additional indications as well as all post-marketing studies. In addition, we will fund the commercialization activities for all indications and lead the manufacturing activities covered by the global development plan.
	D. Accelerated Share Repurchase Agreement
	On February 9, 2015, we entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of our common stock. Approximately 150 million of the shares to be repurchased under the transaction were received by us on February 11, 2015. At settlement of the agreement, which is expected to occur during or prior to the third quarter of 2015, GS&Co. may be required to deliver additional shares of common stock to us, or, under certain circumstances, we may be required to deliver shares of our common stock or may elect to make a cash payment to GS&Co., with the number of shares to be delivered or the amount of such payment based on the difference between the volume-weighted average price, less a discount, of our common stock during the term of the transaction and the initial $5 billion paid. This agreement was entered into pursuant to our previously announced share repurchase authorization.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).
Consolidation	The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the United States (U.S.), the financial information is included as of and for the year ended November 30 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Taxes paid on intercompany sales transactions are deferred until recognized upon sale of the asset to a third party.
Adoption of New Accounting Standards	We adopted the following new accounting and disclosure standards as of January 1, 2014 and there were no impacts to our consolidated financial statements:
	•	A new standard that clarified the accounting for cumulative translation adjustment (CTA) upon derecognition of a group of assets that is a business or an equity-method investment within a foreign entity.
	•	A new standard regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings.
Estimates and Assumptions	In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired in-process research & development (IPR&D) assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income.
	Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.
	As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our financial statements on a prospective basis, unless they are required to be treated retrospectively under relevant accounting standards. It is possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.
Acquisitions	Our consolidated financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed.
	Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net.
	Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
Fair Value	We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.
	When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:
	•	Income approach, which is based on the present value of a future stream of net cash flows.
	•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
	•	Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.
	Our fair value methodologies depend on the following types of inputs:
	•	Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
	•	Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
	•	Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
	A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
Foreign Currency Translation	For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss). The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.
Revenues	Revenue Recognition—We record revenues from product sales when the goods are shipped and title passes to the customer. At the time of sale, we also record estimates for a variety of revenue deductions, such as rebates, chargebacks, sales allowances and sales returns. When we cannot reasonably estimate the amount of future sales returns and/or other revenue deductions, we record revenues when the risk of product return and/or additional revenue deductions has been substantially eliminated.
	Deductions from Revenues––Our gross product revenues are subject to a variety of deductions, that generally are estimated and recorded in the same period that the revenues are recognized, and primarily represent rebates, chargebacks and sales allowances to government agencies, wholesalers/distributors and managed care organizations with respect to our pharmaceutical products. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period.
	Specifically:
	•	In the U.S., we record provisions for pharmaceutical Medicare, Medicaid, and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.
	•	Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds, and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.
	•	Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability.
	•	Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.
	•	We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.
	Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, and sales returns and cash discounts totaled $3.4 billion as of December 31, 2014, of which approximately $2.0 billion is included in Other current liabilities, $300 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, and sales returns and cash discounts totaled $3.3 billion as of December 31, 2013, of which approximately $2.1 billion is included in Other current liabilities, $234 million is included in Other noncurrent liabilities and approximately $1.0 billion is included against Accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet.
	Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
	Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues.
	Collaborative Arrangements—Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded when our collaboration partners ship the product and title passes to their customer. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when our collaboration partners sell the product and title passes to their customers. All royalty payments to collaboration partners are included in Cost of sales.
Accounts Receivable	Accounts Receivable—Accounts receivable are stated at their net realizable value. The allowance against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
Cost of Sales and Inventories	We carry inventories at the lower of cost or market. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.
Selling, Informational and Administrative Expenses	Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.
	Advertising expenses totaled approximately $3.1 billion in 2014, $3.0 billion in 2013 and $2.8 billion in 2012. Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs.
Research and Development Expenses	Research and development (R&D) costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
Property, Plant and Equipment
	•	Property, plant and equipment, less accumulated depreciation—These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
Goodwill and Intangible Assets	Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
	We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
	Specifically:
	•	For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate.
	•	For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.
	•	For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.
	Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
	•	Identifiable intangible assets, less accumulated amortization—These acquired assets are recorded at cost. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the European Union (EU), or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.
	•	Goodwill—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.
Property, Plant and Equipment, Impairment	We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
Restructuring Charges and Certain Acquisition-Related Costs	We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. (If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate). Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other costs incurred in connection with a business acquisition are expensed as incurred.
Cash Equivalents	Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments.
Cash Equivalents and Statement of Cash Flows	Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.
Investments	Our investments are comprised of the following: trading securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and ability to hold the investment to maturity) and private equity investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.
	•	Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.
	•	Available-for-sale debt and equity securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.
	•	Held-to-maturity debt securities are carried at amortized cost.
	•	Private equity securities are carried at equity-method or cost. For equity investments where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity method, we record our share of the investee's income and expenses in Other (income)/deductions—net. The excess of the cost of the investment over our share of the equity of the investee as of the acquisition date is allocated to the identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not include amounts of contingent consideration.
	Realized gains or losses on sales of investments are determined by using the specific identification cost method.
	We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Derivative Financial Instruments	Derivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E).
Deferred Tax Assets and Liabilities and Income Tax Contingencies	Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All current deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount and all noncurrent deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount.
	We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.
	Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to more-likely-than-not; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision for taxes on income and are classified on our consolidated balance sheet with the related tax liability.
Pension and Postretirement Benefit Plans	The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both qualified and supplemental (non-qualified) defined benefit and defined contribution plans, as well as other postretirement benefit plans consisting primarily of healthcare and life insurance for retirees. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic benefit costs are recognized, as required, into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.
Legal and Environmental Contingencies	We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Share-Based Payments	Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.

Acquisitions_Licensing_Agreeme1

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
	The following table provides the amounts and classification of payments (income/(expense)), between us and our collaboration partners:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Revenues—Revenues(a)		$	786		$	1,153		$	1,640
	Revenues—Alliance revenues(b)		957			2,628			3,492
	Total revenues from collaborative arrangements		1,743			3,781			5,132
	Cost of sales(c)		(280		)	(333		)	(362		)
	Selling, informational and administrative expenses(d)		(268		)	(279		)	(290		)
	Research and development expenses(e)		(1,210		)	(73		)	(74		)
	Other income/(deductions)—net(f)		518			103			(15		)
	(a)	Represents sales to our partners of products manufactured by us.
	(b)	Substantially all relates to amounts earned from our partners under co-promotion agreements. The decline in 2014 and 2013 reflects declines in alliance revenues from Enbrel (as a result of the expiration of the co-promotion term of the collaboration agreement on October 31, 2013 in the U.S. and Canada) and Spiriva (as a result of the expiration of the co-promotion collaboration in the U.S. and certain European countries during 2014, combined with the expiration of the collaboration in Australia, Canada and certain other European countries during 2013).
	(c)	Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners.
	(d)	Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
	(e)	Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $1.2 billion in 2014 (related to collaboration with Merck KGaA, see below), $67 million in 2013 and $44 million in 2012.
	(f)	In 2014 and 2013, includes royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and we became entitled to royalties for a 36-month period thereafter.
Schedule of Discontinued Operations-Net of Tax	Total Discontinued Operations
	The following table provides the components of Discontinued operations—net of tax:
			Year Ended December 31,(a)
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Revenues		$	—		$	2,201		$	6,587
	Pre-tax income from discontinued operations(a), (b)		(9		)	408			1,253
	Provision for taxes on income(b), (c)		(3		)	100			459
	Income from discontinued operations––net of tax		(6		)	308			794
	Pre-tax gain on disposal of discontinued operations(b)		51			10,446			7,123
	Provision for taxes on income(b), (d)		(4		)	92			2,340
	Gain on disposal of discontinued operations––net of tax(b)		55			10,354			4,783
	Discontinued operations––net of tax		$	48		$	10,662		$	5,577
	(a)	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.
	(b)	Includes post-close adjustments for the periods subsequent to disposal.
	(c)	Includes a deferred tax benefit of $3 million for 2014, $23 million for 2013 and $23 million for 2012, which is net of a deferred tax expense of $42 million in 2012 related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries indefinitely.
	(d)	For 2013, primarily reflects income tax expense of $122 million resulting from certain legal entity reorganizations. For 2012, includes a deferred tax expense of $1.4 billion, which includes a deferred tax expense of $2.2 billion on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas. For 2012, also includes a deferred tax benefit reflecting the reversal of net deferred tax liabilities associated with the divested Nutrition assets.

Restructuring_Charges_and_Othe1

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Restructuring charges(a):
	Employee terminations		$	68		$	805		$	953
	Asset impairments		45			165			325
	Exit costs		58			68			150
	Total restructuring charges		170			1,038			1,428
	Transaction costs(b)		—			—			1
	Integration costs(c)		80			144			381
	Restructuring charges and certain acquisition-related costs		250			1,182			1,810
	Additional depreciation––asset restructuring recorded in our
	consolidated statements of income as follows(d):
	Cost of sales		228			178			257
	Selling, informational and administrative expenses		1			19			20
	Research and development expenses		31			94			296
	Total additional depreciation––asset restructuring		261			291			573
	Implementation costs recorded in our consolidated statements of income as follows(e):
	Cost of sales		78			53			31
	Selling, informational and administrative expenses		140			145			130
	Research and development expenses		52			33			231
	Other (income)/deductions––net		1			—			—
	Total implementation costs		270			231			392
	Total costs associated with acquisitions and cost-reduction/productivity initiatives		$	781		$	1,704		$	2,775
	(a)	In 2014, Employee terminations represent the expected reduction of the workforce by approximately 1,700 employees, mainly in manufacturing and sales.
	The restructuring charges in 2014 are associated with the following:
	•	Global Innovative Pharmaceutical segment (GIP) ($35 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($28 million); the Global Established Pharmaceutical segment (GEP) ($57 million); Worldwide Research and Development and Medical ($37 million); manufacturing operations ($97 million); and Corporate ($65 million), as well as $149 million of income related to the partial reversal of prior-period restructuring charges, that we are unable to directly associate with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.
	The restructuring charges in 2013 are associated with the following:
	•	Total operating segments ($496 million); Worldwide Research and Development and Medical ($13 million); manufacturing operations ($356 million); and Corporate ($173 million).
	At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
	The restructuring charges in 2012 are associated with the following:
	•	Total operating segments ($640 million); Worldwide Research and Development and Medical ($6 million income); manufacturing operations ($281 million); and Corporate ($513 million).
	At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
	(b)	Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.
	(c)	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
	(d)	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
	(e)	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Restructuring Reserve by Type of Cost
	The following table provides the components of and changes in our restructuring accruals:
	(MILLIONS OF DOLLARS)		Employee			Asset			Exit Costs			Accrual
			Termination			Impairment
			Costs			Charges
	Balance, January 1, 2013		$	1,734		$	—		$	152		$	1,886
	Provision		805			165			68			1,038
	Utilization and other(a)		(854		)	(165		)	(126		)	(1,145		)
	Balance, December 31, 2013(b)		1,685			—			94			1,779
	Provision		68			45			58			170
	Utilization and other(a)		(639		)	(45		)	(100		)	(783		)
	Balance, December 31, 2014(c)		$	1,114		$	—		$	52		$	1,166
	(a)	Includes adjustments for foreign currency translation.
	(b)	Included in Other current liabilities ($1.0 billion) and Other noncurrent liabilities ($767 million).
	(c)	Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).

Other_IncomeDeductions_Net_Tab

Other (Income)/Deductions - Net (Tables)	12 Months Ended
	Dec. 31, 2014
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)
	The following table provides components of Other (income)/deductions––net:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Interest income(a)		$	(425	)	$	(403	)	$	(382	)
	Interest expense(a)		1,360			1,414			1,522
	Net interest expense		935			1,011			1,140
	Royalty-related income(b)		(1,002		)	(523		)	(451		)
	Patent litigation settlement income(c)		—			(1,342		)	—
	Other legal matters, net(d)		993			35			2,220
	Gain associated with the transfer of certain product rights(e)		—			(459		)	—
	Net gains on asset disposals(f)		(288		)	(320		)	(52		)
	Certain asset impairments(g)		469			878			890
	Business and legal entity alignment costs(h)		168			—			—
	Costs associated with the Zoetis IPO(i)		—			18			125
	Other, net(j)		(265		)	170			150
	Other (income)/deductions––net		$	1,009		$	(532	)	$	4,022
	(a)	2014 v. 2013––Interest income increased due to higher cash equivalents and investment balances. Interest expense decreased, primarily due to the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. 2013 v. 2012––Interest income increased due to higher investment balances. Interest expense decreased due to lower outstanding debt, refinancings at lower rates, and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. Capitalized interest expense totaled $41 million in 2014, $32 million in 2013 and $41 million in 2012.
	(b)	Royalty-related income increased in 2014 and 2013 primarily due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and Pfizer became entitled to royalties for a 36-month period thereafter.
	(c)	In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.
	(d)	In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million for an agreement in principle to resolve a securities class action pending against Pfizer in New York federal court, which is subject to court approval, and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable. For additional information, see Note 17A. In 2012, primarily includes a $491 million charge relating to the resolution of an investigation by the U.S. Department of Justice into Wyeth's historical promotional practices in connection with Rapamune, a $450 million settlement of a lawsuit by Brigham Young University related to Celebrex, and charges related to hormone-replacement therapy litigation and Chantix litigation.
	(e)	In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.
	(f)	In 2014, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $76 million; (ii) gross realized gains on sales of available-for-sale debt securities of $138 million; (iii) gross realized losses on sales of available-for-sale debt securities of $436 million; (iv) net gain of $323 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of approximately $135 million; and (vi) gains on sales of investments in private equity securities of approximately $39 million. Proceeds from the sale of available-for-sale securities were $10.2 billion in 2014.
	In 2013, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $87 million; (ii) gross realized gains on sales of available-for-sale debt securities of $442 million; (iii) gross realized losses on sales of available-for-sale debt securities of $310 million; (iv) net loss of $137 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; and (v) a gain of $170 million on the sale of various product rights, including a portion of our in-licensed generic sterile injectables portfolio. Proceeds from the sale of available-for-sale securities were $15.2 billion in 2013.
	In 2012, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $2 million; (ii) gross realized gains on sales of available-for-sale debt securities of $212 million; (iii) gross realized losses on sales of available-for-sale debt securities of $535 million; and (iv) net gain of $351 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale securities. Proceeds primarily from the sale of available-for-sale securities were $19.0 billion in 2012.
	(g)	In 2014, includes intangible asset impairment charges of $396 million, reflecting (i) $190 million for an IPR&D compound for the treatment of skin fibrosis (full write-off); (ii) $159 million for developed technology rights, primarily related to Quillivant XR; and (iii) $47 million for indefinite-lived brands. The intangible asset impairment charges for 2014 are associated with the following: the Global Innovative Pharmaceutical segment ($12 million); Global Established Pharmaceutical segment ($166 million); Worldwide Research and Development ($190 million); and Consumer Healthcare ($28 million). In addition, 2014 includes an impairment charge of approximately $56 million related to our investment in Teuto.
	The intangible asset impairment charges for 2014 reflect, among other things, updated commercial forecasts; and with regard to IPR&D, the impact of changes to the development program and new scientific findings.
	In 2013, includes intangible asset impairment charges of $803 million, reflecting (i) $394 million of developed technology rights (for use in the development of bone and cartilage) acquired in connection with our acquisition of Wyeth; (ii) $227 million related to IPR&D compounds; (iii) $109 million of indefinite-lived brands, primarily related to our biopharmaceutical indefinite-lived brand Xanax/Xanax XR; and (iv) $73 million of other finite-lived intangible assets, related to platform technology, that no longer have an alternative future use. The intangible asset impairment charges for 2013 are associated with the following: the Global Innovative Pharmaceutical segment ($448 million); the Global Established Pharmaceutical segment ($201 million); Worldwide Research and Development ($140 million); and Consumer Healthcare ($14 million). In addition, 2013 includes an impairment charge of approximately $43 million for certain private company investments and an impairment charge of $32 million related to our investment in Teuto.
	The intangible asset impairment charges for 2013 reflect, among other things, updated commercial forecasts and, with regard to IPR&D, also reflect the impact of new scientific findings and delayed launch dates.
	In 2012, includes intangible asset impairment charges of $835 million, reflecting (i) $393 million of IPR&D assets, primarily related to compounds that targeted autoimmune and inflammatory diseases (full write-off) and, to a lesser extent, compounds related to pain treatment; (ii) $175 million related to our Consumer Healthcare indefinite-lived brand assets, primarily Robitussin, a cough suppressant; (iii) $242 million related to developed technology rights, a charge composed of impairments of various products, none of which individually exceeded $45 million; and (iv) $25 million of finite-lived brands. The impairment charges in 2012 are associated with the following: Worldwide Research and Development ($303 million); Consumer Healthcare ($200 million); the Global Innovative Pharmaceutical segment ($173 million); and the Global Established Pharmaceutical segment ($159 million). In addition, in 2012, also includes charges of approximately $55 million for certain investments. These investment impairment charges reflect the difficult global economic environment.
	The intangible asset impairment charges for 2012 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, an increased competitive environment and litigation uncertainties regarding intellectual property.
	(h)	Represents expenses for planning and implementing changes to our infrastructure to operate our new business segments.
	(i)	Represents costs incurred in connection with the IPO of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. For additional information, see Note 2D.
	(j)	Includes the following: (i) in 2014, the gain of approximately $43 million reflecting the change in the fair value of the contingent consideration associated with our acquisition of NextWave and the gain of approximately $89 million reflecting the change in the fair value of the contingent consideration associated with our acquisition of Excaliard Pharmaceuticals, Inc., and in 2013, the gain of approximately $114 million, reflecting the change in the fair value of the contingent consideration associated with our acquisition of NextWave; (ii) in 2013, an estimated loss of $223 million related to an option to acquire the remaining interest in Teuto, and in 2014, income of $55 million resulting from a decline in the estimated loss from the aforementioned option; and (iii) in 2014, a loss of $30 million due to a change in our ownership interest in ViiV, in 2013, a loss of $32 million due to a change in our ownership interest in ViiV and in 2012, a gain of $44 million as a result of ViiV's transaction with Shionogi & Co., Ltd and the resulting change in ownership. For additional information concerning NextWave, see Note 2A. For additional information concerning Teuto and ViiV, see Note 2E.
Schedule of Additional Information About Intangible Assets Impaired
	The following table provides additional information about the intangible assets that were impaired during 2014 in Other (income)/deductions––net :
														Year Ended December 31,
			Fair Value(a)											2014
	(MILLIONS OF DOLLARS)		Amount			Level 1			Level 2			Level 3		Impairment
	Intangible assets––IPR&D(b)		$	—		$	—		$	—		$	—	$	190
	Intangible assets––Developed technology rights(b)		233			—			—			233		159
	Intangible assets––Indefinite-lived Brands(b)		293			—			—			293		47
	Total		$	526		$	—		$	—		$	526	$	396
	(a)	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
	(b)	Reflects intangible assets written down to fair value in 2014. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then we applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax_Matters_Tables

Tax Matters (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign
	The following table provides the components of Income from continuing operations before provision for taxes on income:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	United States		$	(4,744	)		$	(1,678	)		$	(5,148	)
	International		16,984				17,394				16,390
	Income from continuing operations before provision for taxes on income(a), (b)		$	12,240			$	15,716			$	11,242
	(a)	2014 v. 2013––The increase in the domestic loss was primarily due to lower revenues, the non-recurrence of income from a litigation settlement in 2013 with Teva and Sun for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S., higher charges related to other legal matters, a non-tax deductible charge in the third quarter of 2014 to account for an additional year of the Branded Prescription Drug Fee in accordance with final regulations issued by the U.S. Internal Revenue Service (IRS), higher research and development expenses, and higher charges for business and legal entity alignment costs, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, and lower asset impairments. The decrease in international income is primarily related to lower revenues, the non-recurrence of the gain associated with the transfer of certain product rights to Pfizer’s equity-method investment in China (Hisun Pfizer) in 2013, and higher research and development expenses, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives and the non-recurrence of certain charges.
	(b)	2013 v. 2012––The decrease in the domestic loss was primarily due to income from a litigation settlement in the second quarter of 2013 with Teva and Sun for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S., lower charges related to other legal matters, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, partially offset by lower revenues. The increase in international income is primarily related to the gain associated with the transfer of certain product rights to Hisun Pfizer in 2013, lower charges related to other legal matters, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives and lower amortization of intangible assets, partially offset by lower revenues and higher asset impairments and other charges.
Schedule of Provision for Taxes on Income
	The following table provides the components of Provision for taxes on income based on the location of the taxing authorities:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	United States
	Current income taxes:
	Federal		$	393			$	142			$	(941	)
	State and local		85				(106		)		(54		)
	Deferred income taxes:
	Federal		725				2,124				869
	State and local		(256		)		(33		)		(339		)
	Total U.S. tax provision/(benefit)		948				2,127				(465		)
	International
	Current income taxes		2,321				2,544				2,430
	Deferred income taxes		(149		)		(365		)		256
	Total international tax provision		2,172				2,179				2,686
	Provision for taxes on income		$	3,120			$	4,306			$	2,221
Schedule of Effective Income Tax Rate Reconciliation
	The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows:
			Year Ended December 31,
			2014			2013			2012
	U.S. statutory income tax rate		35	%		35	%		35	%
	Taxation of non-U.S. operations(a), (b), (c)		(7.4	)		(2.5	)		(3.5	)
	Tax settlements and resolution of certain tax positions(d)		(2.9	)		(5.7	)		(12.8	)
	U.S. Healthcare Legislation(d)		1			0.6			1
	U.S. R&D tax credit and manufacturing deduction(d)		(0.9	)		(0.8	)		(0.3	)
	Certain legal settlements and charges(d)		—			(0.2	)		1.5
	All other, net		0.5			1			(1.1	)
	Effective tax rate for income from continuing operations		25.5	%		27.4	%		19.8	%
	(a)	For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision for taxes on income.
	(b)	In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations.
	(c)	The favorable rate impact in 2014 also includes the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely. The rate impact in 2013 also includes the non-deductibility of the goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer, and the non-deductibility of the loss on an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely, and the non-deductibility of an impairment charge related to our equity-method investment in Teuto. For additional information, see Note 2E.
	(d)	For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and the impact of certain legal settlements and charges, see Note 5A. The extension of the U.S. R&D tax credit in January 2013 resulted in the full-year benefit of the 2012 and 2013 U.S. R&D tax credit being recorded in 2013.
Schedule of Deferred Tax Assets and Liabilities
	The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:
			2014 Deferred Tax								2013 Deferred Tax
	(MILLIONS OF DOLLARS)		Assets				(Liabilities)				Assets			(Liabilities)
	Prepaid/deferred items		$	1,995			$	(53	)		$	1,913		$	(134	)
	Inventories		219				(56		)		277			(217		)
	Intangible assets		969				(9,224		)		892			(10,331		)
	Property, plant and equipment		174				(1,242		)		376			(1,390		)
	Employee benefits		3,950				(154		)		3,154			(77		)
	Restructurings and other charges		114				(28		)		453			(237		)
	Legal and product liability reserves		1,010				—				904			—
	Net operating loss/tax credit carryforwards(a)		2,918				—				2,043			—
	Unremitted earnings(b)		—				(21,174		)		—			(19,399		)
	State and local tax adjustments		295				—				297			—
	All other		283				(783		)		249			(448		)
			11,927				(32,714		)		10,558			(32,233		)
	Valuation allowances		(1,615		)		—				(1,288		)	—
	Total deferred taxes		$	10,312			$	(32,714	)		$	9,270		$	(32,233	)
	Net deferred tax liability(c), (d)						$	(22,402	)					$	(22,963	)
	(a)	The amounts in 2014 and 2013 are reduced for unrecognized tax benefits of $2.6 billion and $2.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
	(b)	The increase in 2014 reflects additional accruals for certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year. For additional information, see Note 5A.
	(c)	The net deferred tax liability position decreased, reflecting an increase in noncurrent deferred tax assets related to net operating loss and tax credit carryforwards, an increase in current deferred tax assets related to product liability reserves due to settlements, an increase in noncurrent deferred tax assets related to employee benefits, and a decrease in noncurrent deferred tax liabilities resulting from the amortization of identifiable intangible assets, partially offset by the increase in noncurrent deferred tax liabilities related to unremitted earnings.
	(d)	In 2014, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($515 million), Other current liabilities ($43 million) and Noncurrent deferred tax liabilities ($25.0 billion). In 2013, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($569 million), Other current liabilities ($52 million) and Noncurrent deferred tax liabilities ($25.6 billion).
Schedule of Unrecognized Tax Benefits Roll Forward
	The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:
	(MILLIONS OF DOLLARS)		2014				2013				2012
	Balance, beginning		$	(6,087	)		$	(6,315	)		$	(7,309	)
	Divestitures(a)		—				29				85
	Increases based on tax positions taken during a prior period(b)		(110		)		(205		)		(139		)
	Decreases based on tax positions taken during a prior period(b), (c)		473				876				1,442
	Decreases based on settlements for a prior period(d)		70				571				647
	Increases based on tax positions taken during the current period(b)		(795		)		(1,178		)		(1,125		)
	Impact of foreign exchange		161				38				78
	Other, net(b), (e)		106				97				6
	Balance, ending(f)		$	(6,182	)		$	(6,087	)		$	(6,315	)
	(a)	Primarily relates to the sales of our Nutrition and Animal Health (Zoetis) businesses. See also Note 2D.
	(b)	Primarily included in Provision for taxes on income.
	(c)	Primarily related to effectively settling certain tax positions with the U.S. and foreign tax authorities. See also Note 5A.
	(d)	Primarily related to cash payments.
	(e)	Includes decreases as a result of a lapse of applicable statutes of limitations.
	(f)	In 2014, included in Income taxes payable ($13 million), Current deferred tax assets and other current tax assets ($59 million), Noncurrent deferred tax assets and other noncurrent tax assets ($165 million), Current deferred tax liabilities ($13 million), Noncurrent deferred tax liabilities ($2.4 billion) and Other taxes payable ($3.5 billion). In 2013, included in Income taxes payable ($51 million), Current deferred tax assets and other current tax assets ($63 million), Noncurrent deferred tax assets and other noncurrent tax assets ($241 million), Noncurrent deferred tax liabilities ($2.3 billion) and Other taxes payable ($3.4 billion).
Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)
	The following table provides the components of the tax provision/(benefit) on Other comprehensive income/(loss):
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	Foreign currency translation adjustments(a)		$	42			$	111			$	110
	Unrealized holding gains on derivative financial instruments, net		(199		)		217				251
	Reclassification adjustments for realized (gains)/losses		262				(63		)		(144		)
			63				154				107
	Unrealized holding gains/(losses) on available-for-sale securities, net		(56		)		57				15
	Reclassification adjustments for realized (gains)/losses		10				(57		)		47
			(46		)		—				62
	Benefit plans: actuarial gains/(losses), net		(1,416		)		1,422				(721		)
	Reclassification adjustments related to amortization		61				205				171
	Reclassification adjustments related to settlements, net		35				2				105
	Other		61				2				15
			(1,258		)		1,631				(430		)
	Benefit plans: prior service credits and other, net		281				56				7
	Reclassification adjustments related to amortization		(28		)		(23		)		(27		)
	Reclassification adjustments related to curtailments, net		—				(1		)		(51		)
	Other		(1		)		—				(3		)
			253				32				(74		)
	Tax provision/(benefit) on other comprehensive income/(loss)		$	(946	)		$	1,928			$	(225	)
	(a)	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax
	The following table provides the changes, net of tax, in Accumulated other comprehensive income/(loss):
			Net Unrealized Gain/(Losses)									Benefit Plans
	(MILLIONS OF DOLLARS)		Foreign Currency Translation Adjustments			Derivative Financial Instruments			Available-For-Sale Securities			Actuarial Gains/(Losses)			Prior Service (Costs)/ Credits and Other			Accumulated Other Comprehensive Income/(Loss)
	Balance, January 1, 2012		$	944		$	(183	)	$	(132	)	$	(5,120	)	$	362		$	(4,129	)
	Other comprehensive income/(loss)(a)		(1,121		)	22			368			(990		)	(103		)	(1,824		)
	Balance, December 31, 2012		(177		)	(161		)	236			(6,110		)	259			(5,953		)
	Other comprehensive income/(loss)(a)		(440		)	240			(86		)	2,887			54			2,655
	Sale of 19.8% of subsidiary through an IPO(b)		27			—			—			—			—			27
	Balance, December 31, 2013		(590		)	79			150			(3,223		)	313			(3,271		)
	Other comprehensive income/(loss)(a)		(2,099		)	438			(372		)	(2,432		)	419			(4,045		)
	Balance, December 31, 2014		$	(2,689	)	$	517		$	(222	)	$	(5,654	)	$	733		$	(7,316	)
	(a)	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $3 million gain in 2014, $62 million loss in 2013 and $7 million loss in 2012.
	(b)	Relates to Zoetis (our former Animal Health subsidiary). See Note 2D.

Financial_Instruments_Tables

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2014
Financial Instruments [Abstract]
Information about Certain Financial Assets and Liabilities
	The following table provides additional information about certain of our financial assets and liabilities:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014				2013
	Selected financial assets measured at fair value on a recurring basis(a)
	Trading securities(b)		$	105			$	126
	Available-for-sale debt securities(c)		39,762				34,899
	Available-for-sale money market funds		2,174				945
	Available-for-sale equity securities, excluding money market funds(c)		397				356
	Derivative financial instruments in a receivable position(d):
	Interest rate swaps		801				468
	Foreign currency swaps		593				871
	Foreign currency forward-exchange contracts		547				172
			44,379				37,837
	Other selected financial assets
	Held-to-maturity debt securities, carried at amortized cost(c), (e)		7,255				9,139
	Private equity securities, carried at equity-method or at cost(e), (f)		1,993				2,270
			9,248				11,409
	Total selected financial assets		$	53,627			$	49,246
	Selected financial liabilities measured at fair value on a recurring basis(a)
	Derivative financial instruments in a liability position(g):
	Interest rate swaps		$	17			$	301
	Foreign currency swaps		594				110
	Foreign currency forward-exchange contracts		78				219
			689				630
	Other selected financial liabilities(h)
	Short-term borrowings, carried at historical proceeds, as adjusted(e)		5,141				6,027
	Long-term debt, carried at historical proceeds, as adjusted(i), (j)		31,541				30,462
			36,682				36,489
	Total selected financial liabilities		$	37,371			$	37,119
	(a)	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 1% that use Level 1 inputs.
	(b)	Trading securities are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
	(c)	Gross unrealized gains and losses are not significant.
	(d)	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $159 million as of December 31, 2014; and interest rate swaps with fair values of $38 million, foreign currency swaps with fair values of $30 million and foreign currency forward-exchange contracts with fair values of $66 million as of December 31, 2013.
	(e)	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2014 or December 31, 2013. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs.
	(f)	Our private equity securities represent investments in the life sciences sector.
	(g)	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $121 million and foreign currency forward-exchange contracts with fair values of $54 million as of December 31, 2014; and foreign currency swaps with fair values of $76 million and foreign currency forward-exchange contracts with fair values of $77 million as of December 31, 2013.
	(h)	Some carrying amounts may include adjustments for discount or premium amortization or for the effect of hedging the interest rate fair value risk associated with certain financial liabilities by interest rate swaps.
	(i)	Includes foreign currency debt with fair values of $560 million as of December 31, 2014 and $651 million as of December 31, 2013, which are used as hedging instruments.
	(j)	The fair value of our long-term debt (not including the current portion of long-term debt) was $36.6 billion as of December 31, 2014 and $35.1 billion as of December 31, 2013. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance.
Selected Financial Assets and Liabilities Presented in the Condensed Consolidated Balance Sheets
	The following table provides the classification of these selected financial assets and liabilities in our consolidated balance sheets:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014				2013
	Assets
	Cash and cash equivalents		$	1,389			$	1,104
	Short-term investments		32,779				30,225
	Long-term investments		17,518				16,406
	Other current assets(a)		1,059				286
	Other noncurrent assets(b)		881				1,225
			$	53,627			$	49,246
	Liabilities
	Short-term borrowings, including current portion of long-term debt		$	5,141			$	6,027
	Other current liabilities(c)		93				303
	Long-term debt		31,541				30,462
	Other noncurrent liabilities(d)		596				327
			$	37,371			$	37,119
	(a)	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($34 million), foreign currency swaps ($494 million) and foreign currency forward-exchange contracts ($531 million) and, as of December 31, 2013, include interest rate swaps ($90 million), foreign currency swaps ($24 million) and foreign currency forward-exchange contracts ($172 million).
	(b)	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($767 million) and foreign currency swaps ($99 million) and foreign currency forward-exchange contracts ($15 million) and, as of December 31, 2013, include interest rate swaps ($378 million) and foreign currency swaps ($847 million).
	(c)	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($13 million) and foreign currency forward-exchange contracts ($78 million) and, as of December 31, 2013, include foreign currency swaps ($84 million) and foreign currency forward-exchange contracts ($219 million).
	(d)	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($16 million) and foreign currency swaps ($581 million) and, as of December 31, 2013, include interest rate swaps ($301 million) and foreign currency swaps ($26 million).
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities
	The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:
			Years														December 31,
																	2014
	(MILLIONS OF DOLLARS)		Within 1				Over 1				Over 5			Over 10			Total
							to 5				to 10
	Available-for-sale debt securities
	Western European, Scandinavian and other government debt(a)		$	13,281			$	2,281			$	—		$	—		$	15,561
	Corporate debt(b)		2,756				3,847				1,370			46			8,019
	U.S. government debt		2,246				2,277				21			—			4,543
	Western European, Scandinavian and other government agency debt(a)		2,417				435				—			—			2,853
	Supranational debt(a)		1,293				905				—			—			2,198
	Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities		16				1,850				72			—			1,938
	Reverse repurchase agreements(c)		1,589				—				—			—			1,589
	Government National Mortgage Association and other U.S. government guaranteed asset-backed securities		198				793				27			—			1,017
	Other asset-backed debt(d)		960				1,077				9			—			2,046
	Held-to-maturity debt securities
	Western European, Asian and other government debt(a)		3,893				—				—			—			3,893
	Time deposits, corporate debt and other(b)		3,346				12				3			—			3,361
	Total debt securities		$	31,994			$	13,476			$	1,501		$	46		$	47,017
	(a)	Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade.
	(b)	Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade.
	(c)	Involving U.S. securities.
	(d)	Includes loan-backed, receivable-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and receivable-backed securities are collateralized by credit cards receivables. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
Schedule of Long-term Debt Instruments
	The following table provides the components of our senior unsecured long-term debt:
					As of December 31,
	(MILLIONS OF DOLLARS)		Maturity Date		2014				2013
	6.20%(a)		March 2019		$	3,264			$	3,234
	7.20%(a)		Mar-39		2,902				2,603
	4.75% euro(b)		Jun-16		2,424				2,752
	5.75% euro(b)		Jun-21		2,419				2,748
	6.50% U.K. pound(b)		Jun-38		2,316				2,459
	5.95%(c)		Apr-37		2,083				2,085
	2.10%(c)		May-19		1,507				—
	4.55% euro(d)		May-17		1,201				1,390
	5.50%(b)		Feb-16		1,018				1,033
	5.35%(e)		Mar-15		—				3,037
	Notes and other debt with a weighted-average interest rate of 5.11%(f)		2021–2044		6,698				4,810
	Notes and other debt with a weighted-average interest rate of 3.19%(g)		2017–2018		5,161				3,683
	Foreign currency notes and other foreign currency debt with a weighted-		2015-2016		547				628
	average interest rate of 2.84%(h)
	Long-term debt				$	31,541			$	30,462
	Current portion of long-term debt (not included above)				$	3,011			$	2,060
	(a)	Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.50%, plus, in each case, accrued and unpaid interest.
	(b)	Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at a comparable government bond rate plus 0.20%. plus, in each case, accrued and unpaid interest.
	(c)	The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.25% for the 5.95% notes and 0.07% for the 2.10% notes, plus, in each case, accrued and unpaid interest.
	(d)	The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the price at which the gross redemption yield on the notes would be equal to the gross redemption yield of a comparable European government bond (selected at the discretion of the Trustee) on the basis of the middle market price of such European government bond.
	(e)	At December 31, 2014, the note has been reclassified to Current portion of long-term debt.
	(f)	Contains debt issuances with a weighted-average maturity of approximately 22 years, and the majority of which are redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average 0.22%, plus, in each case, accrued and unpaid interest.
	(g)	Contains debt issuances with a weighted-average maturity of approximately 3 years, and the majority of which are redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average 0.14%, plus, in each case, accrued and unpaid interest.
	(h)	Contains debt issuances with a weighted-average maturity of approximately 1 year.
Schedule of Maturities of Long-term Debt
	The following table provides the maturity schedule of our Long-term debt outstanding as of December 31, 2014:
	(MILLIONS OF DOLLARS)		2016				2017				2018			2019			After 2019			TOTAL
	Maturities		$	3,990			$	3,963			$	2,399		$	4,771		$	16,418		$	31,541
Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk
	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:
			Amount of								Amount of Gains/(Losses)						Amount of Gains/(Losses)
			Gains/(Losses)								Recognized in OCI						Reclassified from
			Recognized in OID(a), (b), (c)								(Effective Portion)(a), (d)						OCI into OID
																	(Effective Portion)(a), (d)
	(MILLIONS OF DOLLARS)		Dec 31,				Dec 31,				Dec 31,			Dec 31,			Dec 31,			Dec 31,
			2014				2013				2014			2013			2014			2013
	Derivative Financial Instruments in Cash Flow Hedge Relationships:
	Foreign currency swaps		$	—			$	—			$	(799	)	$	554		$	(808	)	$	220
	Foreign currency forward-exchange contracts		—				—				823			(66		)	332			(126		)
	Derivative Financial Instruments in Net Investment Hedge Relationships:
	Foreign currency swaps		—				(3		)		78			156			—			—
	Foreign currency forward-exchange contracts		—				(3		)		—			(1		)	—			—
	Derivative Financial Instruments Not Designated as Hedges:
	Foreign currency forward-exchange contracts		164				56				—			—			—			—
	Foreign currency swaps		(2		)		(18		)		—			—			—			—
	Non-Derivative Financial Instruments in Net Investment Hedge Relationships:
	Foreign currency long-term debt		—				—				33			133			—			—
	All other net		(3		)		(1		)		—			—			—			—
			$	160			$	31			$	135		$	776		$	(477	)	$	94
	(a)	OID =ther (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income. OCI =ther comprehensive income/(loss), included in the consolidated statements of comprehensive income.
	(b)	Also includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.
	(c)	There was no significant ineffectiveness for any period presented.
	(d)	For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments.

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current
	The following table provides the components of Inventories:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014		2013
	Finished goods		$	1,905	$	2,216
	Work-in-process		3,248		3,445
	Raw materials and supplies		510		505
	Inventories		$	5,663	$	6,166
	Noncurrent inventories not included above(a)		$	425	$	463
	(a)	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.
Schedule of Component of Inventories, Noncurrent
	The following table provides the components of Inventories:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014		2013
	Finished goods		$	1,905	$	2,216
	Work-in-process		3,248		3,445
	Raw materials and supplies		510		505
	Inventories		$	5,663	$	6,166
	Noncurrent inventories not included above(a)		$	425	$	463
	(a)	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Components of Property, Plant and Equipment
	The following table provides the components of Property, plant and equipment:
			Useful Lives	As of December 31,
	(MILLIONS OF DOLLARS)		(Years)	2014		2013
	Land		—	$	529	$	557
	Buildings		33-50	9,355		10,055
	Machinery and equipment		8-20	9,671		10,050
	Furniture, fixtures and other		3-12 1/2	4,162		3,914
	Construction in progress		—	1,271		1,102
				24,988		25,678
	Less: Accumulated depreciation			13,226		13,281
	Property, plant and equipment(a)			$	11,762	$	12,397
	(a)	The decrease in total property, plant and equipment is primarily due to depreciation and, to a much lesser extent, disposals, impairments and the impact of foreign exchange, partially offset by capital additions.

Identifiable_Intangible_Assets1

Identifiable Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill
	The following table provides the components of and changes in the carrying amount of Goodwill:
	(MILLIONS OF DOLLARS)		GIP				VOC				GEP			Total
	Balance, January 1, 2013		$	13,482			$	11,766			$	18,413		$	43,661
	Derecognition(a)		—				—				(292		)	(292		)
	Other(b)		(272		)		(207		)		(371		)	(850		)
	Balance, December 31, 2013		13,210				11,559				17,750			42,519
	Additions(c)		—				—				125			125
	Other(b)		(178		)		(161		)		(236		)	(575		)
	Balance, December 31, 2014		$	13,032			$	11,398			$	17,639		$	42,069
	(a)	Reflects the goodwill derecognized as part of the transfer of certain product rights, which constituted a business, to our equity-method investment in China. For additional information, see Note 2E.
	(b)	Primarily reflects the impact of foreign exchange.
	(c)	Reflects the acquisition of InnoPharma. For additional information, see Note 2A.
Schedule of Finite-Lived Intangible Assets
	The following table provides the components of Identifiable intangible assets:
			31-Dec-14											December 31, 2013
	(MILLIONS OF DOLLARS)		Gross				Accumulated				Identifiable			Gross			Accumulated			Identifiable
			Carrying				Amortization				Intangible			Carrying			Amortization			Intangible
			Amount								Assets, less			Amount						Assets, less
											Accumulated									Accumulated
											Amortization									Amortization
	Finite-lived intangible assets
	Developed technology rights		$	70,946			$	(44,694	)		$	26,252		$	72,038		$	(41,541	)	$	30,497
	Brands		1,951				(855		)		1,096			1,743			(773		)	970
	Licensing agreements and other		991				(832		)		159			896			(805		)	91
			73,887				(46,381		)		27,506			74,677			(43,119		)	31,558
	Indefinite-lived intangible assets
	Brands and other		7,273								7,273			7,384						7,384
	In-process research and development		387								387			443						443
			7,660								7,660			7,827						7,827
	Identifiable intangible assets(a)		$	81,547			$	(46,381	)		$	35,166		$	82,504		$	(43,119	)	$	39,385
	(a)	The decrease in identifiable intangible assets, less accumulated amortization, is primarily due to amortization and, to a much lesser extent, asset impairment charges, partially offset by assets acquired as part of the InnoPharma acquisition,the Nexium OTC milestones and other asset acquisitions. For information about impairments of intangible assets, see Note 4. For information about the assets acquired from InnoPharma and the Nexium OTC milestones, see Note 2A and Note 2B, respectively.
	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
			December 31, 2014
			GIP			VOC			GEP
	Developed technology rights		33	%		34	%		33	%
	Brands, finite-lived		—	%		80	%		20	%
	Brands, indefinite-lived		—	%		69	%		31	%
	In-process research and development		7	%		31	%		62	%
Schedule of Indefinite-Lived Intangible Assets
	The following table provides the components of Identifiable intangible assets:
			31-Dec-14											December 31, 2013
	(MILLIONS OF DOLLARS)		Gross				Accumulated				Identifiable			Gross			Accumulated			Identifiable
			Carrying				Amortization				Intangible			Carrying			Amortization			Intangible
			Amount								Assets, less			Amount						Assets, less
											Accumulated									Accumulated
											Amortization									Amortization
	Finite-lived intangible assets
	Developed technology rights		$	70,946			$	(44,694	)		$	26,252		$	72,038		$	(41,541	)	$	30,497
	Brands		1,951				(855		)		1,096			1,743			(773		)	970
	Licensing agreements and other		991				(832		)		159			896			(805		)	91
			73,887				(46,381		)		27,506			74,677			(43,119		)	31,558
	Indefinite-lived intangible assets
	Brands and other		7,273								7,273			7,384						7,384
	In-process research and development		387								387			443						443
			7,660								7,660			7,827						7,827
	Identifiable intangible assets(a)		$	81,547			$	(46,381	)		$	35,166		$	82,504		$	(43,119	)	$	39,385
	(a)	The decrease in identifiable intangible assets, less accumulated amortization, is primarily due to amortization and, to a much lesser extent, asset impairment charges, partially offset by assets acquired as part of the InnoPharma acquisition,the Nexium OTC milestones and other asset acquisitions. For information about impairments of intangible assets, see Note 4. For information about the assets acquired from InnoPharma and the Nexium OTC milestones, see Note 2A and Note 2B, respectively.
	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
			December 31, 2014
			GIP			VOC			GEP
	Developed technology rights		33	%		34	%		33	%
	Brands, finite-lived		—	%		80	%		20	%
	Brands, indefinite-lived		—	%		69	%		31	%
	In-process research and development		7	%		31	%		62	%
Schedule of Expected Amortization Expense
	The following table provides the annual amortization expense expected for the years 2015 through 2019:
	(MILLIONS OF DOLLARS)		2015				2016				2017			2018			2019
	Amortization expense		$	3,665			$	3,413			$	3,311		$	3,203		$	2,888

Pension_and_Postretirement_Ben1

Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Periodic Benefit Costs
	The following table provides the annual cost (including, for 2013 and 2012, costs reported as part of discontinued operations) and changes in Other comprehensive income/(loss) for our benefit plans:
			Year Ended December 31,
			Pension Plans
			U.S.											U.S.									International(c)									Postretirement
			Qualified(a)											Supplemental																		Plans(d)
														(Non-Qualified)(b)
	(MILLIONS OF DOLLARS)		2014				2013				2012			2014			2013			2012			2014			2013			2012			2014			2013			2012
	Service cost		$	253			$	301			$	357		$	20		$	26		$	35		$	199		$	216		$	215		$	55		$	61		$	68
	Interest cost		697				666				697			57			67			62			394			378			406			169			166			182
	Expected return on plan assets		(1,043		)		(999		)		(983		)	—			—			—			(459		)	(407		)	(424		)	(63		)	(55		)	(46		)
	Amortization of:
	Actuarial losses		63				355				306			29			51			41			97			129			93			6			46			33
	Prior service credits		(7		)		(7		)		(10		)	(2		)	(2		)	(3		)	(7		)	(5		)	(7		)	(57		)	(44		)	(49		)
	Curtailments		2				—				(62		)	—			—			(9		)	—			(20		)	(16		)	(7		)	(11		)	(65		)
	Settlements		52				113				145			28			40			33			22			22			7			—			—			—
	Special termination benefits		—				—				8			—			—			30			8			4			5			—			—			6
	Net periodic benefit costs reported in Income		16				429				458			132			182			189			254			317			279			102			163			129
	(Income)/cost reported in Other comprehensive income/(loss)(e)		2,768				(3,044		)		461			163			(255		)	110			260			(569		)	759			(174		)	(736		)	267
	(Income)/cost recognized in Comprehensive income		$	2,784			$	(2,615	)		$	919		$	294		$	(73	)	$	299		$	514		$	(252	)	$	1,038		$	(72	)	$	(573	)	$	396
	(a)	2014 v. 2013––The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses), (ii) lower service cost resulting from cost-reduction initiatives, (iii) lower settlement activity and (iv) greater expected return on plan assets resulting from an increased plan asset base, partially offset by higher interest costs resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation. 2013 v. 2012––The decrease in net periodic benefit cost for our U.S. qualified plans was primarily driven by (i) lower service cost resulting from cost reduction initiatives, (ii) lower settlements and (iii) higher expected return on plan assets resulting from an increased plan asset base, partially offset by the curtailment gain in 2012 resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico. Also, the decrease in the discount rate resulted in lower interest costs, as well as an increase in the amounts amortized for actuarial losses.
	(b)	2014 v. 2013––The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation, (ii) lower settlement activity and (iii) lower interest costs. 2013 v. 2012––The decrease in net periodic benefit cost for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) a decrease in special termination benefits, partially offset by (ii) an increase in the amounts amortized for actuarial losses resulting from a decrease in discount rates, and (iii) the curtailment gain in 2012 resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico.
	(c)	2014 v. 2013––The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) greater expected return on plan assets resulting from an increased plan asset base, (ii) the decrease in the amounts amortized for actuarial losses resulting from increases, in 2013, in the discount rates used to determine the benefit obligations, partially offset by (iii) increased curtailment losses primarily due to a loss relating to a U.K. pension plan freeze in the current year and (iv) changes in curtailments related to restructuring initiatives. 2013 v. 2012––The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from changes in assumptions, (ii) lower expected return on plan assets driven by lower expected rate of return in certain significant plans, (iii) higher settlements and (iv) 2012 curtailment gains, partially offset by (v) lower interest costs resulting from the decrease in discount rates.
	(d)	2014 v. 2013––The decrease in net periodic benefit costs for our postretirement plans was primarily driven by the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses). 2013 v. 2012––The increase in net periodic benefit cost for our postretirement plans was primarily driven by (i) 2012 curtailment gains, partially offset by (ii) higher expected return on plan assets and (iii) a decrease in special termination benefits. Also, the decrease in the discount rate resulted in (iv) lower interest costs, as well as (v) an increase in the amounts amortized for actuarial losses.
	(e)	For details of the changes in Other comprehensive income/(loss), see the benefit plan activity in the consolidated statements of comprehensive income.
Schedule of Amounts in Accumulated Other Comprehensive Income/(Loss) Expected to be Amortized into 2014 Net Periodic Benefit Costs
	The following table provides the amounts in Accumulated other comprehensive loss expected to be amortized into 2015 net periodic benefit costs:
			Pension Plans
	(MILLIONS OF DOLLARS)		U.S.				U.S.				International			Postretirement
			Qualified				Supplemental							Plans
							(Non-Qualified)
	Actuarial losses		$	(330	)		$	(46	)		$	(133	)	$	(40	)
	Prior service credits and other		7				2				7			123
	Total		$	(324	)		$	(44	)		$	(126	)	$	84
Schedule of Assumptions Used
	The following table provides the weighted-average actuarial assumptions of our benefit plans:
	(PERCENTAGES)		2014			2013			2012
	Weighted-average assumptions used to determine benefit obligations
	Discount rate:
	U.S. qualified pension plans		4.2	%		5.2	%		4.3	%
	U.S. non-qualified pension plans		4	%		4.8	%		3.9	%
	International pension plans		3	%		3.9	%		3.8	%
	Postretirement plans		4.2	%		5.1	%		4.1	%
	Rate of compensation increase:
	U.S. qualified pension plans		2.8	%		2.8	%		2.8	%
	U.S. non-qualified pension plans		2.8	%		2.8	%		2.8	%
	International pension plans		2.7	%		2.9	%		3.1	%
	Weighted-average assumptions used to determine net periodic benefit cost
	Discount rate:
	U.S. qualified pension plans		5.2	%		4.3	%		5.1	%
	U.S. non-qualified pension plans		4.8	%		3.9	%		5	%
	International pension plans		3.9	%		3.8	%		4.7	%
	Postretirement plans		5.1	%		4.1	%		4.8	%
	Expected return on plan assets:
	U.S. qualified pension plans		8.5	%		8.5	%		8.5	%
	International pension plans		5.8	%		5.6	%		5.9	%
	Postretirement plans		8.5	%		8.5	%		8.5	%
	Rate of compensation increase:
	U.S. qualified pension plans		2.8	%		2.8	%		3.5	%
	U.S. non-qualified pension plans		2.8	%		2.8	%		3.5	%
	International pension plans		2.9	%		3.1	%		3.3	%
Schedule of Health Care Cost Trend Rates
	The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:
			2014			2013
	Healthcare cost trend rate assumed for next year		7	%		7.3	%
	Rate to which the cost trend rate is assumed to decline		4.5	%		4.5	%
	Year that the rate reaches the ultimate trend rate		2027			2027
Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates
	The following table provides the effects as of December 31, 2014 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:
	(MILLIONS OF DOLLARS)		Increase				Decrease
	Effect on total service and interest cost components		$	15			$	(14	)
	Effect on postretirement benefit obligation		228				(217		)
Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans
	The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans (including, for 2013, those reported as part of discontinued operations):
			Year Ended December 31,
			Pension Plans
			U.S. Qualified(a)								U.S. Supplemental						International(c)						Postretirement
											(Non-Qualified)(b)												Plans(d)
	(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
	Change in benefit obligation(e)
	Benefit obligation, beginning		$	13,976			$	16,268			$	1,341		$	1,549		$	10,316		$	10,227		$	3,438		$	4,165
	Service cost		253				301				20			26			197			216			55			61
	Interest cost		697				666				57			67			393			378			169			166
	Employee contributions		—				—				—			—			8			10			75			69
	Plan amendments		—				—				—			—			(54		)	1			(692		)	(152		)
	Changes in actuarial assumptions and other		2,653				(2,257		)		218			(165		)	1,346			229			447			(540		)
	Foreign exchange impact		—				—				—			—			(794		)	(66		)	(10		)	(9		)
	Acquisitions/divestitures, net		—				—				—			37			(55		)	(63		)	—			—
	Curtailments		2				(8		)		—			(1		)	(127		)	(64		)	(4		)	(8		)
	Settlements		(308		)		(444		)		(96		)	(105		)	(32		)	(156		)	—			—
	Special termination benefits		—				—				—			—			8			4			—			—
	Benefits paid		(697		)		(550		)		(58		)	(67		)	(408		)	(400		)	(309		)	(314		)
	Benefit obligation, ending(e)		16,575				13,976				1,481			1,341			10,796			10,316			3,168			3,438
	Change in plan assets
	Fair value of plan assets, beginning		12,869				12,540				—			—			8,250			7,589			741			644
	Actual gain on plan assets		819				1,318				—			—			1,046			976			45			98
	Company contributions		23				5				154			172			316			380			210			244
	Employee contributions		—				—				—			—			8			10			75			69
	Foreign exchange impact		—				—				—			—			(594		)	(95		)	—			—
	Acquisitions/divestitures, net		—				—				—			—			3			(54		)	—			—
	Settlements		(308		)		(444		)		(96		)	(105		)	(32		)	(156		)	—			—
	Benefits paid		(697		)		(550		)		(58		)	(67		)	(408		)	(400		)	(309		)	(314		)
	Fair value of plan assets, ending		12,706				12,869				—			—			8,588			8,250			762			741
	Funded status—Plan assets less than benefit obligation		$	(3,869	)		$	(1,107	)		$	(1,481	)	$	(1,341	)	$	(2,208	)	$	(2,066	)	$	(2,406	)	$	(2,697	)
	(a)	The unfavorable change in the funded status of our U.S. qualified plans is primarily due to (i) a decrease in the discount rate (reflecting lower interest rates) and (ii) a change in mortality assumptions (reflecting a longer life expectancy for plan participants), which more than offset (iii) a gain on plan assets.
	(b)	Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations.
	(c)	The unfavorable change in the international plans' funded status was primarily due to (i) a decrease in the discount rate (reflecting lower interest rates), partially offset by (ii) the strengthening U.S. dollar and (iii) a gain on plan assets.
	(d)	The favorable change in the funded status of our postretirement plans is due to (i) a plan amendment that decreased the benefit obligation by transferring certain plan participants to a retiree drug coverage program eligible for a Medicare Part D plan subsidy, partially offset by (ii) a decrease in the discount rate (reflecting lower interest rates).
	(e)	For the U.S. and international pension plans, the benefit obligation is the projected benefit obligation. For the postretirement plans, the benefit obligation is the accumulated postretirement benefit obligation (ABO). The ABO for all of our U.S. qualified pension plans was $16.3 billion in 2014 and $13.7 billion in 2013. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2014 and $1.3 billion 2013. The ABO for our international pension plans was $10.3 billion in 2014 and $9.7 billion in 2013.
	The following table provides information as to how the funded status is recognized in our consolidated balance sheets:
			As of December 31,
			Pension Plans
			U.S. Qualified								U.S. Supplemental						International						Postretirement
											(Non-Qualified)												Plans
	(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
	Noncurrent assets(a)		$	—			$	—			$	—		$	—		$	509		$	318		$	—		$	—
	Current liabilities(b)		—				—				(136		)	(151		)	(45		)	(46		)	(27		)	(29		)
	Noncurrent liabilities(c)		(3,869		)		(1,107		)		(1,345		)	(1,190		)	(2,671		)	(2,338		)	(2,379		)	(2,668		)
	Funded status		$	(3,869	)		$	(1,107	)		$	(1,481	)	$	(1,341	)	$	(2,208	)	$	(2,066	)	$	(2,406	)	$	(2,697	)
	(a)	Included primarily in Other noncu
Schedule of Amounts Recognized in Balance Sheet	rent assets.
	(b)	Included in Accrued compensation and related items.
	(c)	Included in Pension benefit obligations, net and Postretirement benefit obligations, net, as appropriate.
	The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:
			As of December 31,
			Pension Plans
			U.S. Qualified								U.S. Supplemental						International						Postretirement
											(Non-Qualified)												Plans
	(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
	Actuarial losses(a)		$	(4,735	)		$	(1,974	)		$	(567	)	$	(406	)	$	(2,527	)	$	(2,213	)	$	(745	)	$	(292	)
	Prior service (costs)/credits		35				42				10			11			36			(18		)	1,098			470
	Total		$	(4,700	)		$	(1,932	)		$	(557	)	$	(395	)	$	(2,492	)	$	(2,231	)	$	352		$	178
	(a)	The accumulated actuarial losses
Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)	rimarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants, using the corridor approach. The average amortization periods utilized are 9.5 years for our U.S. qualified plans, 9.4 years for our U.S. supplemental (non-qualified) plans, 17.4 years for our international plans, and 10.6 years for our postretirement plans.
	The following table provides information related to the funded status of selected benefit plans:
			As of December 31,
			Pension Plans
			U.S. Qualified								U.S. Supplemental (Non-Qualified)						International
	(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013
	Pension plans with an accumulated benefit obligation in excess of plan assets:
	Fair value of plan assets		$	12,706			$	12,869			$	—		$	—		$	1,718		$	1,309
	Accumulated benefit obligation		16,323				13,704				1,447			1,294			4,021			3,348
	Pension plans with a projected benefit obligation in excess of plan assets:
	Fair value of plan assets		12,706				12,869				—			—			1,999			2,499
	Projected benefit obligation		16,575				13,976				1,481			1,341			4,715			4,883
	All of our U.S. plans and many of our
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets	i
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets	i
Schedule of Allocation of Plan Assets	e
	n valuation inputs categorized as Level 1, 2 or 3 (see Note 1E).
	(b)	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
	(c)	Primarily includes investments in private equity, private debt and, to a lesser extent, real estate and venture capital.
	(d)	Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
	The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:
			Year Ended December 31,
			U.S. Qualified Pension Plans														International Pension Plans
			Partnership investments								Other commingled funds						Insurance contracts						Other
	(MILLIONS OF DOLLARS)		2014				2013				2014			2013			2014			2013			2014			2013
	Fair value, beginning		$	932			$	950			$	715		$	673		$	300		$	346		$	500		$	389
	Actual return on plan assets:
	Assets held, ending		104				86				47			18			23			15			47			13
	Assets sold during the period		—				—				(7		)	(6		)	—			—			8			—
	Purchases, sales and settlements, net		(78		)		(105		)		341			31			(20		)	(40		)	254			69
	Transfer into/(out of) Level 3		—				—				—			—			—			(16		)	(19		)	27
	Exchange rate changes		—				—				—			—			(29		)	(5		)	(46		)	2
	Fair value, ending		$	958			$	932			$	1,096		$	715		$	274		$	300		$	744		$	500
	A single estimate of fair value can
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	e
Schedule of Expected Future Cash Flow Information
	The following table provides the expected future cash flow information related to our benefit plans:
			Pension Plans
	(MILLIONS OF DOLLARS)		U.S. Qualified				U.S. Supplemental				International			Postretirement Plans
							(Non-Qualified)
	Expected employer contributions:
	2015(a)		$	1,000			$	136			$	227		$	91
	Expected benefit payments:
	2015		$	904			$	136			$	368		$	261
	2016		870				118				376			211
	2017		932				124				383			216
	2018		1,021				129				390			220
	2019		949				114				399			222
	2020–2024		4,874				547				2,125			1,146
	(a)	For the U.S. Qualified plan, the $1.0 billion voluntary contribution was paid in January 2015.

ShareBased_Payments_Tables

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
	The following table provides the components of share-based compensation expense and the associated tax benefit (including those reported as part of discontinued operations in 2013 and 2012):
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	Restricted Stock Units		$	270			$	249			$	235
	Stock Options		150				140				157
	Portfolio Performance Shares		96				56				14
	Total Shareholder Return Units		37				37				35
	Performance Share Awards		30				34				35
	Directors’ compensation		3				7				5
	Share-based payment expense		586				523				481
	Tax benefit for share-based compensation expense		(179		)		(173		)		(149		)
	Share-based payment expense, net of tax		$	407			$	350			$	332
Schedule of Nonvested Restricted Stock Units Activity
	The following table summarizes all RSU activity during 2014:
			Shares				Weighted-
			(Thousands)				Average
							Grant Date
							Fair Value
							Per Share
	Nonvested, December 31, 2013		32,751				$	22.5
	Granted		10,188				32.11
	Vested		(12,613		)		19.74
	Reinvested dividend equivalents		1,071				29.69
	Forfeited		(1,461		)		26.66
	Nonvested, December 31, 2014		$	29,936			$	26.99
	The following table provides data related to all RSU activity:
	(MILLIONS OF DOLLARS)		Year Ended December 31,
			2014				2013				2012
	Total fair value of shares vested		$	401			$	379			$	348
	Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax		$	255			$	239			$	258
	Weighted-average period over which RSU cost is expected to be recognized (years)		1.8				1.8				1.8
Schedule of Valuation Assumptions
	The following table provides the weighted-average assumptions used in the valuation of stock options:
			Year Ended December 31,
			2014			2013			2012
	Expected dividend yield(a)		3.18	%		3.45	%		4.1	%
	Risk-free interest rate(b)		1.94	%		1.16	%		1.28	%
	Expected stock price volatility(c)		19.76	%		19.68	%		23.78	%
	Expected term (years)(d)		6.5			6.5			6.5
	(a)	Determined using a constant dividend yield during the expected term of the option.
	(b)	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
	(c)	Determined using implied volatility, after consideration of historical volatility.
	(d)	Determined using historical exercise and post-vesting termination patterns.
Schedule of Share-based Compensation, Stock Options, Activity
	The following table summarizes data related to all stock option activity:
			Year Ended December 31,
	(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)		2014				2013				2012
	Weighted-average grant date fair value per stock option		$	4.4			$	3.13			$	2.79
	Aggregate intrinsic value on exercise		$	458			$	578			$	263
	Cash received upon exercise		$	1,002			$	1,750			$	568
	Tax benefits realized related to exercise		$	131			$	160			$	81
	Total compensation cost related to nonvested stock options not yet recognized, pre-tax		$	147			$	120			$	148
	Weighted-average period over which stock option compensation cost is expected to be recognized (years)		1.8				1.7				1.7
	The following table summarizes all stock option activity during 2014:
			Shares			Weighted-Average				Weighted-Average		Aggregate
			(Thousands)			Exercise Price				Remaining		Intrinsic
						Per Share				Contractual		Value(a)
										Term		(Millions)
										(Years)
	December 31, 2013(b)		299,653			$	24.33
	Granted		44,599			32.23
	Exercised		(46,960	)		21.44
	Forfeited		(4,396	)		26.36
	Expired		(43,784	)		36.85
	Outstanding, December 31, 2014		249,112			24.05				5.9		$	1,815
	Vested and expected to vest, December 31, 2014(c)		243,297			23.91				5.9		1,805
	Exercisable, December 31, 2014		122,618			$	21.19			3.6		$	1,222
	(a)	Market price of underlying Pfizer common stock less exercise price.
	(b)	Includes approximately 42 million stock options which expired on February 25, 2014 at a grant price of $37.15, which were granted under the 2001 Stock Plan. These stock options were not added into the amount of carry forward shares remaining available for grants under the 2004 Stock Plan.
	(c)	The number of options expected to vest takes into account an estimate of expected forfeitures.
Schedule of Nonvested Performance-based Units Activity
	The following table summarizes all PPS activity during 2014, with the shares representing the maximum award that could be achieved:
			Shares			Weighted-
			(Thousands)			Average
						Intrinsic Value
						Per Share
	Nonvested, December 31, 2013		11,324			$	30.63
	Granted		8,377			32.23
	Vested(a)		(7	)		30.18
	Forfeited		(817	)		30.1
	Nonvested, December 31, 2014(a)		18,877			$	31.15
	(a)Vested and non-vested shares outstanding, but not paid as of December 31, 2014 were 18,877.
	The following table provides data related to all PPS activity:
	(MILLIONS OF DOLLARS)		Year Ended December 31,
			2014				2013			2012
	Total fair value of shares vested		$	—			$	—		$	—
	Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax		$	139			$	107		$	33
	Weighted-average period over which PPS cost is expected to be recognized (years)		1.8				2			2.2
	The following table provides data related to all PSA activity:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014				2013				2012
	Total fair value of shares vested		$	39			$	40			$	13
	Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax		$	21			$	25			$	27
	Weighted-average period over which PSA cost is expected to be recognized (years)		1.7				1.7				1.7
	The following table summarizes all PSA activity during 2014, with the shares granted representing the maximum award that could be achieved:
			Shares			Weighted-Average
			(Thousands)			Intrinsic Value
						Per Share
	Nonvested, December 31, 2013		5,039			$	30.63
	Granted		1,202			32.17
	Vested		(1,231	)		31.99
	Forfeited		(920	)		31.74
	Nonvested, December 31, 2014		4,090			$	31.15
Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions
	The following table provides the weighted-average assumptions used in the valuation of TSRUs:
			Year Ended December 31,
			2014			2013			2012
	Expected dividend yield(a)		3.18	%		3.45	%		4.1	%
	Risk-free interest rate(b)		1.78	%		1.03	%		1.15	%
	Expected stock price volatility(c)		19.76	%		19.68	%		23.8	%
	Contractual term (years)		5.97			5.98			5.97
	(a)	Determined using a constant dividend yield during the expected term of the TSRU.
	(b)	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
	(c)	Determined using implied volatility, after consideration of historical volatility.
Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity
	The following table provides data related to all TSRU activity:
			Year Ended December 31,
	(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)		2014				2013				2012
	Weighted-average grant date fair value per TSRU		$	6.51			$	5.14			$	4.48
	Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax		$	30			$	31			$	31
	Weighted-average period over which TSRU cost is expected to be recognized (years)		1.8				1.6				1.7
	The following table summarizes all outstanding TSRU activity as of December 31, 2014(a):
			Share Units			Weighted-				Weighted-		Aggregate Intrinsic Value (Millions)
			(Thousands)			Average				Average
						Grant Price				Remaining Contractual Term (Years)
						Per Share Unit
	Outstanding		34,842			$	23.41			3.1		$	360
	Vested		13,907			18.92				1.6		220
	Expected to vest		20,935			26.4				4.1		140
	(a)	In 2014, we settled 5,124,197 share units with a weighted-average grant price of $14.67 per share unit.
	The following table summarizes all TSRU activity during 2014:
			Share Units			Weighted-				Weighted-Average
			(Thousands)			Average				Grant Price Per Share Unit
						Grant Date
						Fair Value
						Per Share Unit
	Nonvested, December 31, 2013		24,195			$	4.77			$	22.3
	Granted		6,288			6.51				32.23
	Vested		(8,727	)		4.74				19.38
	Forfeited		(821	)		5.1				25.87
	Nonvested, December 31, 2014		20,935			$	5.29			$	26.4
	The following table summarizes all outstanding TSRU activity as of December 31, 2014(a):
			Share Units			Weighted-				Weighted-		Aggregate Intrinsic Value (Millions)
			(Thousands)			Average				Average
						Grant Price				Remaining Contractual Term (Years)
						Per Share Unit
	Outstanding		34,842			$	23.41			3.1		$	360
	Vested		13,907			18.92				1.6		220
	Expected to vest		20,935			26.4				4.1		140

Earnings_Per_Common_Share_Attr1

Earnings Per Common Share Attributable to Common Shareholders (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share
	The following table provides the detailed calculation of Earnings per common share (EPS):
			Year Ended December 31,
	(IN MILLIONS)		2014		2013		2012
	EPS Numerator––Basic
	Income from continuing operations		$	9,119	$	11,410	$	9,021
	Less: Net income attributable to noncontrolling interests		32		30		28
	Income from continuing operations attributable to Pfizer Inc.		9,087		11,380		8,993
	Less: Preferred stock dividends––net of tax		1		2		2
	Income from continuing operations attributable to Pfizer Inc. common shareholders		9,086		11,378		8,991
	Discontinued operations––net of tax		48		10,662		5,577
	Less: Discontinued operations––net of tax, attributable to noncontrolling interests		—		39		—
	Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders		48		10,623		5,577
	Net income attributable to Pfizer Inc. common shareholders		$	9,134	$	22,001	$	14,568
	EPS Numerator––Diluted
	Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		$	9,087	$	11,380	$	8,993
	Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		48		10,623		5,577
	Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$	9,135	$	22,003	$	14,570
	EPS Denominator
	Weighted-average number of common shares outstanding––Basic		6,346		6,813		7,442
	Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock		78		82		66
	Weighted-average number of common shares outstanding––Diluted		6,424		6,895		7,508
	Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(a)		44		43		177
	`
	(a)	These common stock equivalents were outstanding for the years ended December 31, 2014, 2013 and 2012, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease_Commitments_Tables

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Schedule of Future Minimum Rental Commitments Under Non-Cancelable Operating Leases
	The future minimum rental commitments under non-cancelable operating leases follow:
	(MILLIONS OF DOLLARS)	2015		2016		2017		2018		2019		After 2019
	Lease commitments	$	183	$	159	$	151	$	112	$	88	$	774

Segment_Geographic_and_Other_R1

Segment, Geographic and Other Revenue Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated
	The following table provides selected income statement information by reportable segment:
			Revenues									Earnings(a)									Depreciation and Amortization(b)
			Year Ended December 31,									Year Ended December 31,									Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012			2014			2013			2012			2014		2013		2012
	Reportable Segments:
	Global Innovative Pharmaceutical (GIP)		$	13,861		$	14,317		$	13,756		$	7,780		$	8,549		$	8,325		$	255	$	238	$	250
	Global Vaccines, Oncology and Consumer Healthcare (VOC)		10,144			9,285			8,991			4,692			4,216			3,597			263		231		270
	Global Established Pharmaceutical (GEP)		25,149			27,619			31,678			16,199			17,552			19,910			475		478		595
	Total reportable segments		49,154			51,221			54,426			28,671			30,318			31,832			993		947		1,115
	Other business activities(c)		253			232			231			(3,092		)	(2,828		)	(2,888		)	91		105		117
	Reconciling Items:
	Corporate(d)		—			—			—			(5,200		)	(5,689		)	(6,059		)	384		432		546
	Purchase accounting adjustments(d)		—			—			—			(3,641		)	(4,344		)	(4,905		)	3,782		4,487		4,988
	Acquisition-related costs(d)		—			—			—			(183		)	(376		)	(946		)	53		124		273
	Certain significant items(e)		198			132			—			(3,749		)	(692		)	(5,039		)	207		167		300
	Other unallocated		—			—			—			(567		)	(671		)	(751		)	27		44		55
			$	49,605		$	51,584		$	54,657		$	12,240		$	15,716		$	11,242		$	5,537	$	6,306	$	7,394
	(a)	Income from continuing operations before provision for taxes on income.
	(b)	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
	(c)	Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
	(d)	For a description, see the "Other Costs and Business Activities" section above.
	(e)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
	For Revenues in 2014, certain significant items primarily represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $32 million, (ii) charges for certain legal matters of $999 million, (iii) certain asset impairments of $440 million, (iv) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (v) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (vi) upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vii) charges for business and legal entity alignment of $168 million and (viii) other charges of $197 million. For additional information, see Note 2C, Note 3 and Note 4.
	For Revenues in 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2013, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $16 million, (ii) patent litigation settlement income of $1.3 billion, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iv) net charges for certain legal matters of $21 million, (v) certain asset impairments of $836 million, (vi) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vii) costs associated with the separation of Zoetis of $18 million and (viii) other charges of $306 million. For additional information, see Note 3 and Note 4.
	For Earnings in 2012, certain significant items includes: (i) net charges for certain legal matters of $2.2 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.8 billion, (iii) certain asset impairment charges of $875 million, (iv) costs associated with the separation of Zoetis of $125 million and (v) other charges of $19 million. For additional information, see Note 3 and     Note 4.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
	The following table provides selected income statement information by reportable segment:
			Revenues									Earnings(a)									Depreciation and Amortization(b)
			Year Ended December 31,									Year Ended December 31,									Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012			2014			2013			2012			2014		2013		2012
	Reportable Segments:
	Global Innovative Pharmaceutical (GIP)		$	13,861		$	14,317		$	13,756		$	7,780		$	8,549		$	8,325		$	255	$	238	$	250
	Global Vaccines, Oncology and Consumer Healthcare (VOC)		10,144			9,285			8,991			4,692			4,216			3,597			263		231		270
	Global Established Pharmaceutical (GEP)		25,149			27,619			31,678			16,199			17,552			19,910			475		478		595
	Total reportable segments		49,154			51,221			54,426			28,671			30,318			31,832			993		947		1,115
	Other business activities(c)		253			232			231			(3,092		)	(2,828		)	(2,888		)	91		105		117
	Reconciling Items:
	Corporate(d)		—			—			—			(5,200		)	(5,689		)	(6,059		)	384		432		546
	Purchase accounting adjustments(d)		—			—			—			(3,641		)	(4,344		)	(4,905		)	3,782		4,487		4,988
	Acquisition-related costs(d)		—			—			—			(183		)	(376		)	(946		)	53		124		273
	Certain significant items(e)		198			132			—			(3,749		)	(692		)	(5,039		)	207		167		300
	Other unallocated		—			—			—			(567		)	(671		)	(751		)	27		44		55
			$	49,605		$	51,584		$	54,657		$	12,240		$	15,716		$	11,242		$	5,537	$	6,306	$	7,394
	(a)	Income from continuing operations before provision for taxes on income.
	(b)	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
	(c)	Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
	(d)	For a description, see the "Other Costs and Business Activities" section above.
	(e)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
	For Revenues in 2014, certain significant items primarily represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $32 million, (ii) charges for certain legal matters of $999 million, (iii) certain asset impairments of $440 million, (iv) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (v) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (vi) upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vii) charges for business and legal entity alignment of $168 million and (viii) other charges of $197 million. For additional information, see Note 2C, Note 3 and Note 4.
	For Revenues in 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2013, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $16 million, (ii) patent litigation settlement income of $1.3 billion, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iv) net charges for certain legal matters of $21 million, (v) certain asset impairments of $836 million, (vi) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vii) costs associated with the separation of Zoetis of $18 million and (viii) other charges of $306 million. For additional information, see Note 3 and Note 4.
	For Earnings in 2012, certain significant items includes: (i) net charges for certain legal matters of $2.2 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.8 billion, (iii) certain asset impairment charges of $875 million, (iv) costs associated with the separation of Zoetis of $125 million and (v) other charges of $19 million. For additional information, see Note 3 and     Note 4.
Reconciliation Of Depreciation And Amortization From Segments To Consolidated
	The following table provides selected income statement information by reportable segment:
			Revenues									Earnings(a)									Depreciation and Amortization(b)
			Year Ended December 31,									Year Ended December 31,									Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012			2014			2013			2012			2014		2013		2012
	Reportable Segments:
	Global Innovative Pharmaceutical (GIP)		$	13,861		$	14,317		$	13,756		$	7,780		$	8,549		$	8,325		$	255	$	238	$	250
	Global Vaccines, Oncology and Consumer Healthcare (VOC)		10,144			9,285			8,991			4,692			4,216			3,597			263		231		270
	Global Established Pharmaceutical (GEP)		25,149			27,619			31,678			16,199			17,552			19,910			475		478		595
	Total reportable segments		49,154			51,221			54,426			28,671			30,318			31,832			993		947		1,115
	Other business activities(c)		253			232			231			(3,092		)	(2,828		)	(2,888		)	91		105		117
	Reconciling Items:
	Corporate(d)		—			—			—			(5,200		)	(5,689		)	(6,059		)	384		432		546
	Purchase accounting adjustments(d)		—			—			—			(3,641		)	(4,344		)	(4,905		)	3,782		4,487		4,988
	Acquisition-related costs(d)		—			—			—			(183		)	(376		)	(946		)	53		124		273
	Certain significant items(e)		198			132			—			(3,749		)	(692		)	(5,039		)	207		167		300
	Other unallocated		—			—			—			(567		)	(671		)	(751		)	27		44		55
			$	49,605		$	51,584		$	54,657		$	12,240		$	15,716		$	11,242		$	5,537	$	6,306	$	7,394
	(a)	Income from continuing operations before provision for taxes on income.
	(b)	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
	(c)	Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
	(d)	For a description, see the "Other Costs and Business Activities" section above.
	(e)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
	For Revenues in 2014, certain significant items primarily represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $32 million, (ii) charges for certain legal matters of $999 million, (iii) certain asset impairments of $440 million, (iv) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (v) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (vi) upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vii) charges for business and legal entity alignment of $168 million and (viii) other charges of $197 million. For additional information, see Note 2C, Note 3 and Note 4.
	For Revenues in 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
	For Earnings in 2013, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $16 million, (ii) patent litigation settlement income of $1.3 billion, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iv) net charges for certain legal matters of $21 million, (v) certain asset impairments of $836 million, (vi) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vii) costs associated with the separation of Zoetis of $18 million and (viii) other charges of $306 million. For additional information, see Note 3 and Note 4.
	For Earnings in 2012, certain significant items includes: (i) net charges for certain legal matters of $2.2 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.8 billion, (iii) certain asset impairment charges of $875 million, (iv) costs associated with the separation of Zoetis of $125 million and (v) other charges of $19 million. For additional information, see Note 3 and     Note 4.
Revenue from External Customers by Geographic Areas
	The following table provides revenues by geographic area:
			Year Ended December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	United States		$	19,073		$	20,274		$	21,313
	Developed Europe(a)		11,719			11,739			12,545
	Developed Rest of World(b)		7,314			8,346			9,956
	Emerging Markets(c)		11,499			11,225			10,843
	Revenues		$	49,605		$	51,584		$	54,657
	(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $9.0 billion in 2014, $8.9 billion in 2013 and $9.4 billion in 2012.
	(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
	(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe
Long-lived Assets by Geographic Areas	.
	Long-lived assets by geographic region follow:
			As of December 31,
	(MILLIONS OF DOLLARS)		2014			2013			2012
	Property, plant and equipment, net
	United States		$	5,575		$	5,885		$	6,485
	Developed Europe(a)		4,606			4,845			4,895
	Developed Rest of World(b)		617			696			816
	Emerging Markets(c)		963			971			1,017
	Property, plant and equipment, net		$	11,762		$	12,397		$	13,213
	(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
	(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.
	(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe
Schedule of Significant Product Revenues
	The following table provides detailed revenue information:
				Year Ended December 31,
	(MILLIONS OF DOLLARS)	Business(a)		2014			2013			2012
	Biopharmaceutical revenues:
	Lyrica(b)	GEP/GIP		$	5,168		$	4,595		$	4,158
	Prevnar family	V		4,464			3,974			4,117
	Enbrel (Outside the U.S. and Canada)	GIP		3,850			3,774			3,737
	Celebrex	GEP		2,699			2,918			2,719
	Lipitor	GEP		2,061			2,315			3,948
	Viagra(c)	GEP/GIP		1,685			1,881			2,051
	Zyvox	GEP		1,352			1,353			1,345
	Sutent	O		1,174			1,204			1,236
	Norvasc	GEP		1,112			1,229			1,349
	Premarin family	GEP		1,076			1,092			1,073
	BeneFIX	GIP		856			832			775
	Vfend	GEP		756			775			754
	Pristiq	GEP		737			698			630
	Genotropin	GIP		723			772			832
	Chantix/Champix	GIP		647			648			670
	Refacto AF/Xyntha	GIP		631			602			584
	Xalatan/Xalacom	GEP		495			589			806
	Medrol	GEP		443			464			523
	Xalkori	O		438			282			123
	Zoloft	GEP		423			469			541
	Inlyta	O		410			319			100
	Relpax	GEP		382			359			368
	Fragmin	GEP		364			359			381
	Sulperazon	GEP		354			309			262
	Effexor	GEP		344			440			425
	Rapamune	GIP		339			350			346
	Tygacil	GEP		323			358			335
	Zithromax/Zmax	GEP		314			387			435
	Xeljanz	GIP		308			114			6
	Zosyn/Tazocin	GEP		303			395			484
	EpiPen	GEP		294			273			263
	Toviaz	GIP		288			236			207
	Revatio	GEP		276			307			534
	Cardura	GEP		263			296			338
	Xanax/Xanax XR	GEP		253			276			274
	Inspra	GEP		233			233			214
	Somavert	GIP		229			217			197
	BMP2	GIP		228			209			263
	Diflucan	GEP		220			242			259
	Neurontin	GEP		210			216			235
	Unasyn	GEP		207			212			228
	Detrol/Detrol LA	GEP		201			562			761
	Depo-Provera	GEP		201			191			148
	Protonix/Pantoprazole	GEP		198			185			188
	Dalacin/Cleocin	GEP		184			199			232
	Caduet	GEP		180			223			258
	Alliance revenues(d)	GEP/GIP		957			2,628			3,492
	All other GIP	GIP		469			540			332
	All other GEP	GEP		6,175			6,614			7,442
	All other V/O	V/O		211			164			236
	Total biopharmaceutical revenues	GEP/GIP/V/O		45,708			47,878			51,214
	Other revenues:
	Consumer Healthcare	C		3,446			3,342			3,212
	Other(e)			451			364			231
	Revenues			$	49,605		$	51,584		$	54,657
	(a)	Indicates the business to which the revenues relate. GIP =he Global Innovative Pharmaceutical segment; V=he Global Vaccines
	business; O=he Global Oncology business; C =he global Consumer Healthcare business; and GEP =he Global Established Pharmaceutical segment.
	(b)	Lyrica revenues from all of Europe are included in GEP. All other Lyrica revenues are included in GIP.
	(c)	Viagra revenues from the U.S. and Canada are included in GIP. All other Viagra revenues are included in GEP.
(d)	Includes Enbrel (GIP, in the U.S. and Canada through October 31, 2013), Spiriva (GEP), Rebif (GIP), Aricept (GEP) and Eliquis (GIP).
(e)	Other primarily includes revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and also includes the revenues related to our transitional manufacturing and supply agreements with Zoetis.

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Detail) (USD $)	12 Months Ended						0 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Jun. 24, 2013	Nov. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on disposal of discontinued operations––net of tax	$55,000,000	[1],[2],[3]	$10,354,000,000	[1],[2],[3]	$4,783,000,000	[1],[2],[3]
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns	3,400,000,000		3,300,000,000
Advertising expense	3,100,000,000		3,000,000,000		2,800,000,000
Research and development expenses	8,393,000,000	[1],[4]	6,678,000,000	[1],[4]	7,482,000,000	[1],[4]
Nonsoftware License Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Research and development expenses	1,385,000,000		203,000,000		371,000,000
Other Current Liabilities [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns	2,000,000,000		2,100,000,000
Other Noncurrent Liabilities [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns	300,000,000		234,000,000
Accounts Receivable, Net Of Allowance For Doubtful Accounts [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns	1,100,000,000		1,000,000,000
Minimum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Reimbursements to wholesalers, estimated settlement period	14 days
Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Reimbursements to wholesalers, estimated settlement period	35 days
Zoetis [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on disposal of discontinued operations––net of tax							10,300,000,000
Nutrition [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on disposal of discontinued operations––net of tax								$4,800,000,000
[1]	Amounts may not add due to rounding.
[2]	Includes post-close adjustments for the periods subsequent to disposal.
[3]	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.
[4]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

Acquisitions_Licensing_Agreeme2

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Acquisitions (Details) (USD $)	0 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 24, 2014	Nov. 27, 2012	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012	Feb. 26, 2012	Apr. 01, 2012
Business Acquisition [Line Items]
Goodwill			$42,069	[1]	$42,519	[1]	$43,661
InnoPharma [Member]
Business Acquisition [Line Items]
Cost of acquired entity, cash paid	225
Contingent consideration, liability	67
Maximum amount of contingent consideration	135
Intangible assets	247
Deferred tax liabilities noncurrent	81
Goodwill	125
InnoPharma [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets	212
InnoPharma [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	35
NextWave Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Cost of acquired entity, cash paid		278
Contingent consideration, liability		164
Maximum amount of contingent consideration		425
Intangible assets		519
Deferred tax liabilities noncurrent		166
Goodwill		89
Total consideration transferred		442
Gain on contingent consideration, liability			43		114
NextWave Pharmaceuticals, Inc. [Member] | Other Income (Expense) [Member]
Business Acquisition [Line Items]
Gain on contingent consideration, liability			43		114
NextWave Pharmaceuticals, Inc. [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets		45
NextWave Pharmaceuticals, Inc. [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		474
Alacer Corp. [Member]
Business Acquisition [Line Items]
Intangible assets								181
Deferred tax liabilities noncurrent								69
Goodwill								192
Ferrosan Holding AS [Member]
Business Acquisition [Line Items]
Intangible assets									362
Deferred tax liabilities noncurrent									94
Goodwill									$322
[1]	Amounts may not add due to rounding.

Acquisitions_Licensing_Agreeme3

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Licensing Agreements (Details) (USD $)	12 Months Ended					1 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012	Aug. 31, 2014	Sep. 15, 2014	Jul. 11, 2014	Aug. 13, 2012
						target
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Long-term investments	$17,518	[1]	$16,406	[1]
Acquisitions of intangible assets	384		259		92
Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to licensing partners						80
Number of selected targets						15
Number of collaboration selected targets						4
Collaborative arrangement, milestone, maximum, value						185
Long-term investments						35
Licensing Agreements [Member] | AstraZeneca, Nexium, Global, Over-the-counter Rights [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to licensing partners	300								250
Acquisitions of intangible assets							$50	$200
Licensing Agreements [Member] | Common Stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment, ownership percentage						10.00%
[1]	Amounts may not add due to rounding.

Acquisitions_Licensing_Agreeme4

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Collaborative Arrangements (Detail) (USD $)	12 Months Ended						0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Nov. 17, 2014
							trial
							clinical_program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues	$49,605	[1]	$51,584	[1]	$54,657	[1]
Cost of sales(c)	-9,577	[1],[2]	-9,586	[1],[2]	-9,821	[1],[2]
Selling, informational and administrative expenses(d)	-14,097	[1],[2]	-14,355	[1],[2]	-15,171	[1],[2]
Research and development expenses(e)	-8,393	[1],[2]	-6,678	[1],[2]	-7,482	[1],[2]
Other income/(deductions)—net(f)	-1,009	[1]	532	[1]	-4,022	[1]
Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues	1,743		3,781		5,132
Cost of sales(c)	-280	[3]	-333	[3]	-362	[3]
Selling, informational and administrative expenses(d)	-268	[4]	-279	[4]	-290	[4]
Research and development expenses(e)	-1,210	[5]	-73	[5]	-74	[5]
Other income/(deductions)—net(f)	518	[6]	103	[6]	-15	[6]
Upfront payments and milestone payments	1,189		67		44
Collaborative arrangement sales based milestones payments	80		175		29
Collaborative Arrangement [Member] | Merck KGaA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of collaborative clinical programs							20
Number of clinical trials							6
Potential milestone payments							2,000
Collaborative Arrangement [Member] | Merck KGaA [Member] | Research and Development Expense [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments and milestone payments	1,200
Collaborative Arrangement [Member] | Deferred Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds received from upfront payments and milestone payments			128
Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues—Revenues(a)	786	[7]	1,153	[7]	1,640	[7]
Collaborative Arrangement, Upfront Cash Payment [Member] | Merck KGaA [Member] | Research and Development Expense [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments and milestone payments	850
Collaborative Arrangement, Co-promotion [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues—Alliance revenues(b)	957	[8]	2,628	[8]	3,492	[8]
Collaborative Arrangement, Co-promotion [Member] | Merck KGaA [Member] | Research and Development Expense [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments and milestone payments	$309
[1]	Amounts may not add due to rounding.
[2]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.
[3]	Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners.
[4]	Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
[5]	Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $1.2 billion in 2014 (related to collaboration with Merck KGaA, see below), $67 million in 2013 and $44 million in 2012.
[6]	In 2014 and 2013, includes royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and we became entitled to royalties for a 36-month period thereafter.
[7]	Represents sales to our partners of products manufactured by us.
[8]	Substantially all relates to amounts earned from our partners under co-promotion agreements. The decline in 2014 and 2013 reflects declines in alliance revenues from Enbrel (as a result of the expiration of the co-promotion term of the collaboration agreement on October 31, 2013 in the U.S. and Canada) and Spiriva (as a result of the expiration of the co-promotion collaboration in the U.S. and certain European countries during 2014, combined with the expiration of the collaboration in Australia, Canada and certain other European countries during 2013).

Acquisitions_Licensing_Agreeme5

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Collaborative Arrangements - Footnotes (Detail) (USD $)	12 Months Ended			0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013
Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments and milestone payments	$1,189	$67	$44
Collaborative Arrangement, Co-promotion [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty revenue, term				36 months

Acquisitions_Licensing_Agreeme6

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Discontinued Operations - Net of Tax Narrative (Details) (USD $)	12 Months Ended						0 Months Ended
Share data in Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Jun. 24, 2013	Feb. 06, 2013	Jan. 28, 2013	Nov. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Non-cash exchange of subsidiary senior notes for the retirement of company commercial paper	$0	[1]	$992,000,000	[1]	$0	[1]
Repayments of short-term debt	0	[1]	2,479,000,000	[1]	0	[1]
Noncash transaction sale of subsidiary common stock for company common stock			11,408,000,000	[2],[3]
Gain on disposal of discontinued operations––net of tax	55,000,000	[3],[4],[5]	10,354,000,000	[3],[4],[5]	4,783,000,000	[3],[4],[5]
Proceeds from sale of businesses	0		0		11,850,000,000
Zoetis [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage offered in IPO							80.20%
Gain on disposal of discontinued operations––net of tax							10,300,000,000
Receipt of cash and relief of debt obligations in the aggregate during formation and IPO of subsidiary							6,100,000,000
Administrative service period							24 months
Manufacturing service period							5 years
Zoetis [Member] | Common Stock [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Company shares received in Exchange Offer							405,117
Noncash transaction sale of subsidiary common stock for company common stock							11,400,000,000
Zoetis [Member] | Common Class A [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shares exchanged through exchange offer							400,985
Zoetis [Member] | Subsidiaries [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Excess consideration above net book value of divested interest								2,300,000,000
Zoetis [Member] | Subsidiaries [Member] | Senior Notes [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt instrument, face amount									3,650,000,000
Proceeds from issuance of debt									2,650,000,000
Zoetis [Member] | Parent Company [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Non-cash exchange of subsidiary senior notes for the retirement of company commercial paper									1,000,000,000
Amount of cash received by parent during the formation of subsidiary company									2,600,000,000
Repayments of short-term debt								2,500,000,000
Zoetis [Member] | IPO [Member] | Subsidiaries [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage offered in IPO								19.80%
Zoetis [Member] | IPO [Member] | Subsidiaries [Member] | Common Class A [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shares offered in IPO of subsidiary								99,015
Nutrition [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on disposal of discontinued operations––net of tax										4,800,000,000
Proceeds from sale of businesses										$11,850,000,000
Nutrition [Member] | Minimum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Administrative service period										2 months
Nutrition [Member] | Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Administrative service period										18 months
[1]	See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.
[2]	Relates to Zoetis (our former Animal Health subsidiary). See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.
[3]	Amounts may not add due to rounding.
[4]	Includes post-close adjustments for the periods subsequent to disposal.
[5]	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.

Acquisitions_Licensing_Agreeme7

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Discontinued Operations - Net of Tax (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Revenues	$0	[1]	$2,201	[1]	$6,587	[1]
Pre-tax income from discontinued operations(a), (b)	-9	[1],[2]	408	[1],[2]	1,253	[1],[2]
Provision for taxes on income(b), (c)	-3	[1],[2],[3]	100	[1],[2],[3]	459	[1],[2],[3]
Income from discontinued operations––net of tax	-6	[1],[4]	308	[1],[4]	794	[1],[4]
Pre-tax gain on disposal of discontinued operations(b)	51	[1],[2]	10,446	[1],[2]	7,123	[1],[2]
Provision for taxes on income(b), (d)	-4	[1],[2],[5]	92	[1],[2],[5]	2,340	[1],[2],[5]
Gain on disposal of discontinued operations––net of tax(b)	55	[1],[2],[4]	10,354	[1],[2],[4]	4,783	[1],[2],[4]
Discontinued operations––net of tax	$48	[1],[4]	$10,662	[1],[4]	$5,577	[1],[4]
[1]	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.
[2]	Includes post-close adjustments for the periods subsequent to disposal.
[3]	Includes a deferred tax benefit of $3 million for 2014, $23 million for 2013 and $23 million for 2012, which is net of a deferred tax expense of $42 million in 2012 related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries indefinitely.
[4]	Amounts may not add due to rounding.
[5]	For 2013, primarily reflects income tax expense of $122 million resulting from certain legal entity reorganizations. For 2012, includes a deferred tax expense of $1.4 billion, which includes a deferred tax expense of $2.2 billion on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas. For 2012, also includes a deferred tax benefit reflecting the reversal of net deferred tax liabilities associated with the divested Nutrition assets.

Acquisitions_Licensing_Agreeme8

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Discontinued Operations - Net of Tax - Footnotes (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred income tax expense (benefit), net	$3	$23	$23
Deferred income tax expense			42
Legal Entity Reorganization [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred income tax expense			1,400
Foreign Tax Authority [Member] | Legal Entity Reorganization [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred income tax expense			2,200
Legal Entity Reorganization [Member] | Legal Entity Reorganization [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred income tax expense		$122

Acquisitions_Licensing_Agreeme9

Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures and Equity-Method Investments - Equity Method Investments (Details) (USD $)

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Sep. 06, 2012

Apr. 01, 2014

Oct. 01, 2013

Sep. 29, 2013

Oct. 30, 2012

Oct. 31, 2012

Schedule of Equity Method Investments [Line Items]

Gain associated with the transfer of certain product rights to an equity-method investment

$0

[1]

$459

[1]

$0

[1]

Equity method investment, other than temporary impairment

55

Hisun Pfizer Pharmaceuticals Co. Ltd [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, registered capital

250

Equity method investments

1,400

1,400

122.5

Equity method investment, ownership percentage

49.00%

Gain associated with the transfer of certain product rights to an equity-method investment

459

Gain (loss) associated with indirect retained interest

225

Fair value inputs, discount rate

11.50%

Equity method investment, underlying equity in net assets

780

770

Finite-lived intangible asset, useful life

25 years

ViiV Healthcare Limited [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, ownership percentage

11.70%

12.60%

13.50%

15.00%

ViiV Healthcare Limited [Member] | Shionogi & Co., Ltd. [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, ownership percentage

10.00%

ViiV Healthcare Limited [Member] | Other Nonoperating Income (Expense) [Member]

Schedule of Equity Method Investments [Line Items]

Gain (loss) in increase (reduction) of interest in subsidiary or equity method investment

-30

-32

44

Gain (loss) in increase (reduction) of interest in subsidiary or equity method investment

-32

Shionogi-Viiv Healthcare LLC [Member]

Schedule of Equity Method Investments [Line Items]

Percentage of voting interests acquired

50.00%

Laboratorio Teuto Brasilero [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, ownership percentage

40.00%

Equity method investment, recognized gain (loss)

-223

Equity method investment, other than temporary impairment

56

32

Payments to acquire equity method investments

91.5

Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]

Schedule of Equity Method Investments [Line Items]

Noncontrolling interest, ownership percentage by parent

60.00%

Laboratorio Teuto Brasilero [Member] | Other Nonoperating Income (Expense) [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, recognized gain (loss)

55

-223

Equity method investment, other than temporary impairment

$56

$32

[1]

In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.

Restructuring_Charges_and_Othe2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]
Expected cost	$2,900
Acquisition related costs and implementation costs	781	1,704	2,775
Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of facilities closed	7
Manufacturing Plant Network Rationalization And Optimization [Member] | Acquisition-related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost	300
Restructuring cost incurred to date	182
Manufacturing Plant Network Rationalization And Optimization [Member] | Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost	1,500
Restructuring cost incurred to date	292
Global Commercial Structure Reorganization [Member] | Business Restructuring Reserves [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost	300
Restructuring cost incurred to date	153
Other Cost Reduction / Productivity Initiatives [Member] | Commercial Real Estate [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost	850
Restructuring cost incurred to date	$154

Restructuring_Charges_and_Othe3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Restructuring charges(a):
Employee terminations	$68	[1]	$805	[1]	$953	[1]
Asset impairments	45	[1]	165	[1]	325	[1]
Exit costs	58	[1]	68	[1]	150	[1]
Total restructuring charges	170	[1]	1,038	[1]	1,428	[1]
Transaction costs(b)	0	[2]	0	[2]	1	[2]
Integration costs(c)	80	[3]	144	[3]	381	[3]
Restructuring charges and certain acquisition-related costs	250	[4]	1,182	[4]	1,810	[4]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	261	[5]	291	[5]	573	[5]
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	270	[6]	231	[6]	392	[6]
Total costs associated with acquisitions and cost-reduction/productivity initiatives	781		1,704		2,775
Cost of Sales [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	228	[5]	178	[5]	257	[5]
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	78	[6]	53	[6]	31	[6]
Selling, Informational and Administrative Expenses [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	1	[5]	19	[5]	20	[5]
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	140	[6]	145	[6]	130	[6]
Research and Development Expense [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	31	[5]	94	[5]	296	[5]
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	52	[6]	33	[6]	231	[6]
Other Income (Expense) [Member]
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	$1	[6]	$0	[6]	$0	[6]
[1]	In 2014, Employee terminations represent the expected reduction of the workforce by approximately 1,700 employees, mainly in manufacturing and sales.The restructuring charges in 2014 are associated with the following:•Global Innovative Pharmaceutical segment (GIP) ($35 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($28 million); the Global Established Pharmaceutical segment (GEP) ($57 million); Worldwide Research and Development and Medical ($37 million); manufacturing operations ($97 million); and Corporate ($65 million), as well as $149 million of income related to the partial reversal of prior-period restructuring charges, that we are unable to directly associate with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.The restructuring charges in 2013 are associated with the following:•Total operating segments ($496 million); Worldwide Research and Development and Medical ($13 million); manufacturing operations ($356 million); and Corporate ($173 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.The restructuring charges in 2012 are associated with the following:•Total operating segments ($640 million); Worldwide Research and Development and Medical ($6 million income); manufacturing operations ($281 million); and Corporate ($513 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
[2]	Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.
[3]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
[4]	Amounts may not add due to rounding.
[5]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[6]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring_Charges_and_Othe4

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
	Employee
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated	1,700
Provision	$170	[1]	$1,038	[1]	$1,428	[1]
Sales Force Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Provision	-149
Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Provision	37		13		6
Manufacturing Operations [Member]
Restructuring Cost and Reserve [Line Items]
Provision	97		356		281
Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Provision	65		173		513
Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Provision			496		640
Global Innovative Pharmaceutical [Member]
Restructuring Cost and Reserve [Line Items]
Provision	35
Global Vaccines, Oncology and Consumer Healthcare [Member]
Restructuring Cost and Reserve [Line Items]
Provision	28
Global Established Pharmaceutical [Member]
Restructuring Cost and Reserve [Line Items]
Provision	$57
[1]	In 2014, Employee terminations represent the expected reduction of the workforce by approximately 1,700 employees, mainly in manufacturing and sales.The restructuring charges in 2014 are associated with the following:•Global Innovative Pharmaceutical segment (GIP) ($35 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($28 million); the Global Established Pharmaceutical segment (GEP) ($57 million); Worldwide Research and Development and Medical ($37 million); manufacturing operations ($97 million); and Corporate ($65 million), as well as $149 million of income related to the partial reversal of prior-period restructuring charges, that we are unable to directly associate with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.The restructuring charges in 2013 are associated with the following:•Total operating segments ($496 million); Worldwide Research and Development and Medical ($13 million); manufacturing operations ($356 million); and Corporate ($173 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.The restructuring charges in 2012 are associated with the following:•Total operating segments ($640 million); Worldwide Research and Development and Medical ($6 million income); manufacturing operations ($281 million); and Corporate ($513 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.

Restructuring_Charges_and_Othe5

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Restructuring Reserve [Roll Forward]
Beginning balance	$1,779	[1]	$1,886
Provision	170	[2]	1,038	[2]	1,428	[2]
Utilization and other(a)	-783	[3]	-1,145	[3]
Ending balance	1,166	[4]	1,779	[1]	1,886
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	1,685	[1]	1,734
Provision	68		805
Utilization and other(a)	-639	[3]	-854	[3]
Ending balance	1,114	[4]	1,685	[1]
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	0	[1]	0
Provision	45		165
Utilization and other(a)	-45	[3]	-165	[3]
Ending balance	0	[4]	0	[1]
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	94	[1]	152
Provision	58		68
Utilization and other(a)	-100	[3]	-126	[3]
Ending balance	$52	[4]	$94	[1]
[1]	Included in Other current liabilities ($1.0 billion) and Other noncurrent liabilities ($767 million).
[2]	In 2014, Employee terminations represent the expected reduction of the workforce by approximately 1,700 employees, mainly in manufacturing and sales.The restructuring charges in 2014 are associated with the following:•Global Innovative Pharmaceutical segment (GIP) ($35 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($28 million); the Global Established Pharmaceutical segment (GEP) ($57 million); Worldwide Research and Development and Medical ($37 million); manufacturing operations ($97 million); and Corporate ($65 million), as well as $149 million of income related to the partial reversal of prior-period restructuring charges, that we are unable to directly associate with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.The restructuring charges in 2013 are associated with the following:•Total operating segments ($496 million); Worldwide Research and Development and Medical ($13 million); manufacturing operations ($356 million); and Corporate ($173 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.The restructuring charges in 2012 are associated with the following:•Total operating segments ($640 million); Worldwide Research and Development and Medical ($6 million income); manufacturing operations ($281 million); and Corporate ($513 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).

Restructuring_Charges_and_Othe6

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$1,166	[1]	$1,779	[2]	$1,886
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	735		1,000
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$431		$767
[1]	Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).
[2]	Included in Other current liabilities ($1.0 billion) and Other noncurrent liabilities ($767 million).

Other_IncomeDeductions_Net_Det

Other (Income)/Deductions - Net (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Other Income and Expenses [Abstract]
Interest income(a)	($425)	[1]	($403)	[1]	($382)	[1]
Interest expense(a)	1,360	[1]	1,414	[1]	1,522	[1]
Net interest expense	935		1,011		1,140
Royalty-related income(b)	-1,002	[2]	-523	[2]	-451	[2]
Patent litigation settlement income(c)	0	[3]	-1,342	[3]	0	[3]
Other legal matters, net(d)	993	[4]	35	[4]	2,220	[4]
Gain associated with the transfer of certain product rights(e)	0	[5]	-459	[5]	0	[5]
Net gains on asset disposals(f)	-288	[6]	-320	[6]	-52	[6]
Certain asset impairments(g)	469	[7]	878	[7]	890	[7]
Business and legal entity alignment costs(h)	168	[8]	0	[8]	0	[8]
Costs associated with the Zoetis IPO(i)	0	[9]	18	[9]	125	[9]
Other, net(j)	-265	[10]	170	[10]	150	[10]
Other (income)/deductions––net	$1,009	[11]	($532)	[11]	$4,022	[11]
[1]	2014 v. 2013––Interest income increased due to higher cash equivalents and investment balances. Interest expense decreased, primarily due to the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. 2013 v. 2012––Interest income increased due to higher investment balances. Interest expense decreased due to lower outstanding debt, refinancings at lower rates, and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. Capitalized interest expense totaled $41 million in 2014, $32 million in 2013 and $41 million in 2012.
[2]	Royalty-related income increased in 2014 and 2013 primarily due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and Pfizer became entitled to royalties for a 36-month period thereafter.
[3]	In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.
[4]	In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million for an agreement in principle to resolve a securities class action pending against Pfizer in New York federal court, which is subject to court approval, and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable. For additional information, see Note 17A. In 2012, primarily includes a $491 million charge relating to the resolution of an investigation by the U.S. Department of Justice into Wyeth's historical promotional practices in connection with Rapamune, a $450 million settlement of a lawsuit by Brigham Young University related to Celebrex, and charges related to hormone-replacement therapy litigation and Chantix litigation.
[5]	In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.
[6]	In 2014, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $76 million; (ii) gross realized gains on sales of available-for-sale debt securities of $138 million; (iii) gross realized losses on sales of available-for-sale debt securities of $436 million; (iv) net gain of $323 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of approximately $135 million; and (vi) gains on sales of investments in private equity securities of approximately $39 million. Proceeds from the sale of available-for-sale securities were $10.2 billion in 2014.In 2013, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $87 million; (ii) gross realized gains on sales of available-for-sale debt securities of $442 million; (iii) gross realized losses on sales of available-for-sale debt securities of $310 million; (iv) net loss of $137 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; and (v) a gain of $170 million on the sale of various product rights, including a portion of our in-licensed generic sterile injectables portfolio. Proceeds from the sale of available-for-sale securities were $15.2 billion in 2013.In 2012, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $2 million; (ii) gross realized gains on sales of available-for-sale debt securities of $212 million; (iii) gross realized losses on sales of available-for-sale debt securities of $535 million; and (iv) net gain of $351 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale securities. Proceeds primarily from the sale of available-for-sale securities were $19.0 billion in 2012.
[7]	In 2014, includes intangible asset impairment charges of $396 million, reflecting (i) $190 million for an IPR&D compound for the treatment of skin fibrosis (full write-off); (ii) $159 million for developed technology rights, primarily related to Quillivant XR; and (iii) $47 million for indefinite-lived brands. The intangible asset impairment charges for 2014 are associated with the following: the Global Innovative Pharmaceutical segment ($12 million); Global Established Pharmaceutical segment ($166 million); Worldwide Research and Development ($190 million); and Consumer Healthcare ($28 million). In addition, 2014 includes an impairment charge of approximately $56 million related to our investment in Teuto.The intangible asset impairment charges for 2014 reflect, among other things, updated commercial forecasts; and with regard to IPR&D, the impact of changes to the development program and new scientific findings.In 2013, includes intangible asset impairment charges of $803 million, reflecting (i) $394 million of developed technology rights (for use in the development of bone and cartilage) acquired in connection with our acquisition of Wyeth; (ii) $227 million related to IPR&D compounds; (iii) $109 million of indefinite-lived brands, primarily related to our biopharmaceutical indefinite-lived brand Xanax/Xanax XR; and (iv) $73 million of other finite-lived intangible assets, related to platform technology, that no longer have an alternative future use. The intangible asset impairment charges for 2013 are associated with the following: the Global Innovative Pharmaceutical segment ($448 million); the Global Established Pharmaceutical segment ($201 million); Worldwide Research and Development ($140 million); and Consumer Healthcare ($14 million). In addition, 2013 includes an impairment charge of approximately $43 million for certain private company investments and an impairment charge of $32 million related to our investment in Teuto.The intangible asset impairment charges for 2013 reflect, among other things, updated commercial forecasts and, with regard to IPR&D, also reflect the impact of new scientific findings and delayed launch dates. In 2012, includes intangible asset impairment charges of $835 million, reflecting (i) $393 million of IPR&D assets, primarily related to compounds that targeted autoimmune and inflammatory diseases (full write-off) and, to a lesser extent, compounds related to pain treatment; (ii) $175 million related to our Consumer Healthcare indefinite-lived brand assets, primarily Robitussin, a cough suppressant; (iii) $242 million related to developed technology rights, a charge composed of impairments of various products, none of which individually exceeded $45 million; and (iv) $25 million of finite-lived brands. The impairment charges in 2012 are associated with the following: Worldwide Research and Development ($303 million); Consumer Healthcare ($200 million); the Global Innovative Pharmaceutical segment ($173 million); and the Global Established Pharmaceutical segment ($159 million). In addition, in 2012, also includes charges of approximately $55 million for certain investments. These investment impairment charges reflect the difficult global economic environment.The intangible asset impairment charges for 2012 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, an increased competitive environment and litigation uncertainties regarding intellectual property.
[8]	Represents expenses for planning and implementing changes to our infrastructure to operate our new business segments.
[9]	Represents costs incurred in connection with the IPO of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. For additional information, see Note 2D.
[10]	Includes the following: (i) in 2014, the gain of approximately $43 million reflecting the change in the fair value of the contingent consideration associated with our acquisition of NextWave and the gain of approximately $89 million reflecting the change in the fair value of the contingent consideration associated with our acquisition of Excaliard Pharmaceuticals, Inc., and in 2013, the gain of approximately $114 million, reflecting the change in the fair value of the contingent consideration associated with our acquisition of NextWave; (ii) in 2013, an estimated loss of $223 million related to an option to acquire the remaining interest in Teuto, and in 2014, income of $55 million resulting from a decline in the estimated loss from the aforementioned option; and (iii) in 2014, a loss of $30 million due to a change in our ownership interest in ViiV, in 2013, a loss of $32 million due to a change in our ownership interest in ViiV and in 2012, a gain of $44 million as a result of ViiV's transaction with Shionogi & Co., Ltd and the resulting change in ownership. For additional information concerning NextWave, see Note 2A. For additional information concerning Teuto and ViiV, see Note 2E.
[11]	Amounts may not add due to rounding.

Other_IncomeDeductions_Net_Foo

Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Other Income and Expenses [Abstract]
Interest costs capitalized	$41	$32	$41

Other_IncomeDeductions_Net_Foo1

Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details) (USD $)	12 Months Ended						0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Oct. 31, 2013
Loss Contingencies [Line Items]
Litigation settlement income (loss)	$0	[1]	$1,342	[1]	$0	[1]
Violation Of Securities Law, Failure to Disclose Material Information [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)	-400
Accrual No Longer Deemed Probable [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)	130
Number of reversed legal accruals	2
Enbrel [Member]
Loss Contingencies [Line Items]
Royalty revenue, term							36 months
Neurontin [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)	-610
Effexor [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)	-56
Rapamune [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)					-491
Celebrex [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)					($450)
[1]	In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.

Other_IncomeDeductions_Net_Foo2

Other (Income)/Deductions - Net - Footnotes - Investments (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 24, 2013	Feb. 06, 2013
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains (losses), sale proceeds	$10,200,000,000	$15,200,000,000	$19,000,000,000
Equity method investment, other than temporary impairment			55,000,000
Equity Securities [Member]
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains	76,000,000	87,000,000	2,000,000
Debt Securities [Member]
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains	138,000,000	442,000,000	212,000,000
Available-for-sale securities, gross realized losses	436,000,000	310,000,000	535,000,000
Private Equity Funds [Member]
Investment Holdings [Line Items]
Gain on sale of investments	39,000,000
Zoetis [Member]
Investment Holdings [Line Items]
Percentage offered in IPO				80.20%
Zoetis [Member] | Subsidiaries [Member] | IPO [Member]
Investment Holdings [Line Items]
Percentage offered in IPO					19.80%
Certain Private Company Investments [Member]
Investment Holdings [Line Items]
Equity method investment, other than temporary impairment		43,000,000
Laboratorio Teuto Brasilero [Member]
Investment Holdings [Line Items]
Equity method investment, other than temporary impairment	56,000,000	32,000,000
Equity method investment, recognized gain (loss)		-223,000,000
Laboratorio Teuto Brasilero [Member] | Other Nonoperating Income (Expense) [Member]
Investment Holdings [Line Items]
Equity method investment, other than temporary impairment	56,000,000	32,000,000
Equity method investment, recognized gain (loss)	55,000,000	-223,000,000
ViiV Healthcare Limited [Member] | Other Nonoperating Income (Expense) [Member]
Investment Holdings [Line Items]
Gain (loss) in increase (reduction) of interest in subsidiary or equity method investment	-30,000,000	-32,000,000	44,000,000
Various Product Rights, Including In-Licensed Generic Sterile Injectibles Portfolio [Member]
Investment Holdings [Line Items]
Gain on sale of investments		170,000,000
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Debt Securities [Member]
Investment Holdings [Line Items]
Gain (loss) on derivative instruments, net, pretax	$323,000,000	($137,000,000)	$351,000,000

Other_IncomeDeductions_Net_Foo3

Other (Income)/Deductions - Net - Footnotes - Finite-Lived Intangibles (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Distribution Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gain (loss) on disposition of intangible assets	$135
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived	159	[1]	394	242
Developed Technology Rights [Member] | Various Products [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived				45
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived				25
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived			$73
[1]	Reflects intangible assets written down to fair value in 2014. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then we applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Other_IncomeDeductions_Net_Foo4

Other (Income)/Deductions - Net - Footnotes - Indefinite-Lived Intangibles (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments	$396		$803	$835
NextWave Pharmaceuticals, Inc. [Member]
Indefinite-lived Intangible Assets [Line Items]
Gain on contingent consideration, liability	43		114
Excaliard Pharmaceuticals, Inc. [Member]
Indefinite-lived Intangible Assets [Line Items]
Gain on contingent consideration, liability	89
Global Innovative Pharmaceutical [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments	12		448	173
Global Established Pharmaceutical [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments	166		201	159
Research and Development Expense [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments	190		140	303
Consumer Healthcare [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments	28		14
Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets, indefinite-lived (excluding goodwill)	47	[1]
Trade Names [Member] | Xanax/Xanax XR [Member]
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets, indefinite-lived (excluding goodwill)			109
Trade Names [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | Robitussin [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				175
Trade Names [Member] | Consumer Healthcare [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				200
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				393
Impairment of intangible assets, indefinite-lived (excluding goodwill)	190	[1]	227
In Process Research and Development [Member] | Skin Fibrosis [Member]
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets, indefinite-lived (excluding goodwill)	$190
[1]	Reflects intangible assets written down to fair value in 2014. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then we applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Other_IncomeDeductions_Net_Add

Other (Income)/Deductions - Net - Additional Information about Intangible Assets (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	$526	[1]
Intangible asset impairments	396		803	835
Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	233	[1],[2]
Impairment of intangible assets, finite-lived	159	[2]	394	242
In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	0	[1],[2]
Impairment of intangible assets, indefinite-lived	190	[2]	227
Intangible asset impairments				393
Brands [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	293	[1],[2]
Impairment of intangible assets, indefinite-lived	47	[2]
Fair value inputs Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	0	[1]
Fair value inputs Level 1 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	0	[1],[2]
Fair value inputs Level 1 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	0	[1],[2]
Fair value inputs Level 1 [Member] | Brands [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	0	[1],[2]
Fair value inputs Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	0	[1]
Fair value inputs Level 2 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	0	[1],[2]
Fair value inputs Level 2 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	0	[1],[2]
Fair value inputs Level 2 [Member] | Brands [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	0	[1],[2]
Fair value inputs Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	526	[1]
Fair value inputs Level 3 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	233	[1],[2]
Fair value inputs Level 3 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	0	[1],[2]
Fair value inputs Level 3 [Member] | Brands [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	$293	[1],[2]
[1]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
[2]	Reflects intangible assets written down to fair value in 2014. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then we applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax_Matters_Narrative_Detail

Tax Matters - Narrative (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	jurisdiction
Income Tax Contingency [Line Items]
Undistributed earnings of foreign subsidiaries	$74,000,000,000
Unrecognized tax benefits excluding associated interest	4,700,000,000	4,400,000,000
Number of tax jurisdiction associated with uncertain tax positions	1
Deferred tax assets associated with unrecognized tax benefits	1,500,000,000	1,700,000,000
Unrecognized tax benefits, interest on income taxes expense	40,000,000	16,000,000	120,000,000
Unrecognized tax benefits, interest on income taxes accrued	643,000,000	621,000,000
Unrecognized accrued interest decrease as a result of cash payments	18,000,000	120,000,000
Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit		100,000,000
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Contingency [Line Items]
Deferred tax assets associated with unrecognized tax benefits	966,000,000	926,000,000
Deferred Tax Liabilities, Net, Noncurrent [Member]
Income Tax Contingency [Line Items]
Deferred tax assets associated with unrecognized tax benefits	527,000,000	766,000,000
Income Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued	15,000,000	14,000,000
Current Deferred Tax Assets And Other Current Tax Assets [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued		12,000,000
Other Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued	$628,000,000	$595,000,000

Tax_Matters_Income_from_Contin

Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Income Tax Disclosure [Abstract]
United States	($4,744)		($1,678)		($5,148)
International	16,984		17,394		16,390
Income from continuing operations before provision for taxes on income(a), (b)	$12,240	[1],[2]	$15,716	[1],[2]	$11,242	[1],[2]
[1]	2014 v. 2013––The increase in the domestic loss was primarily due to lower revenues, the non-recurrence of income from a litigation settlement in 2013 with Teva and Sun for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S., higher charges related to other legal matters, a non-tax deductible charge in the third quarter of 2014 to account for an additional year of the Branded Prescription Drug Fee in accordance with final regulations issued by the U.S. Internal Revenue Service (IRS), higher research and development expenses, and higher charges for business and legal entity alignment costs, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, and lower asset impairments. The decrease in international income is primarily related to lower revenues, the non-recurrence of the gain associated with the transfer of certain product rights to Pfizer’s equity-method investment in China (Hisun Pfizer) in 2013, and higher research and development expenses, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives and the non-recurrence of certain charges.
[2]	2013 v. 2012––The decrease in the domestic loss was primarily due to income from a litigation settlement in the second quarter of 2013 with Teva and Sun for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S., lower charges related to other legal matters, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, partially offset by lower revenues. The increase in international income is primarily related to the gain associated with the transfer of certain product rights to Hisun Pfizer in 2013, lower charges related to other legal matters, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives and lower amortization of intangible assets, partially offset by lower revenues and higher asset impairments and other charges.

Tax_Matters_Provision_for_Taxe

Tax Matters - Provision for Taxes on Income (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Current income taxes:
Current federal income taxes	$393		$142		($941)
Current state and local income taxes	85		-106		-54
Deferred income taxes:
Deferred federal income taxes	725		2,124		869
Deferred state and local income taxes	-256		-33		-339
Total U.S. tax provision/(benefit)	948		2,127		-465
International
Current income taxes	2,321		2,544		2,430
Deferred income taxes	-149		-365		256
Total international tax provision	2,172		2,179		2,686
Provision for taxes on income	$3,120	[1]	$4,306	[1]	$2,221	[1]
[1]	Amounts may not add due to rounding.

Tax_Matters_Provision_for_Taxe1

Tax Matters - Provision for Taxes on Income (Narrative) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Income Tax Disclosure [Abstract]
Deferred income taxes on certain current-year funds earned outside of the U.S.	$2,200,000,000		$2,300,000,000		$2,200,000,000
Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Amount	350,000,000		430,000,000		1,100,000,000
Tax adjustments, settlements, and unusual provisions			470,000,000		310,000,000
Selling, informational and administrative expenses	362,000,000		280,000,000		336,000,000
Schedule of Equity Method Investments [Line Items]
Derecognition(c)			292,000,000	[1]
Equity method investment, other than temporary impairment					55,000,000
Loss Contingencies [Line Items]
Patent litigation settlement income (loss)	0	[2]	1,342,000,000	[2]	0	[2]
Rapamune [Member]
Loss Contingencies [Line Items]
Patent litigation settlement income (loss)					-491,000,000
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Derecognition(c)			292,000,000
Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, recognized gain (loss)			-223,000,000
Equity method investment, other than temporary impairment	$56,000,000		$32,000,000
[1]	Reflects the goodwill derecognized as part of the transfer of certain product rights, which constituted a business, to our equity-method investment in China. For additional information, see Note 2E.
[2]	In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.

Tax_Matters_Tax_Rate_Reconcili

Tax Matters - Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	35.00%		35.00%		35.00%
Taxation of non-U.S. operations(a), (b), (c)	-7.40%	[1],[2],[3]	-2.50%	[1],[2],[3]	-3.50%	[1],[2],[3]
Tax settlements and resolution of certain tax positions(d)	-2.90%	[4]	-5.70%	[4]	-12.80%	[4]
U.S. Healthcare Legislation(d)	1.00%	[4]	0.60%	[4]	1.00%	[4]
U.S. R&D tax credit and manufacturing deduction(d)	-0.90%	[4]	-0.80%	[4]	-0.30%	[4]
Certain legal settlements and charges(d)	0.00%	[4]	-0.20%	[4]	1.50%	[4]
All other, net	0.50%		1.00%		-1.10%
Effective tax rate for income from continuing operations	25.50%		27.40%		19.80%
Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	40.00%
[1]	The favorable rate impact in 2014 also includes the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely. The rate impact in 2013 also includes the non-deductibility of the goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer, and the non-deductibility of the loss on an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely, and the non-deductibility of an impairment charge related to our equity-method investment in Teuto. For additional information, see Note 2E.
[2]	For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision for taxes on income.
[3]	In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations.
[4]	For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and the impact of certain legal settlements and charges, see Note 5A. The extension of the U.S. R&D tax credit in January 2013 resulted in the full-year benefit of the 2012 and 2013 U.S. R&D tax credit being recorded in 2013.

Tax_Matters_Deferred_Taxes_Det

Tax Matters - Deferred Taxes (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Deferred Tax Assets
Prepaid/deferred items - Deferred tax assets	$1,995		$1,913
Inventories - Deferred tax assets	219		277
Intangibles - Deferred tax assets	969		892
Property, plant and equipment - Deferred tax assets	174		376
Employee benefits - Deferred tax assets	3,950		3,154
Restructurings and other charges - Deferred tax assets	114		453
Legal and product liability reserves - Deferred tax assets	1,010		904
Net operating loss/credit carryforwards - Deferred tax assets	2,918	[1]	2,043	[1]
State and local tax adjustments - Deferred tax assets	295		297
All other - Deferred tax assets	283		249
Subtotal - Deferred tax assets	11,927		10,558
Valuation allowance	-1,615		-1,288
Total deferred taxes - Deferred tax assets	10,312		9,270
Deferred Tax Liabilities
Prepaid/deferred items - Deferred tax liabilities	-53		-134
Inventories - Deferred tax liabilities	-56		-217
Intangibles - Deferred tax liabilities	-9,224		-10,331
Property, plant and equipment - Deferred tax liabilities	-1,242		-1,390
Employee benefits - Deferred tax liabilities	-154		-77
Restructurings and other charges - Deferred tax liabilities	-28		-237
Unremitted earnings - Deferred tax liabilities	-21,174	[2]	-19,399	[2]
All other - Deferred tax liabilities	-783		-448
Deferred Tax Liabilities, Gross	-32,714		-32,233
Net deferred tax liability	($22,402)	[3],[4]	($22,963)	[3],[4]
[1]	The amounts in 2014 and 2013 are reduced for unrecognized tax benefits of $2.6 billion and $2.3 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
[2]	The increase in 2014 reflects additional accruals for certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year. For additional information, see Note 5A.
[3]	The net deferred tax liability position decreased, reflecting an increase in noncurrent deferred tax assets related to net operating loss and tax credit carryforwards, an increase in current deferred tax assets related to product liability reserves due to settlements, an increase in noncurrent deferred tax assets related to employee benefits, and a decrease in noncurrent deferred tax liabilities resulting from the amortization of identifiable intangible assets, partially offset by the increase in noncurrent deferred tax liabilities related to unremitted earnings.
[4]	In 2014, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($515 million), Other current liabilities ($43 million) and Noncurrent deferred tax liabilities ($25.0 billion). In 2013, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($569 million), Other current liabilities ($52 million) and Noncurrent deferred tax liabilities ($25.6 billion).

Tax_Matters_Deferred_Taxes_Foo

Tax Matters - Deferred Taxes - Footnotes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Income Tax Examination [Line Items]
Reduction for unrecognized tax benefit	$2,600,000,000		$2,300,000,000
Net deferred tax liability	22,402,000,000	[1],[2]	22,963,000,000	[1],[2]
Current Deferred Tax Assets And Other Current Tax Assets [Member]
Income Tax Examination [Line Items]
Net deferred tax liability	2,100,000,000		2,100,000,000
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Examination [Line Items]
Net deferred tax liability	515,000,000		569,000,000
Other Current Liabilities [Member]
Income Tax Examination [Line Items]
Net deferred tax liability	43,000,000		52,000,000
Noncurrent Deferred Tax Liabilities [Member]
Income Tax Examination [Line Items]
Net deferred tax liability	$25,000,000,000		$25,600,000,000
[1]	The net deferred tax liability position decreased, reflecting an increase in noncurrent deferred tax assets related to net operating loss and tax credit carryforwards, an increase in current deferred tax assets related to product liability reserves due to settlements, an increase in noncurrent deferred tax assets related to employee benefits, and a decrease in noncurrent deferred tax liabilities resulting from the amortization of identifiable intangible assets, partially offset by the increase in noncurrent deferred tax liabilities related to unremitted earnings.
[2]	In 2014, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($515 million), Other current liabilities ($43 million) and Noncurrent deferred tax liabilities ($25.0 billion). In 2013, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($569 million), Other current liabilities ($52 million) and Noncurrent deferred tax liabilities ($25.6 billion).

Tax_Matters_Reconciliation_of_

Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Income Tax Disclosure [Abstract]
Balance, beginning	($6,087)	[1]	($6,315)	[1]	($7,309)
Divestitures(a)	0	[2]	29	[2]	85	[2]
Increases based on tax positions taken during a prior period(b)	-110	[3]	-205	[3]	-139	[3]
Decreases based on tax positions taken during a prior period(b), (c)	473	[3],[4]	876	[3],[4]	1,442	[3],[4]
Decreases based on settlements for a prior period(d)	70	[5]	571	[5]	647	[5]
Increases based on tax positions taken during the current period(b)	-795	[3]	-1,178	[3]	-1,125	[3]
Impact of foreign exchange	161		38		78
Other, net(b), (e)	106	[3],[6]	97	[3],[6]	6	[3],[6]
Balance, ending(f)	($6,182)	[1]	($6,087)	[1]	($6,315)	[1]
[1]	In 2014, included in Income taxes payable ($13 million), Current deferred tax assets and other current tax assets ($59 million), Noncurrent deferred tax assets and other noncurrent tax assets ($165 million), Current deferred tax liabilities ($13 million), Noncurrent deferred tax liabilities ($2.4 billion) and Other taxes payable ($3.5 billion). In 2013, included in Income taxes payable ($51 million), Current deferred tax assets and other current tax assets ($63 million), Noncurrent deferred tax assets and other noncurrent tax assets ($241 million), Noncurrent deferred tax liabilities ($2.3 billion) and Other taxes payable ($3.4 billion).
[2]	Primarily relates to the sales of our Nutrition and Animal Health (Zoetis) businesses. See also Note 2D.
[3]	Primarily included in Provision for taxes on income.
[4]	Primarily related to effectively settling certain tax positions with the U.S. and foreign tax authorities. See also Note 5A.
[5]	Primarily related to cash payments.
[6]	Includes decreases as a result of a lapse of applicable statutes of limitations.

Tax_Matters_Reconciliation_of_1

Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
In Millions, unless otherwise specified
Income Tax Contingency [Line Items]
Net deferred tax liability	$22,402	[1],[2]	$22,963	[1],[2]
Unrecognized tax benefits	6,182	[3]	6,087	[3]	6,315	[3]	7,309
Income Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	13		51
Current Deferred Tax Assets And Other Current Tax Assets [Member]
Income Tax Contingency [Line Items]
Net deferred tax liability	2,100		2,100
Unrecognized tax benefits	59		63
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Contingency [Line Items]
Net deferred tax liability	515		569
Unrecognized tax benefits	165		241
Current Deferred Tax Liability [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	13
Other Current Liabilities [Member]
Income Tax Contingency [Line Items]
Net deferred tax liability	43		52
Noncurrent Deferred Tax Liabilities [Member]
Income Tax Contingency [Line Items]
Net deferred tax liability	25,000		25,600
Unrecognized tax benefits	2,400		2,300
Other Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	$3,500		$3,400
[1]	The net deferred tax liability position decreased, reflecting an increase in noncurrent deferred tax assets related to net operating loss and tax credit carryforwards, an increase in current deferred tax assets related to product liability reserves due to settlements, an increase in noncurrent deferred tax assets related to employee benefits, and a decrease in noncurrent deferred tax liabilities resulting from the amortization of identifiable intangible assets, partially offset by the increase in noncurrent deferred tax liabilities related to unremitted earnings.
[2]	In 2014, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($515 million), Other current liabilities ($43 million) and Noncurrent deferred tax liabilities ($25.0 billion). In 2013, included in Current deferred tax assets and other current tax assets ($2.1 billion), Noncurrent deferred tax assets and other noncurrent tax assets ($569 million), Other current liabilities ($52 million) and Noncurrent deferred tax liabilities ($25.6 billion).
[3]	In 2014, included in Income taxes payable ($13 million), Current deferred tax assets and other current tax assets ($59 million), Noncurrent deferred tax assets and other noncurrent tax assets ($165 million), Current deferred tax liabilities ($13 million), Noncurrent deferred tax liabilities ($2.4 billion) and Other taxes payable ($3.5 billion). In 2013, included in Income taxes payable ($51 million), Current deferred tax assets and other current tax assets ($63 million), Noncurrent deferred tax assets and other noncurrent tax assets ($241 million), Noncurrent deferred tax liabilities ($2.3 billion) and Other taxes payable ($3.4 billion).

Tax_Matters_Taxes_on_Items_of_

Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)
Foreign currency translation adjustments(a)	$42	[1]	$111	[1]	$110	[1]
Unrealized holding gains on derivative financial instruments, net	-199		217		251
Reclassification adjustments for realized (gains)/losses	262		-63		-144
Other comprehensive income (loss), derivatives qualifying as hedges, tax, total	63		154		107
Unrealized holding gains/(losses) on available-for-sale securities, net	-56		57		15
Reclassification adjustments for realized (gains)/losses	10		-57		47
Other comprehensive income (loss), available-for-sale securities, tax, total	-46		0		62
Benefit plans: actuarial gains/(losses), net	-1,416		1,422		-721
Reclassification adjustments related to amortization	61		205		171
Reclassification adjustments related to settlements, net	35		2		105
Other	61		2		15
Defined benefit plan, amounts recognized in other comprehensive income (loss), net actuarial gain (loss), tax	-1,258		1,631		-430
Benefit plans: prior service credits and other, net	281		56		7
Reclassification adjustments related to amortization	-28		-23		-27
Reclassification adjustments related to curtailments, net	0		-1		-51
Other	-1		0		-3
Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax	253		32		-74
Tax provision/(benefit) on other comprehensive income/(loss)	($946)	[2],[3]	$1,928	[2],[3]	($225)	[2],[3]
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).
[3]	Amounts may not add due to rounding.

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	($3,271)	[1]
Other comprehensive income/(loss)(a)	-4,042	[1]	2,593	[1]	-1,831	[1]
Ending balance	-7,316	[1]	-3,271	[1]
Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	-3,271		-5,953		-4,129
Other comprehensive income/(loss)(a)	-4,045	[1],[2]	2,655	[1],[2]	-1,824	[1],[2]
Sale of 19.8% of subsidiary through an IPO(b)			27	[3]
Ending balance	-7,316		-3,271		-5,953
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	-590		-177		944
Other comprehensive income/(loss)(a)	-2,099	[2]	-440	[2]	-1,121	[2]
Sale of 19.8% of subsidiary through an IPO(b)			27	[3]
Ending balance	-2,689		-590		-177
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	79		-161		-183
Other comprehensive income/(loss)(a)	438	[2]	240	[2]	22	[2]
Sale of 19.8% of subsidiary through an IPO(b)			0	[3]
Ending balance	517		79		-161
Available-For-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	150		236		-132
Other comprehensive income/(loss)(a)	-372	[2]	-86	[2]	368	[2]
Sale of 19.8% of subsidiary through an IPO(b)			0	[3]
Ending balance	-222		150		236
Actuarial Gains/(Losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	-3,223		-6,110		-5,120
Other comprehensive income/(loss)(a)	-2,432	[2]	2,887	[2]	-990	[2]
Sale of 19.8% of subsidiary through an IPO(b)			0	[3]
Ending balance	-5,654		-3,223		-6,110
Prior Service (Costs)/ Credits and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	313		259		362
Other comprehensive income/(loss)(a)	419	[2]	54	[2]	-103	[2]
Sale of 19.8% of subsidiary through an IPO(b)			0	[3]
Ending balance	$733		$313		$259
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $3 million gain in 2014, $62 million loss in 2013 and $7 million loss in 2012.
[3]	Relates to Zoetis (our former Animal Health subsidiary). See Note 2D.

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Detail) (USD $)	12 Months Ended			0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 24, 2013	Feb. 06, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustments attributable to noncontrolling interests	$3	($62)	($7)
Zoetis [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage offered in IPO				80.20%
IPO [Member] | Zoetis [Member] | Subsidiaries [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage offered in IPO					19.80%

Accumulated_Other_Comprehensiv4

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Narrative (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Prior service credits related primarily to benefit plan amendments	$419
Actuarial Gains/(Losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Prior service credits related primarily to benefit plan amendments	-549
Prior Service (Costs)/ Credits and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Prior service credits related primarily to benefit plan amendments	$138

Financial_Instruments_Assets_a

Financial Instruments Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Other selected financial assets
Total selected financial assets	$53,627		$49,246
Other selected financial liabilities(h)
Short-term borrowings, carried at historical proceeds, as adjusted(e)	5,141	[1]	6,027	[1]
Long-term debt, carried at historical proceeds, as adjusted(i), (j)	31,541	[1]	30,462	[1]
Total selected financial liabilities	37,371	[2]	37,119	[2]
Reported Value Measurement [Member]
Other selected financial assets
Held-to-maturity debt securities, carried at amortized cost(c), (e)	7,255	[3],[4]	9,139	[3],[4]
Private equity securities, carried at equity-method or at cost(e), (f)	1,993	[4],[5]	2,270	[4],[5]
Total	9,248		11,409
Other selected financial liabilities(h)
Short-term borrowings, carried at historical proceeds, as adjusted(e)	5,141	[4],[6]	6,027	[4],[6]
Long-term debt, carried at historical proceeds, as adjusted(i), (j)	31,541	[6],[7],[8]	30,462	[6],[7],[8]
Total	36,682	[6]	36,489	[6]
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading securities	105	[2],[9]	126	[2],[9]
Selected financial assets measured at fair value on a recurring basis(a)	44,379	[2]	37,837	[2]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	689	[10]	630	[10]
Fair Value, Measurements, Recurring [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in a receivable position(d):	801	[11],[2]	468	[11],[2]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	17	[10],[2]	301	[10],[2]
Fair Value, Measurements, Recurring [Member] | Currency Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in a receivable position(d):	593	[11],[2]	871	[11],[2]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	594	[10],[2]	110	[10],[2]
Fair Value, Measurements, Recurring [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in a receivable position(d):	547	[11],[2]	172	[11],[2]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	78	[10],[2]	219	[10],[2]
Fair Value, Measurements, Recurring [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	39,762	[2],[3]	34,899	[2],[3]
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	2,174	[2]	945	[2]
Fair Value, Measurements, Recurring [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	$397	[2],[3]	$356	[2],[3]
[1]	Amounts may not add due to rounding.
[2]	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 1% that use Level 1 inputs.
[3]	Gross unrealized gains and losses are not significant.
[4]	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2014 or December 31, 2013. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs.
[5]	Our private equity securities represent investments in the life sciences sector.
[6]	Some carrying amounts may include adjustments for discount or premium amortization or for the effect of hedging the interest rate fair value risk associated with certain financial liabilities by interest rate swaps.
[7]	Includes foreign currency debt with fair values of $560 million as of December 31, 2014 and $651 million as of December 31, 2013, which are used as hedging instruments.
[8]	The fair value of our long-term debt (not including the current portion of long-term debt) was $36.6 billion as of December 31, 2014 and $35.1 billion as of December 31, 2013. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance.
[9]	Trading securities are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
[10]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $121 million and foreign currency forward-exchange contracts with fair values of $54 million as of December 31, 2014; and foreign currency swaps with fair values of $76 million and foreign currency forward-exchange contracts with fair values of $77 million as of December 31, 2013.
[11]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $159 million as of December 31, 2014; and interest rate swaps with fair values of $38 million, foreign currency swaps with fair values of $30 million and foreign currency forward-exchange contracts with fair values of $66 million as of December 31, 2013.

Financial_Instruments_Assets_a1

Financial Instruments Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	$36,600	$35,100
Designated as Hedging Instrument [Member] | Foreign Currency Long Term Debt [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	560	651
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Instruments used as offsets (assets)	159	66
Instruments used as offsets (liabilities)	54	77
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Instruments used as offsets (assets)		38
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument [Member] | Currency Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Instruments used as offsets (assets)		30
Instruments used as offsets (liabilities)	$121	$76
Maximum [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of financial assets and liabilities measured at fair value inputs Level 1 and Level 3 inputs	1.00%

Financial_Instruments_by_Balan

Financial Instruments by Balance Sheet Grouping (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	$53,627		$49,246
Selected financial liabilities	37,371	[1]	37,119	[1]
Cash and Cash Equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	1,389		1,104
Short-term Investments [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	32,779		30,225
Long-term Investments [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	17,518		16,406
Other Current Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	1,059	[2]	286	[2]
Other Noncurrent Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	881	[3]	1,225	[3]
Short-Term Debt And Current Portion of Long-Term Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	5,141		6,027
Other Current Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	93	[4]	303	[4]
Long-term Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	31,541		30,462
Other Noncurrent Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	$596	[5]	$327	[5]
[1]	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 1% that use Level 1 inputs.
[2]	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($34 million), foreign currency swaps ($494 million) and foreign currency forward-exchange contracts ($531 million) and, as of December 31, 2013, include interest rate swaps ($90 million), foreign currency swaps ($24 million) and foreign currency forward-exchange contracts ($172 million).
[3]	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($767 million) and foreign currency swaps ($99 million) and foreign currency forward-exchange contracts ($15 million) and, as of December 31, 2013, include interest rate swaps ($378 million) and foreign currency swaps ($847 million).
[4]	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($13 million) and foreign currency forward-exchange contracts ($78 million) and, as of December 31, 2013, include foreign currency swaps ($84 million) and foreign currency forward-exchange contracts ($219 million).
[5]	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($16 million) and foreign currency swaps ($581 million) and, as of December 31, 2013, include interest rate swaps ($301 million) and foreign currency swaps ($26 million).

Financial_Instruments_by_Balan1

Financial Instruments by Balance Sheet Grouping - Footnotes (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	$53,627		$49,246
Selected financial liabilities	37,371	[1]	37,119	[1]
Other Current Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	1,059	[2]	286	[2]
Other Current Assets [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	34		90
Other Current Assets [Member] | Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	494		24
Other Current Assets [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	531		172
Other Noncurrent Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	881	[3]	1,225	[3]
Other Noncurrent Assets [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	767		378
Other Noncurrent Assets [Member] | Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	99		847
Other Noncurrent Assets [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	15
Other Current Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	93	[4]	303	[4]
Other Current Liabilities [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	1
Other Current Liabilities [Member] | Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	13		84
Other Current Liabilities [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	78		219
Other Noncurrent Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	596	[5]	327	[5]
Other Noncurrent Liabilities [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	16		301
Other Noncurrent Liabilities [Member] | Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	$581		$26
[1]	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 1% that use Level 1 inputs.
[2]	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($34 million), foreign currency swaps ($494 million) and foreign currency forward-exchange contracts ($531 million) and, as of December 31, 2013, include interest rate swaps ($90 million), foreign currency swaps ($24 million) and foreign currency forward-exchange contracts ($172 million).
[3]	As of December 31, 2014, derivative instruments at fair value include interest rate swaps ($767 million) and foreign currency swaps ($99 million) and foreign currency forward-exchange contracts ($15 million) and, as of December 31, 2013, include interest rate swaps ($378 million) and foreign currency swaps ($847 million).
[4]	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($13 million) and foreign currency forward-exchange contracts ($78 million) and, as of December 31, 2013, include foreign currency swaps ($84 million) and foreign currency forward-exchange contracts ($219 million).
[5]	At December 31, 2014, derivative instruments at fair value include interest rate swaps ($16 million) and foreign currency swaps ($581 million) and, as of December 31, 2013, include interest rate swaps ($301 million) and foreign currency swaps ($26 million).

Financial_Instruments_Investme

Financial Instruments - Investments in Debt Securities (Detail) (USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Debt securities maturities within 1 year	$31,994
Debt securities maturities over 1 to 5 years	13,476
Debt securities maturities over 5 to 10 years	1,501
Debt securities maturities after 10 Years	46
Total debt securities	47,017
Western European, Asian and other government debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	13,281	[1]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	2,281	[1]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0	[1]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[1]
Available-for-sale debt securities maturities total	15,561	[1]
Corporate debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	2,756	[2]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	3,847	[2]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	1,370	[2]
Available-for-sale securities, debt maturities, over 10 years, fair value	46	[2]
Available-for-sale debt securities maturities total	8,019	[2]
U.S. government debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	2,246
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	2,277
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	21
Available-for-sale securities, debt maturities, over 10 years, fair value	0
Available-for-sale debt securities maturities total	4,543
Western European, Asian, Scandinavia And Other Government Agency Debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	2,417	[1]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	435	[1]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0	[1]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[1]
Available-for-sale debt securities maturities total	2,853	[1]
Supranational debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	1,293	[1]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	905	[1]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0	[1]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[1]
Available-for-sale debt securities maturities total	2,198	[1]
Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	16
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	1,850
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	72
Available-for-sale securities, debt maturities, over 10 years, fair value	0
Available-for-sale debt securities maturities total	1,938
Reverse repurchase agreements [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	1,589	[3]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	0	[3]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0	[3]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[3]
Available-for-sale debt securities maturities total	1,589	[3]
Government National Mortgage Association Certificates and Obligations (GNMA) [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	198
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	793
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	27
Available-for-sale securities, debt maturities, over 10 years, fair value	0
Available-for-sale debt securities maturities total	1,017
Asset-backed Securities [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	960	[4]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	1,077	[4]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	9	[4]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[4]
Available-for-sale debt securities maturities total	2,046	[4]
Western European, Asian And Other Government Agency Debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Held-to-maturity securities, debt maturities, within 1 year, fair value	3,893	[1]
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value	0	[1]
Held-to-maturity securities, debt maturities, over 5 to 10 years, fair value	0	[1]
Held-to-maturity securities, debt maturities, over 10 years, fair value	0	[1]
Held-to-maturity debt securities maturities total	3,893	[1]
Time Deposits, Corporate Debt And Other [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Held-to-maturity securities, debt maturities, within 1 year, fair value	3,346	[2]
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value	12	[2]
Held-to-maturity securities, debt maturities, over 5 to 10 years, fair value	3	[2]
Held-to-maturity securities, debt maturities, over 10 years, fair value	0	[2]
Held-to-maturity debt securities maturities total	$3,361	[2]
[1]	Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade.
[2]	Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade.
[3]	Involving U.S. securities.
[4]	Includes loan-backed, receivable-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and receivable-backed securities are collateralized by credit cards receivables. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.

Financial_Instruments_Narrativ

Financial Instruments - Narrative (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Derivative, net liability position, aggregate fair value	$233,000,000
Collateral already posted, aggregate fair value	231,000,000
Additional collateral, aggregate fair value	5,000,000
Cash and Cash Equivalents [Member]
Credit Risk Derivatives, at Fair Value, Net [Abstract]
Securities received as collateral	1,600,000,000
Derivative [Member]
Credit Risk Derivatives, at Fair Value, Net [Abstract]
Concentration risk, credit risk, financial instrument, maximum exposure	3,500,000,000
Commercial Paper [Member]
Short-term Debt [Abstract]
Commercial paper	570,000,000	3,000,000,000
Commercial paper, weighted average interest rate	2.50%	1.70%
Line of Credit [Member]
Short-term Debt [Abstract]
Line of credit facility, current borrowing capacity	8,400,000,000
Line of credit facility, current borrowing capacity, expiring within one year	822,000,000
Debt instrument, expiration period	1 year
Line of credit facility, remaining borrowing capacity	8,100,000,000
Line of credit facility, committed amount	7,100,000,000
Line of Credit [Member] | Commercial Paper [Member]
Short-term Debt [Abstract]
Line of credit facility, remaining borrowing capacity	$7,000,000,000

Financial_Instruments_LongTerm

Financial Instruments - Long-Term Debt (Details) (USD $)	12 Months Ended					1 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013		15-May-14	Jun. 03, 2013
Debt Instrument [Line Items]
Long-term debt	$31,541,000,000
Principal payments on long-term debt	2,104,000,000		4,146,000,000		1,513,000,000
Short term borrowings, current portion of long term debt	3,011,000,000	[1]	2,060,000,000	[1]		2,060,000,000	[1]
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt instrument, face amount								4,500,000,000	4,000,000,000
Long-term debt	31,541,000,000		30,462,000,000			30,462,000,000
Short term borrowings, current portion of long term debt	3,011,000,000		2,060,000,000			2,060,000,000
Unsecured Debt [Member] | Senior Unsecured Debt, 3.625%, Due 2013 [Member]
Debt Instrument [Line Items]
Interest rate, percentage									3.63%
Long-term debt					2,400,000,000
Unsecured Debt [Member] | Senior Unsecured Debt, 5.5%, Due 2014 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.50%		5.50%			5.50%
Principal payments on long-term debt						1,800,000,000
Unsecured Debt [Member] | Senior Unsecured Debt, 6.2%, Due 2019 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	6.20%
Long-term debt	3,264,000,000	[2]	3,234,000,000	[2]		3,234,000,000	[2]
Unsecured Debt [Member] | Senior Unsecured Debt, 7.2%, Due 2039 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	7.20%
Long-term debt	2,902,000,000	[2]	2,603,000,000	[2]		2,603,000,000	[2]
Unsecured Debt [Member] | Senior Unsecured Euro Debt, 4.75%, Due 2016 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	4.75%
Long-term debt	2,424,000,000	[3]	2,752,000,000	[3]		2,752,000,000	[3]
Unsecured Debt [Member] | Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.75%
Long-term debt	2,419,000,000	[3]	2,748,000,000	[3]		2,748,000,000	[3]
Unsecured Debt [Member] | Senior Unsecured Great Britain Pound Debt, 6.5%, Due 2038 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	6.50%
Long-term debt	2,316,000,000	[3]	2,459,000,000	[3]		2,459,000,000	[3]
Unsecured Debt [Member] | Senior Unsecured Debt, 5.95%, Due 2037 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.95%
Long-term debt	2,083,000,000	[4]	2,085,000,000	[4]		2,085,000,000	[4]
Unsecured Debt [Member] | Senior Unsecured Debt, 2.10%, Due 2019 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	2.10%
Long-term debt	1,507,000,000	[4]	0	[4]		0	[4]
Unsecured Debt [Member] | Senior Unsecured Euro Debt, 4.55%, Due 2017 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	4.55%
Long-term debt	1,201,000,000	[5]	1,390,000,000	[5]		1,390,000,000	[5]
Unsecured Debt [Member] | Senior Unsecured Debt, 5.5%, Due 2016 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.50%
Long-term debt	1,018,000,000	[3]	1,033,000,000	[3]		1,033,000,000	[3]
Unsecured Debt [Member] | Senior Unsecured Debt, 5.35%, Due 2015 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.35%
Long-term debt	0	[6]	3,037,000,000	[6]		3,037,000,000	[6]
Unsecured Debt [Member] | Notes Payable And Other Debt, Weighted Average Interest Rate 5.11% Percent, Various Maturity Dates [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.11%
Long-term debt	6,698,000,000	[7]	4,810,000,000	[7]		4,810,000,000	[7]
Unsecured Debt [Member] | Notes Payable And Other Debt, Weighted Average Interest Rate 3.19%, Various Maturity Dates [Member]
Debt Instrument [Line Items]
Interest rate, percentage	3.19%
Long-term debt	5,161,000,000	[8]	3,683,000,000	[8]		3,683,000,000	[8]
Unsecured Debt [Member] | Foreign Currency Notes Payable And Other Foreign Currency Debt, Weighted Average Interest Rate, 2.84%, Various Maturity Dates [Member]
Debt Instrument [Line Items]
Interest rate, percentage	2.84%
Long-term debt	$547,000,000	[9]	$628,000,000	[9]		$628,000,000	[9]
[1]	Amounts may not add due to rounding.
[2]	Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.50%, plus, in each case, accrued and unpaid interest.
[3]	Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at a comparable government bond rate plus 0.20%. plus, in each case, accrued and unpaid interest.
[4]	The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.25% for the 5.95% notes and 0.07% for the 2.10% notes, plus, in each case, accrued and unpaid interest.
[5]	The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the price at which the gross redemption yield on the notes would be equal to the gross redemption yield of a comparable European government bond (selected at the discretion of the Trustee) on the basis of the middle market price of such European government bond.
[6]	At December 31, 2014, the note has been reclassified to Current portion of long-term debt.
[7]	Contains debt issuances with a weighted-average maturity of approximately 22 years, and the majority of which are redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average 0.22%, plus, in each case, accrued and unpaid interest.
[8]	Contains debt issuances with a weighted-average maturity of approximately 3 years, and the majority of which are redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average 0.14%, plus, in each case, accrued and unpaid interest.
[9]	Contains debt issuances with a weighted-average maturity of approximately 1 year.

Financial_Instruments_LongTerm1

Financial Instruments - Long-Term Debt - Footnotes (Detail)	12 Months Ended
	Dec. 31, 2014
Senior Unsecured Debt, 2.10%, Due 2019 [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.07%
Senior Unsecured Debt, 5.95%, Due 2037 [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.25%
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt redemption price, percentage	100.00%
Unsecured Debt [Member] | Senior Unsecured Debt, 2.10%, Due 2019 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	2.10%
Unsecured Debt [Member] | Senior Unsecured Debt, 5.95%, Due 2037 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.95%
Unsecured Debt [Member] | Notes Payable And Other Debt, Weighted Average Interest Rate 5.11% Percent, Various Maturity Dates [Member]
Debt Instrument [Line Items]
Interest rate, percentage	5.11%
Debt redemption price, basis spread percentage	0.22%
Long term debt weighted average maturity	22 years
Unsecured Debt [Member] | Notes Payable And Other Debt, Weighted Average Interest Rate 3.19%, Various Maturity Dates [Member]
Debt Instrument [Line Items]
Interest rate, percentage	3.19%
Debt redemption price, basis spread percentage	0.14%
Long term debt weighted average maturity	3 years
Unsecured Debt [Member] | Foreign Currency Notes Payable And Other Foreign Currency Debt, Weighted Average Interest Rate, 2.84%, Various Maturity Dates [Member]
Debt Instrument [Line Items]
Interest rate, percentage	2.84%
Long term debt weighted average maturity	1 year
Unsecured Debt [Member] | US Treasury Rate [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.50%
Unsecured Debt [Member] | Government Bond Rate [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.20%

Financial_Instruments_LongTerm2

Financial Instruments - Long-Term Debt Outstanding Maturities (Detail) (USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
Disclosure - Financial Instruments - Long-Term Debt Outstanding Maturities [Abstract]
2016	$3,990
2017	3,963
2018	2,399
2019	4,771
AFTER 2019	16,418
Total	$31,541

Financial_Instruments_Derivati

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt	$31,541,000,000	[1]	$30,462,000,000	[1]
Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	135,000,000	[2],[3]	776,000,000	[2],[3]
Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	160,000,000	[2],[4],[5]	31,000,000	[2],[4],[5]
Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	-477,000,000	[2],[3]	94,000,000	[2],[3]
Currency Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount	36,600,000,000
Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount	17,500,000,000
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Currency Swap [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	-799,000,000	[2],[3]	554,000,000	[2],[3]
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Currency Swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	0	[2],[4],[5]	0	[2],[4],[5]
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Currency Swap [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	-808,000,000	[2],[3]	220,000,000	[2],[3]
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	823,000,000	[2],[3]	-66,000,000	[2],[3]
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	0	[2],[4],[5]	0	[2],[4],[5]
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	332,000,000	[2],[3]	-126,000,000	[2],[3]
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Currency Swap [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	78,000,000	[2],[3]	156,000,000	[2],[3]
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Currency Swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	0	[2],[4],[5]	-3,000,000	[2],[4],[5]
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Currency Swap [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	0	[2],[3]
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	-1,000,000	[2],[3]
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	0	[2],[4],[5]	-3,000,000	[2],[4],[5]
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)			0	[2],[3]
Designated as Hedging Instrument [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	33,000,000	[2],[3]	133,000,000	[2],[3]
Designated as Hedging Instrument [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	0	[2],[4],[5]	0	[2],[4],[5]
Designated as Hedging Instrument [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Designated as Hedging Instrument [Member] | All other, net [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Designated as Hedging Instrument [Member] | All other, net [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	-3,000,000	[2],[4],[5]	-1,000,000	[2],[4],[5]
Designated as Hedging Instrument [Member] | All other, net [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Not Designated as Hedging Instrument [Member] | Currency Swap [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Not Designated as Hedging Instrument [Member] | Currency Swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	-2,000,000	[2],[4],[5]	-18,000,000	[2],[4],[5]
Not Designated as Hedging Instrument [Member] | Currency Swap [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID(a), (b), (c)	164,000,000	[2],[4],[5]	56,000,000	[2],[4],[5]
Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)(a), (d)	0	[2],[3]	0	[2],[3]
Senior Debt, Two Billion Five Hundred Million Pound, Due June 2023 [Member] | Unsecured Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt	$2,300,000,000
[1]	Amounts may not add due to rounding.
[2]	OID =ther (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income. OCI =ther comprehensive income/(loss), included in the consolidated statements of comprehensive income.
[3]	For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments.
[4]	There was no significant ineffectiveness for any period presented.
[5]	Also includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.

Inventories_Detail

Inventories (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]
Finished goods	$1,905		$2,216
Work-in-process	3,248		3,445
Raw materials and supplies	510		505
Inventories	5,663	[1]	6,166	[1]
Noncurrent inventories not included above(a)	$425	[2]	$463	[2]
[1]	Amounts may not add due to rounding.
[2]	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	24,988		$25,678
Less: Accumulated depreciation	13,226		13,281
Property, plant and equipment(a)	11,762	[1],[2]	12,397	[1],[2]	13,213
Land [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	529		557
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	9,355		10,055
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	9,671		10,050
Furniture, Fixtures and Other [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	4,162		3,914
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	1,271		$1,102
Minimum [Member] | Buildings [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	33 years
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	8 years
Minimum [Member] | Furniture, Fixtures and Other [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	3 years
Maximum [Member] | Buildings [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	50 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	20 years
Maximum [Member] | Furniture, Fixtures and Other [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	12 years 6 months
[1]	Amounts may not add due to rounding.
[2]	The decrease in total property, plant and equipment is primarily due to depreciation and, to a much lesser extent, disposals, impairments and the impact of foreign exchange, partially offset by capital additions.

Identifiable_Intangible_Assets2

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	$73,887		$74,677
Finite-lived intangible assets, accumulated amortization	-46,381	[1]	-43,119	[1]
Finite-lived intangible assets, less accumulated amortization	27,506		31,558
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	7,660		7,827
Intangible assets, gross carrying amount	81,547	[1]	82,504	[1]
Identifiable intangible assets, less accumulated amortization	35,166	[1],[2]	39,385	[1],[2]
Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	7,273		7,384
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	387		443
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	70,946		72,038
Finite-lived intangible assets, accumulated amortization	-44,694		-41,541
Finite-lived intangible assets, less accumulated amortization	26,252		30,497
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	1,951		1,743
Finite-lived intangible assets, accumulated amortization	-855		-773
Finite-lived intangible assets, less accumulated amortization	1,096		970
Licensing Agreements And Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	991		896
Finite-lived intangible assets, accumulated amortization	-832		-805
Finite-lived intangible assets, less accumulated amortization	$159		$91
[1]	The decrease in identifiable intangible assets, less accumulated amortization, is primarily due to amortization and, to a much lesser extent, asset impairment charges, partially offset by assets acquired as part of the InnoPharma acquisition,the Nexium OTC milestones and other asset acquisitions. For information about impairments of intangible assets, see Note 4. For information about the assets acquired from InnoPharma and the Nexium OTC milestones, see Note 2A and Note 2B, respectively.
[2]	Amounts may not add due to rounding.

Identifiable_Intangible_Assets3

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details) (Details)	Dec. 31, 2014
Global Innovative Pharmaceutical [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	33.00%
Global Innovative Pharmaceutical [Member] | Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	0.00%
Global Vaccines, Oncology and Consumer Healthcare [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	34.00%
Global Vaccines, Oncology and Consumer Healthcare [Member] | Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	80.00%
Global Established Pharmaceutical [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	33.00%
Global Established Pharmaceutical [Member] | Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	20.00%

Identifiable_Intangible_Assets4

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details) (Details)	Dec. 31, 2014
Global Vaccines, Oncology and Consumer Healthcare [Member] | Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	69.00%
Global Vaccines, Oncology and Consumer Healthcare [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	31.00%
Global Established Pharmaceutical [Member] | Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	31.00%
Global Established Pharmaceutical [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	62.00%
Global Innovative Pharmaceutical [Member] | Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	0.00%
Global Innovative Pharmaceutical [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	7.00%

Identifiable_Intangible_Assets5

Identifiable Intangible Assets and Goodwill - Narrative (Details) (USD $)	12 Months Ended
In Billions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets	$4.10	$4.80	$5.30
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years

Identifiable_Intangible_Assets6

Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Detail) (USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$3,665
2016	3,413
2017	3,311
2018	3,203
2019	$2,888

Identifiable_Intangible_Assets7

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Goodwill [Roll Forward]
Beginning balance	$42,519	[1]	$43,661
Derecognition(a)			-292	[2]
Additions(c)	125	[3]
Other(b)	-575	[4]	-850	[4]
Ending balance	42,069	[1]	42,519	[1]
Global Innovative Pharmaceutical [Member]
Goodwill [Roll Forward]
Beginning balance	13,210		13,482
Derecognition(a)			0	[2]
Additions(c)	0	[3]
Other(b)	-178	[4]	-272	[4]
Ending balance	13,032		13,210
Global Vaccines, Oncology and Consumer Healthcare [Member]
Goodwill [Roll Forward]
Beginning balance	11,559		11,766
Derecognition(a)			0	[2]
Additions(c)	0	[3]
Other(b)	-161	[4]	-207	[4]
Ending balance	11,398		11,559
Global Established Pharmaceutical [Member]
Goodwill [Roll Forward]
Beginning balance	17,750		18,413
Derecognition(a)			-292	[2]
Additions(c)	125	[3]
Other(b)	-236	[4]	-371	[4]
Ending balance	$17,639		$17,750
[1]	Amounts may not add due to rounding.
[2]	Reflects the goodwill derecognized as part of the transfer of certain product rights, which constituted a business, to our equity-method investment in China. For additional information, see Note 2E.
[3]	Reflects the acquisition of InnoPharma. For additional information, see Note 2A.
[4]	Primarily reflects the impact of foreign exchange.

Pension_and_Postretirement_Ben2

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Defined contribution plan, cost recognized	$278	$266	$297

Pension_and_Postretirement_Ben3

Pension and Postretirement Benefit Plans and Defined Contribution Plans (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost	$253	[1]	$301	[1]	$357	[1]
Interest Cost	697	[1]	666	[1]	697	[1]
Expected return on plan assets	-1,043	[1]	-999	[1]	-983	[1]
Actuarial losses	63	[1]	355	[1]	306	[1]
Prior service credits	-7	[1]	-7	[1]	-10	[1]
Curtailments	2	[1]	0	[1]	-62	[1]
Settlements	52	[1]	113	[1]	145	[1]
Special termination benefits	0	[1]	0	[1]	8	[1]
Net periodic benefit costs reported in Income	16	[1]	429	[1]	458	[1]
(Income)/cost reported in Other comprehensive income/(loss)(e)	2,768	[1],[2]	-3,044	[1],[2]	461	[1],[2]
(Income)/cost recognized in Comprehensive income	2,784	[1]	-2,615	[1]	919	[1]
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost	20	[3]	26	[3]	35	[3]
Interest Cost	57	[3]	67	[3]	62	[3]
Expected return on plan assets	0	[3]	0	[3]	0	[3]
Actuarial losses	29	[3]	51	[3]	41	[3]
Prior service credits	-2	[3]	-2	[3]	-3	[3]
Curtailments	0	[3]	0	[3]	-9	[3]
Settlements	28	[3]	40	[3]	33	[3]
Special termination benefits	0	[3]	0	[3]	30	[3]
Net periodic benefit costs reported in Income	132	[3]	182	[3]	189	[3]
(Income)/cost reported in Other comprehensive income/(loss)(e)	163	[2],[3]	-255	[2],[3]	110	[2],[3]
(Income)/cost recognized in Comprehensive income	294	[4]	-73	[4]	299	[4]
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost	199	[4]	216	[4]	215	[4]
Interest Cost	394	[4]	378	[4]	406	[4]
Expected return on plan assets	-459	[4]	-407	[4]	-424	[4]
Actuarial losses	97	[4]	129	[4]	93	[4]
Prior service credits	-7	[4]	-5	[4]	-7	[4]
Curtailments	0	[4]	-20	[4]	-16	[4]
Settlements	22	[4]	22	[4]	7	[4]
Special termination benefits	8	[4]	4	[4]	5	[4]
Net periodic benefit costs reported in Income	254	[4]	317	[4]	279	[4]
(Income)/cost reported in Other comprehensive income/(loss)(e)	260	[2],[4]	-569	[2],[4]	759	[2],[4]
(Income)/cost recognized in Comprehensive income	514	[4]	-252	[4]	1,038	[4]
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost	55	[5]	61	[5]	68	[5]
Interest Cost	169	[5]	166	[5]	182	[5]
Expected return on plan assets	-63	[5]	-55	[5]	-46	[5]
Actuarial losses	6	[5]	46	[5]	33	[5]
Prior service credits	-57	[5]	-44	[5]	-49	[5]
Curtailments	-7	[5]	-11	[5]	-65	[5]
Settlements	0	[5]	0	[5]	0	[5]
Special termination benefits	0	[5]	0	[5]	6	[5]
Net periodic benefit costs reported in Income	102	[5]	163	[5]	129	[5]
(Income)/cost reported in Other comprehensive income/(loss)(e)	-174	[2],[5]	-736	[2],[5]	267	[2],[5]
(Income)/cost recognized in Comprehensive income	($72)	[5]	($573)	[5]	$396	[5]
[1]	2014 v. 2013––The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses), (ii) lower service cost resulting from cost-reduction initiatives, (iii) lower settlement activity and (iv) greater expected return on plan assets resulting from an increased plan asset base, partially offset by higher interest costs resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation. 2013 v. 2012––The decrease in net periodic benefit cost for our U.S. qualified plans was primarily driven by (i) lower service cost resulting from cost reduction initiatives, (ii) lower settlements and (iii) higher expected return on plan assets resulting from an increased plan asset base, partially offset by the curtailment gain in 2012 resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico. Also, the decrease in the discount rate resulted in lower interest costs, as well as an increase in the amounts amortized for actuarial losses.
[2]	For details of the changes in Other comprehensive income/(loss), see the benefit plan activity in the consolidated statements of comprehensive income.
[3]	2014 v. 2013––The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation, (ii) lower settlement activity and (iii) lower interest costs. 2013 v. 2012––The decrease in net periodic benefit cost for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) a decrease in special termination benefits, partially offset by (ii) an increase in the amounts amortized for actuarial losses resulting from a decrease in discount rates, and (iii) the curtailment gain in 2012 resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico.
[4]	2014 v. 2013––The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) greater expected return on plan assets resulting from an increased plan asset base, (ii) the decrease in the amounts amortized for actuarial losses resulting from increases, in 2013, in the discount rates used to determine the benefit obligations, partially offset by (iii) increased curtailment losses primarily due to a loss relating to a U.K. pension plan freeze in the current year and (iv) changes in curtailments related to restructuring initiatives. 2013 v. 2012––The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from changes in assumptions, (ii) lower expected return on plan assets driven by lower expected rate of return in certain significant plans, (iii) higher settlements and (iv) 2012 curtailment gains, partially offset by (v) lower interest costs resulting from the decrease in discount rates.
[5]	2014 v. 2013––The decrease in net periodic benefit costs for our postretirement plans was primarily driven by the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses). 2013 v. 2012––The increase in net periodic benefit cost for our postretirement plans was primarily driven by (i) 2012 curtailment gains, partially offset by (ii) higher expected return on plan assets and (iii) a decrease in special termination benefits. Also, the decrease in the discount rate resulted in (iv) lower interest costs, as well as (v) an increase in the amounts amortized for actuarial losses.

Pension_and_Postretirement_Ben4

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$330
Prior service credits and other	-7
Total	-324
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	46
Prior service credits and other	-2
Total	-44
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	133
Prior service credits and other	-7
Total	-126
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	40
Prior service credits and other	-123
Total	$84

Pension_and_Postretirement_Ben5

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
U.S. Qualified Pension Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate	4.20%	5.20%	4.30%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase	2.80%	2.80%	2.80%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate	5.20%	4.30%	5.10%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets	8.50%	8.50%	8.50%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase	2.80%	2.80%	3.50%
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate	4.00%	4.80%	3.90%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase	2.80%	2.80%	2.80%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate	4.80%	3.90%	5.00%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase	2.80%	2.80%	3.50%
International Pension Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate	3.00%	3.90%	3.80%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase	2.70%	2.90%	3.10%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate	3.90%	3.80%	4.70%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets	5.80%	5.60%	5.90%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase	2.90%	3.10%	3.30%
Postretirement Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate	4.20%	5.10%	4.10%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate	5.10%	4.10%	4.80%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets	8.50%	8.50%	8.50%

Pension_and_Postretirement_Ben6

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Detail) (Postretirement Plans [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Healthcare cost trend rate assumed for next year	7.00%	7.30%
Rate to which the cost trend rate is assumed to decline	4.50%	4.50%
Year that the rate reaches the ultimate trend rate	2027	2027

Pension_and_Postretirement_Ben7

Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Detail) (Postretirement Plans [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Effect on total service and interest cost components, increase	$15
Effect on total service and interest cost components, decrease	-14
Effect on postretirement benefit obligation, increase	228
Effect on postretirement benefit obligation, decrease	($217)

Pension_and_Postretirement_Ben8

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
U.S. Qualified Pension Plans [Member]
Change in benefit obligation(e)
Benefit obligation, beginning	$13,976,000,000	[1],[2]	$16,268,000,000	[1],[2]
Service cost	253,000,000	[1],[2]	301,000,000	[1],[2]
Interest cost	697,000,000	[1],[2]	666,000,000	[1],[2]
Plan amendments	0	[1],[2]	0	[1],[2]
Changes in actuarial assumptions and other	2,653,000,000	[1],[2]	-2,257,000,000	[1],[2]
Foreign exchange impact	0	[1],[2]
Acquisitions/divestitures, net	0	[1],[2]	0	[1],[2]
Curtailments	2,000,000	[1],[2]	-8,000,000	[1],[2]
Settlements	-308,000,000	[1],[2]	-444,000,000	[1],[2]
Special termination benefits	0	[1],[2]	0	[1],[2]
Benefits paid	-697,000,000	[1],[2]	-550,000,000	[1],[2]
Benefit obligation, ending(e)	16,575,000,000	[1],[2]	13,976,000,000	[1],[2]
Change in plan assets
Fair value of plan assets, beginning	12,869,000,000	[2]	12,540,000,000	[2]
Actual gain on plan assets	819,000,000	[2]	1,318,000,000	[2]
Company contributions	23,000,000	[2]	5,000,000	[2]
Foreign exchange impact	0	[2]
Acquisitions/divestitures, net	0	[2]
Settlements	-308,000,000	[2]	-444,000,000	[2]
Benefits paid	-697,000,000	[1],[2]	-550,000,000	[1],[2]
Fair value of plan assets, ending	12,706,000,000	[2]	12,869,000,000	[2]
Funded status—Plan assets less than benefit obligation	-3,869,000,000	[2]	-1,107,000,000	[2]
Defined benefit plan, accumulated benefit obligation	16,300,000,000		13,700,000,000
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Change in benefit obligation(e)
Benefit obligation, beginning	1,341,000,000	[1],[3]	1,549,000,000	[1],[3]
Service cost	20,000,000	[1],[3]	26,000,000	[1],[3]
Interest cost	57,000,000	[1],[3]	67,000,000	[1],[3]
Plan amendments	0	[1],[3]	0	[1],[3]
Changes in actuarial assumptions and other	218,000,000	[1],[3]	-165,000,000	[1],[3]
Foreign exchange impact	0	[1],[3]
Acquisitions/divestitures, net			37,000,000	[1],[3]
Curtailments	0	[1],[3]	-1,000,000	[1],[3]
Settlements	-96,000,000	[1],[3]	-105,000,000	[1],[3]
Special termination benefits	0	[1],[3]	0	[1],[3]
Benefits paid	-58,000,000	[1],[3]	-67,000,000	[1],[3]
Benefit obligation, ending(e)	1,481,000,000	[1],[3]	1,341,000,000	[1],[3]
Change in plan assets
Fair value of plan assets, beginning	0	[3]
Company contributions	154,000,000	[3]	172,000,000	[3]
Foreign exchange impact	0	[3]
Settlements	-96,000,000	[3]	-105,000,000	[3]
Benefits paid	-58,000,000	[1],[3]	-67,000,000	[1],[3]
Fair value of plan assets, ending	0	[3]	0	[3]
Funded status—Plan assets less than benefit obligation	-1,481,000,000	[3]	-1,341,000,000	[3]
Defined benefit plan, accumulated benefit obligation	1,400,000,000		1,300,000,000
International Pension Plans [Member]
Change in benefit obligation(e)
Benefit obligation, beginning	10,316,000,000	[1],[4]	10,227,000,000	[1],[4]
Service cost	197,000,000	[1],[4]	216,000,000	[1],[4]
Interest cost	393,000,000	[1],[4]	378,000,000	[1],[4]
Employee contributions	8,000,000	[1],[4]	10,000,000	[1],[4]
Plan amendments	-54,000,000	[1],[4]	1,000,000	[1],[4]
Changes in actuarial assumptions and other	1,346,000,000	[1],[4]	229,000,000	[1],[4]
Foreign exchange impact	-794,000,000	[1],[4]	-66,000,000	[1],[4]
Acquisitions/divestitures, net	-55,000,000	[1],[4]	-63,000,000	[1],[4]
Curtailments	-127,000,000	[1],[4]	-64,000,000	[1],[4]
Settlements	-32,000,000	[1],[4]	-156,000,000	[1],[4]
Special termination benefits	8,000,000	[1],[4]	4,000,000	[1],[4]
Benefits paid	-408,000,000	[1],[4]	-400,000,000	[1],[4]
Benefit obligation, ending(e)	10,796,000,000	[1],[4]	10,316,000,000	[1],[4]
Change in plan assets
Fair value of plan assets, beginning	8,250,000,000	[4]	7,589,000,000	[4]
Actual gain on plan assets	1,046,000,000	[4]	976,000,000	[4]
Company contributions	316,000,000	[4]	380,000,000	[4]
Employee contributions	8,000,000	[1],[4]	10,000,000	[1],[4]
Foreign exchange impact	-594,000,000	[4]	-95,000,000	[4]
Acquisitions/divestitures, net	3,000,000	[4]	-54,000,000	[4]
Settlements	-32,000,000	[4]	-156,000,000	[4]
Benefits paid	-408,000,000	[1],[4]	-400,000,000	[1],[4]
Fair value of plan assets, ending	8,588,000,000	[4]	8,250,000,000	[4]
Funded status—Plan assets less than benefit obligation	-2,208,000,000	[4]	-2,066,000,000	[4]
Defined benefit plan, accumulated benefit obligation	10,300,000,000		9,700,000,000
Postretirement Plans [Member]
Change in benefit obligation(e)
Benefit obligation, beginning	3,438,000,000	[1],[5]	4,165,000,000	[1],[5]
Service cost	55,000,000	[1],[5]	61,000,000	[1],[5]
Interest cost	169,000,000	[1],[5]	166,000,000	[1],[5]
Employee contributions	75,000,000	[1],[5]	69,000,000	[1],[5]
Plan amendments	-692,000,000	[1],[5]	-152,000,000	[1],[5]
Changes in actuarial assumptions and other	447,000,000	[1],[5]	-540,000,000	[1],[5]
Foreign exchange impact	-10,000,000	[1],[5]	-9,000,000	[1],[5]
Acquisitions/divestitures, net	0	[1],[5]
Curtailments	-4,000,000	[1],[5]	-8,000,000	[1],[5]
Special termination benefits	0	[1],[5]	0	[1],[5]
Benefits paid	-309,000,000	[1],[5]	-314,000,000	[1],[5]
Benefit obligation, ending(e)	3,168,000,000	[1],[5]	3,438,000,000	[1],[5]
Change in plan assets
Fair value of plan assets, beginning	741,000,000	[5],[6]	644,000,000	[5]
Actual gain on plan assets	45,000,000	[5]	98,000,000	[5]
Company contributions	210,000,000	[5]	244,000,000	[5]
Employee contributions	75,000,000	[1],[5]	69,000,000	[1],[5]
Benefits paid	-309,000,000	[1],[5]	-314,000,000	[1],[5]
Fair value of plan assets, ending	762,000,000	[5],[6]	741,000,000	[5],[6]
Funded status—Plan assets less than benefit obligation	($2,406,000,000)	[5]	($2,697,000,000)	[5]
[1]	lans, the benefit obligation is the projected benefit obligation. For the postretirement plans, the benefit obligation is the accumulated postretirement benefit obligation (ABO). The ABO for all of our U.S. qualified pension plans was $16.3 billion in 2014 and $13.7 billion in 2013. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2014 and $1.3 billion 2013. The ABO for our international pension plans was $10.3 billion in 2014 and $9.7 billion in 2013.The following table provides information as to how the funded status is recognized in our consolidated balance sheets: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental(Non-Qualified) International PostretirementPlans(MILLIONS OF DOLLARS) 2014 2013 2014 2013 2014 2013 2014 2013Noncurrent assets(a) $— $— $— $— $509 $318 $— $—Current liabilities(b) — — (136) (151) (45) (46) (27) (29)Noncurrent liabilities(c) (3,869) (1,107) (1,345) (1,190) (2,671) (2,338) (2,379) (2,668)Funded status $(3,869) $(1,107) $(1,481) $(1,341) $(2,208) $(2,066) $(2,406) $(2,697)(a) Included primarily in Other noncu
[2]	The unfavorable change in the funded status of our U.S. qualified plans is primarily due to (i) a decrease in the discount rate (reflecting lower interest rates) and (ii) a change in mortality assumptions (reflecting a longer life expectancy for plan participants), which more than offset (iii) a gain on plan assets.
[3]	Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations.
[4]	rable change in the international plans' funded status was primarily due to (i) a decrease in the discount rate (reflecting lower interest rates), partially offset by (ii) the strengthening U.S. dollar and (iii) a gain on plan assets.(d) The favorab
[5]	he funded status of our postretirement plans is due to (i) a plan amendment that decreased the benefit obligation by transferring certain plan participants to a retiree drug coverage program eligible for a Medicare Part D plan subsidy, partially offset by (ii) a decrease in the discount rate (reflecting lower interest rates).(e) For the U.S. and international p
[6]	ch support a portion of our U.S. retiree medical plans.(c) Primarily includes investments in p

Pension_and_Postretirement_Ben9

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets(a)	$0	[1]	$0	[1]
Current liabilities(b)	0	[2]	0	[2]
Noncurrent liabilities(c)	-3,869	[3]	-1,107	[3]
Funded status	-3,869		-1,107
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets(a)	509	[1]	318	[1]
Current liabilities(b)	-45	[2]	-46	[2]
Noncurrent liabilities(c)	-2,671	[3]	-2,338	[3]
Funded status	-2,208		-2,066
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets(a)	0	[1]	0	[1]
Current liabilities(b)	-136	[2]	-151	[2]
Noncurrent liabilities(c)	-1,345	[3]	-1,190	[3]
Funded status	-1,481		-1,341
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets(a)	0	[1]	0	[1]
Current liabilities(b)	-27	[2]	-29	[2]
Noncurrent liabilities(c)	-2,379	[3]	-2,668	[3]
Funded status	($2,406)		($2,697)
[1]	ssets.(b) Included in Accrued compensation an
[2]	ated items.(c) Included in Pension benefit obligat
[3]	net and Postretirement benefit obligations, net, as appropriate.The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental(Non-Qualified) International PostretirementPlans(MILLIONS OF DOLLARS) 2014 2013 2014 2013 2014 2013 2014 2013Actuarial losses(a) $(4,735) $(1,974) $(567) $(406) $(2,527) $(2,213) $(745) $(292)Prior service (costs)/credits 35 42 10 11 36 (18) 1,098 470Total $(4,700) $(1,932) $(557) $(395) $(2,492) $(2,231) $352 $178(a) The accumulated actuarial losses

Recovered_Sheet1

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses(a)	($4,735)	[1]	($1,974)	[1]
Prior service (costs)/credits	35		42
Total	-4,700		-1,932
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses(a)	-567	[1]	-406	[1]
Prior service (costs)/credits	10		11
Total	-557		-395
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses(a)	-2,527	[1]	-2,213	[1]
Prior service (costs)/credits	36		-18
Total	-2,492		-2,231
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses(a)	-745	[1]	-292	[1]
Prior service (costs)/credits	1,098		470
Total	$352		$178
[1]	ly represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants, using the corridor approach. The average amortization periods utilized are 9.5 years for our U.S. qualified plans, 9.4 years for our U.S. supplemental (non-qualified) plans, 17.4 years for our international plans, and 10.6 years for our postretirement plans.The following table provides information related to the funded status of selected benefit plans: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International(MILLIONS OF DOLLARS) 2014 2013 2014 2013 2014 2013Pension plans with an accumulated benefit obligation in excess of plan assets: Fair value of plan assets $12,706 $12,869 $— $— $1,718 $1,309Accumulated benefit obligation 16,323 13,704 1,447 1,294 4,021 3,348Pension plans with a projected benefit obligation in excess of plan assets: Fair value of plan assets 12,706 12,869 — — 1,999 2,499Projected benefit obligation 16,575 13,976 1,481 1,341 4,715 4,883All of our U.S. plans and many of our

Recovered_Sheet2

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income - Footnotes (Detail)	12 Months Ended
	Dec. 31, 2014
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	9 years 6 months
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	9 years 4 months 24 days
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	17 years 4 months 24 days
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	10 years 7 months 6 days

Recovered_Sheet3

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
U.S. Qualified Pension Plans [Member]
Pension plans with an accumulated benefit obligation in excess of plan assets:
Fair value of plan assets	$12,706	$12,869
Accumulated benefit obligation	16,323	13,704
Pension plans with a projected benefit obligation in excess of plan assets:
Fair value of plan assets	12,706	12,869
Projected benefit obligation	16,575	13,976
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Pension plans with an accumulated benefit obligation in excess of plan assets:
Accumulated benefit obligation	1,447	1,294
Pension plans with a projected benefit obligation in excess of plan assets:
Projected benefit obligation	1,481	1,341
International Pension Plans [Member]
Pension plans with an accumulated benefit obligation in excess of plan assets:
Fair value of plan assets	1,718	1,309
Accumulated benefit obligation	4,021	3,348
Pension plans with a projected benefit obligation in excess of plan assets:
Fair value of plan assets	1,999	2,499
Projected benefit obligation	$4,715	$4,883

Recovered_Sheet4

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$12,706	[1]	$12,869	[1]	$12,540	[1]
U.S. Qualified Pension Plans [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,475	[2]	4,328	[2]
U.S. Qualified Pension Plans [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,024	[2]	6,894	[2]
U.S. Qualified Pension Plans [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,207	[2]	1,647	[2]
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	756		360
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	84	[2]
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	672	[2]	360	[2]
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,394		4,335
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,845		2,294
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,391	[2]	4,328	[2]
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	[2]	7	[2]
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,698	[2]	2,294	[2]
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 3 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	[2]	0	[2]
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 3 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	147	[2]
U.S. Qualified Pension Plans [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,013		2,042
U.S. Qualified Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,008	[2]	2,042	[2]
U.S. Qualified Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5	[2]
U.S. Qualified Pension Plans [Member] | Government Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,124		1,235
U.S. Qualified Pension Plans [Member] | Government Bonds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,124	[2]	1,235	[2]
U.S. Qualified Pension Plans [Member] | Government Bonds [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	[2]
U.S. Qualified Pension Plans [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	242		675
U.S. Qualified Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	242	[2]	675	[2]
U.S. Qualified Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	[2]	0	[2]
U.S. Qualified Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	958	[3]	932	[3]
U.S. Qualified Pension Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	958	[2],[3]	932	[2],[3]	950
U.S. Qualified Pension Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	278		281
U.S. Qualified Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	[2]
U.S. Qualified Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	278	[2]	281	[2]
U.S. Qualified Pension Plans [Member] | Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,096	[4]	715	[4]
U.S. Qualified Pension Plans [Member] | Other [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,096	[2],[4]	715	[2],[4]	673
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8,588	[5]	8,250	[5]	7,589	[5]
International Pension Plans [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,132	[2]	1,832	[2]
International Pension Plans [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,359	[2]	5,554	[2]
International Pension Plans [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,097	[2]	864	[2]
International Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	331		229
International Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	[2]
International Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	306	[2]	229	[2]
International Pension Plans [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,781		1,833
International Pension Plans [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,851		2,446
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,674	[2]	1,832	[2]
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	19	[2]
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	107	[2]	1	[2]
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,832	[2]	2,446	[2]
International Pension Plans [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	773		614
International Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	183	[2]
International Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	590	[2]	614	[2]
International Pension Plans [Member] | Government Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,213		812
International Pension Plans [Member] | Government Bonds [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140	[2]
International Pension Plans [Member] | Government Bonds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,073	[2]	812	[2]
International Pension Plans [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,037		968
International Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	44	[2]
International Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	969	[2]	968	[2]
International Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24	[2]
International Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	61	[3]	69	[3]
International Pension Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	[2],[3]	5	[2],[3]
International Pension Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	55	[2],[3]	64	[2],[3]
International Pension Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	425		421
International Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	[2]
International Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	150	[2]	121	[2]
International Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	274	[2]	300	[2]	346
International Pension Plans [Member] | Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,116	[4]	858	[4]
International Pension Plans [Member] | Other [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46	[2],[4]
International Pension Plans [Member] | Other [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	326	[2],[4]	358	[2],[4]
International Pension Plans [Member] | Other [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	744	[2],[4]	500	[2],[4]	389
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	762	[6],[7]	741	[6],[7]	644	[6]
Postretirement Plans [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	90	[2],[7]	105	[2],[7]
Postretirement Plans [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	614	[2],[7]	636	[2],[7]
Postretirement Plans [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	58	[2],[7]	0	[2],[7]
Postretirement Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18	[7]	29	[7]
Postretirement Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	[2],[7]
Postretirement Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	17	[2],[7]	29	[2],[7]
Postretirement Plans [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	89	[7]	105	[7]
Postretirement Plans [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	49	[7]	56	[7]
Postretirement Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	89	[2],[7]	105	[2],[7]
Postretirement Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	45	[2],[7]	56	[2],[7]
Postretirement Plans [Member] | Equity Securities [Member] | Fair value inputs Level 3 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4	[2],[7]
Postretirement Plans [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	79	[7]	50	[7]
Postretirement Plans [Member] | Corporate debt [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	79	[2],[7]	50	[2],[7]
Postretirement Plans [Member] | Government Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	[7]	30	[7]
Postretirement Plans [Member] | Government Bonds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	[2],[7]	30	[2],[7]
Postretirement Plans [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	[7]	16	[7]
Postretirement Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	[2],[7]	16	[2],[7]
Postretirement Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	[7],[8]	23	[7],[8]
Postretirement Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	[2],[7],[8]	23	[2],[7],[8]
Postretirement Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	[2],[7],[8]	0	[2],[7],[8]
Postretirement Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	437	[7]	415	[7]
Postretirement Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	437	[2],[7]	415	[2],[7]
Postretirement Plans [Member] | Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29	[4],[7]	17	[4],[7]
Postretirement Plans [Member] | Other [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	[2],[4],[7]	17	[2],[4],[7]
Postretirement Plans [Member] | Other [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$29	[2],[4],[7]
[1]	The unfavorable change in the funded status of our U.S. qualified plans is primarily due to (i) a decrease in the discount rate (reflecting lower interest rates) and (ii) a change in mortality assumptions (reflecting a longer life expectancy for plan participants), which more than offset (iii) a gain on plan assets.
[2]	ation inputs categorized as Level 1, 2 or 3 (see Note 1E).(b) Reflects postretirement plan assets
[3]	e equity, private debt and, to a lesser extent, real estate and venture capital.(d) Primarily includes, for U.S. plan a
[4]	, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs: Year Ended December 31, U.S. Qualified Pension Plans International Pension Plans Partnership investments Other commingled funds Insurance contracts Other(MILLIONS OF DOLLARS) 2014 2013 2014 2013 2014 2013 2014 2013Fair value, beginning $932 $950 $715 $673 $300 $346 $500 $389Actual return on plan assets: Assets held, ending 104 86 47 18 23 15 47 13Assets sold during the period — — (7) (6) — — 8 —Purchases, sales and settlements, net (78) (105) 341 31 (20) (40) 254 69Transfer into/(out of) Level 3 — — — — — (16) (19) 27Exchange rate changes — — — — (29) (5) (46) 2Fair value, ending $958 $932 $1,096 $715 $274 $300 $744 $500A single estimate of fair value can
[5]	rable change in the international plans' funded status was primarily due to (i) a decrease in the discount rate (reflecting lower interest rates), partially offset by (ii) the strengthening U.S. dollar and (iii) a gain on plan assets.(d) The favorab
[6]	he funded status of our postretirement plans is due to (i) a plan amendment that decreased the benefit obligation by transferring certain plan participants to a retiree drug coverage program eligible for a Medicare Part D plan subsidy, partially offset by (ii) a decrease in the discount rate (reflecting lower interest rates).(e) For the U.S. and international p
[7]	ch support a portion of our U.S. retiree medical plans.(c) Primarily includes investments in p
[8]	2014 v. 2013––The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) greater expected return on plan assets resulting from an increased plan asset base, (ii) the decrease in the amounts amortized for actuarial losses resulting from increases, in 2013, in the discount rates used to determine the benefit obligations, partially offset by (iii) increased curtailment losses primarily due to a loss relating to a U.K. pension plan freeze in the current year and (iv) changes in curtailments related to restructuring initiatives. 2013 v. 2012––The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from changes in assumptions, (ii) lower expected return on plan assets driven by lower expected rate of return in certain significant plans, (iii) higher settlements and (iv) 2012 curtailment gains, partially offset by (v) lower interest costs resulting from the decrease in discount rates.

Recovered_Sheet5

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	$12,869	[1]			$12,540	[1]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Exchange rate changes	0	[1]
Fair value of plan assets, ending	12,706	[1]			12,540	[1]
U.S. Qualified Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	958	[2]	932	[2]
U.S. Qualified Pension Plans [Member] | Other Funds [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	1,096	[3]	715	[3]
U.S. Qualified Pension Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	278		281
International Pension Plans [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	8,250	[4]	7,589	[4]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Exchange rate changes	-594	[4]	-95	[4]
Fair value of plan assets, ending	8,588	[4]	8,250	[4]
International Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	61	[2]	69	[2]
International Pension Plans [Member] | Other Funds [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	1,116	[3]	858	[3]
International Pension Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	425		421
Fair value inputs Level 3 [Member] | U.S. Qualified Pension Plans [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	2,207	[5]	1,647	[5]
Fair value inputs Level 3 [Member] | U.S. Qualified Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	932	[2],[5]	950
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Assets held, ending	104		86
Assets sold during the period			0
Purchases, sales and settlements, net	-78		-105
Fair value of plan assets, ending	958	[2],[5]	932	[2],[5]
Fair value inputs Level 3 [Member] | U.S. Qualified Pension Plans [Member] | Other Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	715	[3],[5]	673
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Assets held, ending	47		18
Assets sold during the period	-7		-6
Purchases, sales and settlements, net	341		31
Fair value of plan assets, ending	1,096	[3],[5]	715	[3],[5]
Fair value inputs Level 3 [Member] | International Pension Plans [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	1,097	[5]	864	[5]
Fair value inputs Level 3 [Member] | International Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	55	[2],[5]	64	[2],[5]
Fair value inputs Level 3 [Member] | International Pension Plans [Member] | Other Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	500	[3],[5]	389
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Assets held, ending	47		13
Assets sold during the period	8
Purchases, sales and settlements, net	254		69
Transfer into/(out of) Level 3	-19		27
Exchange rate changes	-46		2
Fair value of plan assets, ending	744	[3],[5]	500	[3],[5]
Fair value inputs Level 3 [Member] | International Pension Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	300	[5]	346
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Assets held, ending	23		15
Purchases, sales and settlements, net	-20		-40
Transfer into/(out of) Level 3			-16
Exchange rate changes	-29		-5
Fair value of plan assets, ending	$274	[5]	$300	[5]
[1]	The unfavorable change in the funded status of our U.S. qualified plans is primarily due to (i) a decrease in the discount rate (reflecting lower interest rates) and (ii) a change in mortality assumptions (reflecting a longer life expectancy for plan participants), which more than offset (iii) a gain on plan assets.
[2]	e equity, private debt and, to a lesser extent, real estate and venture capital.(d) Primarily includes, for U.S. plan a
[3]	, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs: Year Ended December 31, U.S. Qualified Pension Plans International Pension Plans Partnership investments Other commingled funds Insurance contracts Other(MILLIONS OF DOLLARS) 2014 2013 2014 2013 2014 2013 2014 2013Fair value, beginning $932 $950 $715 $673 $300 $346 $500 $389Actual return on plan assets: Assets held, ending 104 86 47 18 23 15 47 13Assets sold during the period — — (7) (6) — — 8 —Purchases, sales and settlements, net (78) (105) 341 31 (20) (40) 254 69Transfer into/(out of) Level 3 — — — — — (16) (19) 27Exchange rate changes — — — — (29) (5) (46) 2Fair value, ending $958 $932 $1,096 $715 $274 $300 $744 $500A single estimate of fair value can
[4]	rable change in the international plans' funded status was primarily due to (i) a decrease in the discount rate (reflecting lower interest rates), partially offset by (ii) the strengthening U.S. dollar and (iii) a gain on plan assets.(d) The favorab
[5]	ation inputs categorized as Level 1, 2 or 3 (see Note 1E).(b) Reflects postretirement plan assets

Recovered_Sheet6

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage	100.00%
Equity and debt securities, percentage of plan assets	100.00%	100.00%
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	0.00%
Equity and debt securities, target allocation percentage, maximum	10.00%
Equity and debt securities, percentage of plan assets	5.90%	2.80%
U.S. Qualified Pension Plans [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	35.00%
Equity and debt securities, target allocation percentage, maximum	55.00%
Equity and debt securities, percentage of plan assets	41.20%	51.50%
U.S. Qualified Pension Plans [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	28.00%
Equity and debt securities, target allocation percentage, maximum	53.00%
Equity and debt securities, percentage of plan assets	34.50%	30.70%
U.S. Qualified Pension Plans [Member] | Real Estate Investment [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	5.00%
Equity and debt securities, target allocation percentage, maximum	20.00%
Equity and debt securities, percentage of plan assets	18.40%	15.00%
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage	100.00%
Equity and debt securities, percentage of plan assets	100.00%	100.00%
International Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	0.00%
Equity and debt securities, target allocation percentage, maximum	10.00%
Equity and debt securities, percentage of plan assets	3.90%	2.80%
International Pension Plans [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	35.00%
Equity and debt securities, target allocation percentage, maximum	55.00%
Equity and debt securities, percentage of plan assets	42.30%	51.90%
International Pension Plans [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	28.00%
Equity and debt securities, target allocation percentage, maximum	53.00%
Equity and debt securities, percentage of plan assets	35.20%	29.00%
International Pension Plans [Member] | Real Estate Investment [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	5.00%
Equity and debt securities, target allocation percentage, maximum	20.00%
Equity and debt securities, percentage of plan assets	18.60%	16.30%
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage	100.00%
Equity and debt securities, percentage of plan assets	100.00%	100.00%
Postretirement Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	0.00%
Equity and debt securities, target allocation percentage, maximum	5.00%
Equity and debt securities, percentage of plan assets	2.40%	4.00%
Postretirement Plans [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	10.00%
Equity and debt securities, target allocation percentage, maximum	35.00%
Equity and debt securities, percentage of plan assets	18.10%	21.70%
Postretirement Plans [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	5.00%
Equity and debt securities, target allocation percentage, maximum	30.00%
Equity and debt securities, percentage of plan assets	15.10%	13.00%
Postretirement Plans [Member] | Real Estate Investment [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	55.00%
Equity and debt securities, target allocation percentage, maximum	70.00%
Equity and debt securities, percentage of plan assets	64.40%	61.30%

Recovered_Sheet7

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Detail) (USD $)	12 Months Ended				1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Jan. 31, 2015
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2015	$1,000	[1]
Expected benefit payments:
2015	904
2016	870
2017	932
2018	1,021
2019	949
2020-2024	4,874
Company contributions	23	[2]	5	[2]
U.S. Qualified Pension Plans [Member] | Subsequent Event [Member]
Expected benefit payments:
Company contributions					1,000
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2015	136	[1]
Expected benefit payments:
2015	136
2016	118
2017	124
2018	129
2019	114
2020-2024	547
Company contributions	154	[3]	172	[3]
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2015	227	[1]
Expected benefit payments:
2015	368
2016	376
2017	383
2018	390
2019	399
2020-2024	2,125
Company contributions	316	[4]	380	[4]
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2015	91	[1]
Expected benefit payments:
2015	261
2016	211
2017	216
2018	220
2019	222
2020-2024	1,146
Company contributions	$210	[5]	$244	[5]
[1]	For the U.S. Qualified plan, the $1.0 billion voluntary contribution was paid in January 2015.
[2]	The unfavorable change in the funded status of our U.S. qualified plans is primarily due to (i) a decrease in the discount rate (reflecting lower interest rates) and (ii) a change in mortality assumptions (reflecting a longer life expectancy for plan participants), which more than offset (iii) a gain on plan assets.
[3]	Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations.
[4]	rable change in the international plans' funded status was primarily due to (i) a decrease in the discount rate (reflecting lower interest rates), partially offset by (ii) the strengthening U.S. dollar and (iii) a gain on plan assets.(d) The favorab
[5]	he funded status of our postretirement plans is due to (i) a plan amendment that decreased the benefit obligation by transferring certain plan participants to a retiree drug coverage program eligible for a Medicare Part D plan subsidy, partially offset by (ii) a decrease in the discount rate (reflecting lower interest rates).(e) For the U.S. and international p

Equity_Narrative_Detail

Equity Narrative (Detail) (USD $)	12 Months Ended						0 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Jun. 24, 2013	Oct. 23, 2014	Jun. 27, 2013	Nov. 01, 2012	Dec. 12, 2011
	employee_stock_ownership_plan
Equity, Class of Treasury Stock [Line Items]
Amount of shares authorized in stock purchase plan, value								$11,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000
Total shares repurchased, shares	165,000,000		563,000,000		349,000,000
Total cost of shares repurchased	5,000,000,000	[1]	16,290,000,000	[1]	8,228,000,000	[1]
Amount of remaining shares authorized in stock purchase plan, value	11,500,000,000
Noncash transaction sale of subsidiary common stock for company common stock			11,408,000,000	[1],[2]
Number of employee stock ownership plans	2
Common ESOP Plan [Member]
Equity, Class of Treasury Stock [Line Items]
ESOP compensation expense	136,000,000		133,000,000		139,000,000
Common Stock [Member] | Preferred Employee Stock Ownership Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Series A convertible perpetual preferred stock, common stock shares when converted	2,574.87
Convertible preferred stock, number of shares convertible	2,000,000
Common Stock [Member] | Common ESOP Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Employee Stock Ownership Plan (ESOP), Shares in ESOP	61,000,000
Common Stock [Member] | Zoetis [Member]
Equity, Class of Treasury Stock [Line Items]
Company shares received in Exchange Offer							405,117,000
Noncash transaction sale of subsidiary common stock for company common stock							$11,400,000,000
Preferred Stock [Member] | Series A, Convertible Preferred Stock [Member] | Preferred Employee Stock Ownership Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Series A convertible perpetual preferred stock, dividends rate	6.25%
Series A convertible perpetual preferred stock, per share stated value	$40,300
Preferred stock, redemption price per share	$40,300
[1]	Amounts may not add due to rounding.
[2]	Relates to Zoetis (our former Animal Health subsidiary). See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures.

ShareBased_Payments_Narrative_

Share-Based Payments - Narrative (Detail)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for award	595,000,000
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized	520,000,000
Number of equity awards period	36 months
Maximum shares available per individual during the plan period	20,000,000
2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity awards period	36 months
Maximum shares available per individual during the plan period	8,000,000
Restricted Stock Units (RSUs) [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Restricted Stock Units (RSUs) [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	2
Portfolio Performance Shares [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Portfolio Performance Shares [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	2,000,000
Performance Shares [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Performance Shares [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	2,000,000
Employee Stock Option [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1
Employee Stock Option [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1
Total Shareholder Return Units (TSRU) [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1
Total Shareholder Return Units (TSRU) [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1,000,000

ShareBased_Payments_Impact_on_

Share-Based Payments - Impact on Net Income (Detail) (2004 Stock Plan, Amended and Restated [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	$586	$523	$481
Tax benefit for share-based compensation expense	-179	-173	-149
Share-based payment expense, net of tax	407	350	332
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	270	249	235
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	150	140	157
Portfolio Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	96	56	14
Total Shareholder Return Units (TSRU) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	37	37	35
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	30	34	35
Directors' compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	$3	$7	$5

ShareBased_Payments_Restricted

Share-Based Payments - Restricted Stock Unit Activity (Detail) (Restricted Stock Units [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	32,751
Granted, shares	10,188
Vested, shares	-12,613
Reinvested dividend equivalents, shares	1,071
Forfeited, shares	-1,461
Nonvested, end of period, shares	29,936
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share	$22.50
Granted, weighted-average grant date fair value per share	$32.11
Vested, weighted-average grant date fair value per share	$19.74
Reinvested dividend equivalents, weighted-average grant date fair value per share	$29.69
Forfeited, weighted-average grant date fair value per share	$26.66
Nonvested, end of period, weighted-average grant date fair value per share	$26.99

ShareBased_Payments_Data_Relat

Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail) (Restricted Stock Units [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$401	$379	$348
Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax	$255	$239	$258
Weighted-average period over which RSU cost is expected to be recognized (years)	1 year 10 months	1 year 10 months	1 year 10 months

ShareBased_Payments_Stock_Opti

Share-Based Payments - Stock Option Narrative (Details) (Employee Stock Option [Member])	12 Months Ended
	Dec. 31, 2014
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Contractual term (years)	10 years
Holding period	1 year
Exercise period in the event of a divestiture or restructuring	3 months

ShareBased_Payments_Valuation_

Share-Based Payments - Valuation Assumptions of Stock Options (Detail) (Employee Stock Option [Member])	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield(a)	3.18%	[1]	3.45%	[1]	4.10%	[1]
Risk-free interest rate(b)	1.94%	[2]	1.16%	[2]	1.28%	[2]
Expected stock price volatility(c)	19.76%	[3]	19.68%	[3]	23.78%	[3]
Expected term (years)(d)	6 years 6 months	[4]	6 years 6 months	[4]	6 years 6 months	[4]
[1]	Determined using a constant dividend yield during the expected term of the option.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility, after consideration of historical volatility.
[4]	Determined using historical exercise and post-vesting termination patterns.The following table summarizes all stock option activity during 2014: Shares(Thousands) Weighted-AverageExercise PricePer Share Weighted-AverageRemainingContractualTerm(Years) AggregateIntrinsicValue(a)(Millions)December 31, 2013(b) 299,653 $24.33 Granted 44,599 32.23 Exercised (46,960) 21.44 Forfeited (4,396) 26.36 Expired (43,784) 36.85 Outstanding, December 31, 2014 249,112 24.05 5.9 $1,815Vested and expected to vest, December 31, 2014(c) 243,297 23.91 5.9 1,805Exercisable, December 31, 2014 122,618 $21.19 3.6 $1,222

ShareBased_Payments_Stock_Opti1

Share-Based Payments - Stock Option Activity (Detail) (USD $)	12 Months Ended		0 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014		Feb. 25, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning of period, shares	299,653,000	[1]
Granted, shares	44,599,000
Exercised, shares	-46,960,000
Forfeited, shares	-4,396,000
Canceled, shares	-43,784,000
Outstanding, end of period, shares	249,112,000
Vested and expected to vest, end of period, shares	243,297,000	[2]
Exercisable, end of period, shares	122,618,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period, weighted-average exercise price per share	$24.33	[1]
Granted, weighted-average exercise price per share	$32.23
Exercised, weighted-average exercise price per share	$21.44
Forfeited, weighted-average exercise price per share	$26.36
Expired, weighted-average exercise price per share	$36.85
Outstanding, end of period, weighted-average exercise price per share	$24.05
Vested and expected to vest, end of period, weighted-average exercise price per share	$23.91	[2]
Exercisable, end of period, weighted-average exercise price per share	$21.19
Outstanding, end of period, weighted-average remaining contractual term	5 years 10 months 24 days
Vested and expected to vest, end of period, weighted-average remaining contractual term	5 years 10 months 24 days	[2]
Exercisable, end of period, weighted-average remaining contractual term	3 years 7 months 6 days
Outstanding, end of period, aggregate intrinsic value	$1,815	[3]
Vested and expected to vest, end of period, aggregate intrinsic value	1,805	[2],[3]
Exercisable, end of period, aggregate intrinsic value	$1,222	[3]
2001 Stock Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Canceled, shares			-42,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Expired, weighted-average exercise price per share			$37.15
[1]	Includes approximately 42 million stock options which expired on February 25, 2014 at a grant price of $37.15, which were granted under the 2001 Stock Plan. These stock options were not added into the amount of carry forward shares remaining available for grants under the 2004 Stock Plan.
[2]	The number of options expected to vest takes into account an estimate of expected forfeitures.
[3]	Market price of underlying Pfizer common stock less exercise price.

ShareBased_Payments_Data_Relat1

Share-Based Payments - Data Related to All Stock Option Activity (Detail) (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value per stock option (in dollars per share)	$4.40	$3.13	$2.79
Aggregate intrinsic value on exercise	$458	$578	$263
Cash received upon exercise	1,002	1,750	568
Tax benefits realized related to exercise	131	160	81
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost related to nonvested stock options not yet recognized, pre-tax	$147	$120	$148
Weighted-average period over which stock option compensation cost is expected to be recognized (years)	1 year 10 months	1 year 8 months	1 year 8 months

ShareBased_Payments_Portfolio_

Share-Based Payments - Portfolio Performance Shares Narrative (Details) (Portfolio Performance Shares [Member])	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period	3 years
Award vesting period	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	200.00%

ShareBased_Payments_Portfolio_1

Share-Based Payments - Portfolio Performance Shares Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Vested and expected to vest, end of period, shares	243,297,000	[1]
Portfolio Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	11,324,000
Granted, shares	8,377,000
Vested, shares	-7,000	[2]
Forfeited, shares	-817,000
Nonvested, end of period, shares	18,877,000	[2]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share	$30.63
Granted, weighted-average grant date fair value per share	$32.23
Vested, weighted-average grant date fair value per share	$30.18	[2]
Forfeited, weighted-average grant date fair value per share	$30.10
Nonvested, end of period, weighted-average grant date fair value per share	$31.15	[2]
Vested and expected to vest, end of period, shares			18,877
[1]	The number of options expected to vest takes into account an estimate of expected forfeitures.
[2]	Vested and non-vested shares outstanding, but not paid as of December 31, 2014 were 18,877.

ShareBased_Payments_Data_Relat2

Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details) (Portfolio Performance Shares [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011
Portfolio Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$0	$0	$0
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$139	$107	$33
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 10 months	2 years 0 months	2 years 2 months 12 days

ShareBased_Payments_Total_Shar

Share-Based Payments - Total Shareholder Return Units Narrative (Details) (Total Shareholder Return Units (TSRU) [Member])	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of trading days	20 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term (years)	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term (years)	7 years

ShareBased_Payments_Valuation_1

Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail) (Total Shareholder Return Units (TSRU) [Member])	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Total Shareholder Return Units (TSRU) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield(a)	3.18%	[1]	3.45%	[1]	4.10%	[1]
Risk-free interest rate(b)	1.78%	[2]	1.03%	[2]	1.15%	[2]
Expected stock price volatility(c)	19.76%	[3]	19.68%	[3]	23.80%	[3]
Contractual term (years)	5 years 11 months 19 days		5 years 11 months 24 days		5 years 11 months 19 days
[1]	Determined using a constant dividend yield during the expected term of the TSRU.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility, after consideration of historical volatility.

ShareBased_Payments_Total_Shar1

Share-Based Payments - Total Shareholder Return Units Activity (Details) (Total Shareholder Return Units (TSRU) [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Total Shareholder Return Units (TSRU) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	24,195
Granted, shares	6,288
Vested, shares	-8,727
Forfeited, shares	-821
Nonvested, end of period, shares	20,935	[1]	24,195
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, beginning of period, weighted-average grant date fair value per share	$4.77
Granted, weighted-average grant date fair value per share	$6.51		$5.14	$4.48
Vested, weighted-average grant date fair value per share	$4.74
Forfeited, weighted-average grant date fair value per share	$5.10
Nonvested, end of period, weighted-average grant date fair value per share	$5.29		$4.77
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]
Outstanding, beginning of period, weighted-average exercise price per share	$22.30
Granted, weighted-average exercise price per share	$32.23
Forfeited, weighted-average exercise price per share	$19.38
Expired, weighted-average exercise price per share	$25.87
Outstanding, end of period, weighted-average exercise price per share	$26.40	[1]	$22.30
[1]	In 2014, we settled 5,124,197 share units with a weighted-average grant price of $14.67 per share unit.

ShareBased_Payments_Outstandin

Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details) (Total Shareholder Return Units (TSRU) [Member], USD $)	12 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Total Shareholder Return Units (TSRU) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Share Units	34,842	[1]
Outstanding, Weighted-Average Grant Price Per Share Unit	$23.41	[1]
Outstanding, Weighted-Average Remaining Contractual Term (Years)	3 years 1 month 6 days	[1]
Outstanding, Aggregate Intrinsic Value	$360	[1]
Vested, Share Units	13,907	[1]
Vested, Weighted-Average Grant Price Per Share Unit	$18.92	[1]
Vested, Weighted-Average Remaining Contractual Term (Years)	1 year 7 months 6 days	[1]
Vested, Aggregate Intrinsic Value	220	[1]
Expected to vest, Share Units	20,935	[1]	24,195
Expected to vest, Weighted-Average Grant Price Per Share Unit	$26.40	[1]	$22.30
Expected to vest, Weighted-Average Remaining Contractual Term (Years)	4 years 1 month 6 days	[1]
Expected to vest, Aggregate Intrinsic Value	$140	[1]
Settled, Share Units	5,124
Settled, Weighted-Average Grant Price Per Share	$14.67
[1]	In 2014, we settled 5,124,197 share units with a weighted-average grant price of $14.67 per share unit.

ShareBased_Payments_Data_Relat3

Share-Based Payments - Data Related to All Total Shareholder Return Units (Details) (Total Shareholder Return Units (TSRU) [Member], USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Total Shareholder Return Units (TSRU) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value per stock option	$6.51	$5.14	$4.48
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$30	$31	$31
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 9 months 18 days	1 year 7 months 14 days	1 year 8 months

ShareBased_Payments_Performanc

Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details) (Performance Shares [Member])	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	200.00%

ShareBased_Payments_Performanc1

Share-Based Payments - Performance Share Awards (PSAs) Activity (Details) (Performance Shares [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	5,039
Granted, shares	1,202
Vested, shares	-1,231
Forfeited, shares	-920
Nonvested, end of period, shares	4,090
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share	$30.63
Granted, weighted-average grant date fair value per share	$32.17
Vested, weighted-average grant date fair value per share	$31.99
Forfeited, weighted-average grant date fair value per share	$31.74
Nonvested, end of period, weighted-average grant date fair value per share	$31.15

ShareBased_Payments_Data_Relat4

Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details) (Performance Shares [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$39	$40	$13
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$21	$25	$27
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 8 months 12 days	1 year 8 months	1 year 8 months

Earnings_Per_Common_Share_Attr2

Earnings Per Common Share Attributable to Common Shareholders - Basic and Diluted Numerator and Denominator (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
EPS Numerator-Basic
Income from continuing operations	$9,119	[1]	$11,410	[1]	$9,021	[1]
Less: Net income attributable to noncontrolling interests	32		30		28
Income from continuing operations attributable to Pfizer Inc.	9,087		11,380		8,993
Less: Preferred stock dividends––net of tax	1		2		2
Income from continuing operations attributable to Pfizer Inc. common shareholders	9,086		11,378		8,991
Discontinued operations––net of tax	48	[1],[2]	10,662	[1],[2]	5,577	[1],[2]
Less: Discontinued operations––net of tax, attributable to noncontrolling interests	0		39		0
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders	48		10,623		5,577
Net income attributable to Pfizer Inc. common shareholders	9,134		22,001		14,568
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	9,087		11,380		8,993
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$9,135		$22,003		$14,570
EPS Denominator
Weighted-average number of common shares outstanding––Basic	6,346	[1]	6,813	[1]	7,442	[1]
Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock	78		82		66
Weighted-average number of common shares outstanding––Diluted	6,424	[1]	6,895	[1]	7,508	[1]
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(a)	44	[3]	43	[3]	177	[3]
[1]	Amounts may not add due to rounding.
[2]	Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal.
[3]	These common stock equivalents were outstanding for the years ended December 31, 2014, 2013 and 2012, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease_Commitments_Detail

Lease Commitments (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Leases [Abstract]
Operating leases, rent expense, net	$216	$233	$301
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	183
2016	159
2017	151
2018	112
2019	88
After 2019	$774

Commitments_and_Contingencies_

Commitments and Contingencies (Action In Which We Are the Plaintiff) (Details) (Patent Infringement [Member])	1 Months Ended
	Mar. 31, 2009	Oct. 31, 2010	Oct. 31, 2014	Jun. 30, 2010	Apr. 30, 2014	Mar. 31, 2013	Jun. 30, 2013
	Patents		Patents	Patents	Defendant		Patents
Lyrica [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon	3
Viagra [Member] | Pfizer Versus Apotex Inc. and Apotex Corp., Mylan Pharmaceuticals Inc. and Mylan Inc., Actavis, Inc. and Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Exclusivity period		6 months
Sutent [Member] | Pfizer Versus Mylan Pharmaceuticals Inc. [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon				3
Number of patents infringed upon			2
Celebrex [Member] | Pfizer Versus Teva Pharmaceuticals USA, Inc., Mylan, Watson, Lupin Pharmaceuticals USA, Inc., Apotex Corp. and Apotex Inc. [Member] | Settled Litigation [Member]
Gain Contingencies [Line Items]
Exclusivity period						6 months
Number of defendants					2
Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon							5
Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon							3

Commitments_and_Contingencies_1

Commitments and Contingencies (Action In Which We Are The Defendant) (Details)

12 Months Ended

0 Months Ended

12 Months Ended

24 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2014

Jun. 30, 2014

Dec. 31, 2006

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Jan. 31, 2015

Apr. 30, 2014

Sep. 28, 2014

Dec. 31, 2008

Mar. 31, 2013

Dec. 31, 2009

USD ($)

USD ($)

USD ($)

Effexor [Member]

Neurontin [Member]

Patent Infringement [Member]

Patent Infringement [Member]

Patent Infringement [Member]

Damages from Product Defects [Member]

Damages from Product Defects [Member]

Violation Of Securities Law, Failure to Disclose Material Information [Member]

Violation Of Securities Law, Failure to Disclose Material Information [Member]

Sales And Marketing Inconsistent with Patent [Member]

Average Wholesale Price [Member]

Misappropriation of Information [Member]

Environmental Remediation Litigation [Member]

Product Pricing [Member]

USD ($)

USD ($)

Teva Canada Limited Versus Pfizer Canada Inc. [Member]

Teva Canada Limited Versus Pfizer Canada Inc. [Member]

Teva Canada Limited Versus Pfizer Canada Inc. [Member]

Reglan [Member]

Class Action Versus American Optical Corporation And Various Other Defendants [Member]

USD ($)

U.S. District Court For The Southern District Of New York Versus Pfizer And Several Of Our Current And Former Officers [Member]

Class Action Versus Pfizer Inc. [Member]

State Governments Versus Pfizer, Pfizer Subsidiaries and Other Pharmaceutical Manufacturers [Member]

Ischemia Research and Education Foundation Versus Pfizer [Member]

lagoon

U.S. Department of Justice Versus Pfizer [Member]

Effexor [Member]

Effexor [Member]

Effexor [Member]

court

Pending Litigation [Member]

Settled Litigation [Member]

Neurontin [Member]

Pending Litigation [Member]

Pending Litigation [Member]

Protonix / Pantoprazole [Member]

Pending Litigation [Member]

Pending Litigation [Member]

Pending Litigation [Member]

state

Claim

Subsequent Event [Member]

Settled Litigation [Member]

Actions

USD ($)

Actions

CAD

Patents

CAD

USD ($)

USD ($)

Loss Contingencies [Line Items]

Number of patents allegedly infringed

1

Litigation settlement income (loss)

$0

[1]

$1,342

[1]

$0

[1]

($56)

($610)

-52.5

($400)

$400

Damages awarded

125

38.7

Number of claims seeking damages

61,000

Litigation settlement, amount

($325)

Number of federal and state courts which have rejected the theory of liability

100

Number of states which are applying the theory of liability

30

Feasibility study, number of lagoons

2

Number of actions

2

2

[1]

In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.

Commitments_and_Contingencies_2

Commitments and Contingencies (Certain Matters Resolved And Purchase Commitments) (Details) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Jul. 31, 2014	Apr. 30, 2014	Mar. 31, 2009	Jan. 31, 2011
		Actions		Patents	Actions
Loss Contingencies [Line Items]
Long-term purchase commitment, amount	$4,100,000,000
Neurontin [Member] | Class Action Versus Pfizer Inc. [Member] | Settled Litigation [Member] | Antitrust [Member]
Loss Contingencies [Line Items]
Number of actions					4
Litigation settlement, amount			($190,000,000)
Number of claims settled		2
Lyrica [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Settled Litigation [Member] | Patent Infringement [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				3
Lyrica Other Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Settled Litigation [Member] | Patent Infringement [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				2

Segment_Geographic_and_Other_R2

Segment, Geographic and Other Revenue Information - Narrative (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
	Operating_Segment
	business
Segment Reporting Information [Line Items]
Number of businesses	2
Number of operating segments (in operating segments)	3
Selling, informational and administrative expenses	$14,097	[1],[2]	$14,355	[1],[2]	$15,171	[1],[2]
Research and development expenses	8,393	[1],[2]	6,678	[1],[2]	7,482	[1],[2]
Total assets	169,274	[1]	172,101	[1]
Global Vaccines, Oncology and Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Number of businesses	3
Innovative Products [Member]
Segment Reporting Information [Line Items]
Number of operating segments (in operating segments)	2
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Outside United States [Member]
Segment Reporting Information [Line Items]
Number of countries outside the U.S	13		12		14
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | United States
Segment Reporting Information [Line Items]
Percentage of total revenues	10.00%		10.00%		10.00%
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Japan
Segment Reporting Information [Line Items]
Percentage of total revenues			10.00%		10.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler One [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues	13.00%		12.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler Two [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues	10.00%		9.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler Three [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues	9.00%		8.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest U.S. Wholesaler Customers [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues	24.00%		20.00%
Operating Segments [Member]
Segment Reporting Information [Line Items]
Selling, informational and administrative expenses			2,100		2,320
Research and development expenses			$800		$990
[1]	Amounts may not add due to rounding.
[2]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

Segment_Geographic_and_Other_R3

Segment, Geographic and Other Revenue Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues	$49,605	[1]	$51,584	[1]	$54,657	[1]
Earnings(a)	12,240	[1],[2]	15,716	[1],[2]	11,242	[1],[2]
Depreciation and Amortization(b)	5,537	[3]	6,306	[3]	7,394	[3]
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	253	[4]	232	[4]	231	[4]
Earnings(a)	-3,092	[2],[4]	-2,828	[2],[4]	-2,888	[2],[4]
Depreciation and Amortization(b)	91	[3],[4]	105	[3],[4]	117	[3],[4]
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Revenues	0	[5]	0	[5]	0	[5]
Earnings(a)	-5,200	[2],[5]	-5,689	[2],[5]	-6,059	[2],[5]
Depreciation and Amortization(b)	384	[3],[5]	432	[3],[5]	546	[3],[5]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues	0	[5]	0	[5]	0	[5]
Earnings(a)	-3,641	[2],[5]	-4,344	[2],[5]	-4,905	[2],[5]
Depreciation and Amortization(b)	3,782	[3],[5]	4,487	[3],[5]	4,988	[3],[5]
Business Combinations, Acquisition Related Costs [Member]
Segment Reporting Information [Line Items]
Revenues	0	[5]	0	[5]	0	[5]
Earnings(a)	-183	[2],[5]	-376	[2],[5]	-946	[2],[5]
Depreciation and Amortization(b)	53	[3],[5]	124	[3],[5]	273	[3],[5]
Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	198	[6]	132	[6]	0	[6]
Earnings(a)	-3,749	[2],[6]	-692	[2],[6]	-5,039	[2],[6]
Depreciation and Amortization(b)	207	[3],[6]	167	[3],[6]	300	[3],[6]
Other Unallocated [Member]
Segment Reporting Information [Line Items]
Revenues	0		0		0
Earnings(a)	-567	[2]	-671	[2]	-751	[2]
Depreciation and Amortization(b)	27	[3]	44	[3]	55	[3]
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	49,154		51,221		54,426
Earnings(a)	28,671	[2]	30,318	[2]	31,832	[2]
Depreciation and Amortization(b)	993	[3]	947	[3]	1,115	[3]
Global Innovative Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	13,861		14,317		13,756
Earnings(a)	7,780	[2]	8,549	[2]	8,325	[2]
Depreciation and Amortization(b)	255	[3]	238	[3]	250	[3]
Global Vaccines, Oncology and Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues	10,144		9,285		8,991
Earnings(a)	4,692	[2]	4,216	[2]	3,597	[2]
Depreciation and Amortization(b)	263	[3]	231	[3]	270	[3]
Global Established Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	25,149		27,619		31,678
Earnings(a)	16,199	[2]	17,552	[2]	19,910	[2]
Depreciation and Amortization(b)	$475	[3]	$478	[3]	$595	[3]
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income.
[3]	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
[4]	Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
[5]	For a description, see the "Other Costs and Business Activities" section above
[6]	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in 2014, certain significant items primarily represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.For Earnings in 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $32 million, (ii) charges for certain legal matters of $999 million, (iii) certain asset impairments of $440 million, (iv) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (v) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (vi) upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vii) charges for business and legal entity alignment of $168 million and (viii) other charges of $197 million. For additional information, see Note 2C, Note 3 and Note 4.For Revenues in 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.For Earnings in 2013, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $16 million, (ii) patent litigation settlement income of $1.3 billion, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iv) net charges for certain legal matters of $21 million, (v) certain asset impairments of $836 million, (vi) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vii) costs associated with the separation of Zoetis of $18 million and (viii) other charges of $306 million. For additional information, see Note 3 and Note 4.For Earnings in 2012, certain significant items includes: (i) net charges for certain legal matters of $2.2 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.8 billion, (iii) certain asset impairment charges of $875 million, (iv) costs associated with the separation of Zoetis of $125 million and (v) other charges of $19 million. For additional information, see Note 3 and Note 4.

Segment_Geographic_and_Other_R4

Segment, Geographic and Other Revenue Information - Footnotes (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information [Line Items]
Income	$12,240	[1],[2]	$15,716	[1],[2]	$11,242	[1],[2]
Litigation settlement income (loss)	0	[3]	1,342	[3]	0	[3]
Gain associated with the transfer of certain product rights to an equity-method investment	0	[4]	459	[4]	0	[4]
Costs associated with the Zoetis IPO(i)	0	[5]	18	[5]	125	[5]
Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Income	-3,749	[2],[6]	-692	[2],[6]	-5,039	[2],[6]
Other legal matters, net(d)	999		21		2,200
Certain asset impairments(g)	440		836		875
Branded prescription drug fee	215
Restructuring charges and implementation costs	598		1,300		1,800
Alignment costs	168
Other charges	197		306		19
Litigation settlement income (loss)			1,300
Gain associated with the transfer of certain product rights to an equity-method investment			459
Certain Significant Items [Member] | Merck KGaA [Member]
Segment Reporting Information [Line Items]
Upfront payments and milestone payments	1,200
Certain Significant Items [Member] | Zoetis [Member]
Segment Reporting Information [Line Items]
Income	32		16
Costs associated with the Zoetis IPO(i)			$18		$125
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income.
[3]	In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.
[4]	In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.
[5]	Represents costs incurred in connection with the IPO of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. For additional information, see Note 2D.
[6]	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in 2014, certain significant items primarily represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.For Earnings in 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $32 million, (ii) charges for certain legal matters of $999 million, (iii) certain asset impairments of $440 million, (iv) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (v) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (vi) upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vii) charges for business and legal entity alignment of $168 million and (viii) other charges of $197 million. For additional information, see Note 2C, Note 3 and Note 4.For Revenues in 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.For Earnings in 2013, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $16 million, (ii) patent litigation settlement income of $1.3 billion, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iv) net charges for certain legal matters of $21 million, (v) certain asset impairments of $836 million, (vi) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vii) costs associated with the separation of Zoetis of $18 million and (viii) other charges of $306 million. For additional information, see Note 3 and Note 4.For Earnings in 2012, certain significant items includes: (i) net charges for certain legal matters of $2.2 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.8 billion, (iii) certain asset impairment charges of $875 million, (iv) costs associated with the separation of Zoetis of $125 million and (v) other charges of $19 million. For additional information, see Note 3 and Note 4.

Segment_Geographic_and_Other_R5

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$49,605	[1]	$51,584	[1]	$54,657	[1]
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	19,073		20,274		21,313	[2]
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	11,719	[2]	11,739	[2]	12,545	[2]
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	7,314	[3]	8,346	[3]	9,956	[3]
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$11,499	[4]	$11,225	[4]	$10,843	[4]
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $9.0 billion in 2014, $8.9 billion in 2013 and $9.4 billion in 2012.
[3]	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.

Segment_Geographic_and_Other_R6

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$49,605	[1]	$51,584	[1]	$54,657	[1]
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	11,719	[2]	11,739	[2]	12,545	[2]
Euro Member Countries, Euro | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$9,000		$8,900		$9,400
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $9.0 billion in 2014, $8.9 billion in 2013 and $9.4 billion in 2012.

Segment_Geographic_and_Other_R7

Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$11,762	[1],[2]	$12,397	[1],[2]	$13,213
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	5,575		5,885		6,485
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	4,606	[3]	4,845	[3]	4,895	[3]
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	617	[4]	696	[4]	816	[4]
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$963	[5]	$971	[5]	$1,017	[5]
[1]	Amounts may not add due to rounding.
[2]	The decrease in total property, plant and equipment is primarily due to depreciation and, to a much lesser extent, disposals, impairments and the impact of foreign exchange, partially offset by capital additions.
[3]	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
[4]	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.
[5]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.

Segment_Geographic_and_Other_R8

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Revenue from External Customer [Line Items]
Revenues	$49,605	[1]	$51,584	[1]	$54,657	[1]
Biopharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	45,708		47,878		51,214
Effexor [Member]
Revenue from External Customer [Line Items]
Revenues	344		440		425
Other Products [Member]
Revenue from External Customer [Line Items]
Revenues	451	[2]	364	[2]	231	[2]
Global Innovative and Established Pharmaceutical [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	5,168	[3]	4,595	[3]	4,158	[3]
Global Innovative and Established Pharmaceutical [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	1,685	[4]	1,881	[4]	2,051	[4]
Global Innovative and Established Pharmaceutical [Member] | Alliance Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	957	[5]	2,628	[5]	3,492	[5]
Global Innovative Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	13,861		14,317		13,756
Global Innovative Pharmaceutical [Member] | Enbrel [Member]
Revenue from External Customer [Line Items]
Revenues	3,850		3,774		3,737
Global Innovative Pharmaceutical [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues	856		832		775
Global Innovative Pharmaceutical [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues	723		772		832
Global Innovative Pharmaceutical [Member] | Chantix Champix [Member]
Revenue from External Customer [Line Items]
Revenues	647		648		670
Global Innovative Pharmaceutical [Member] | ReFacto AF Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues	631		602		584
Global Innovative Pharmaceutical [Member] | Rapamune [Member]
Revenue from External Customer [Line Items]
Revenues	339		350		346
Global Innovative Pharmaceutical [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues	308		114		6
Global Innovative Pharmaceutical [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues	288		236		207
Global Innovative Pharmaceutical [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues	229		217		197
Global Innovative Pharmaceutical [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues	228		209		263
Global Innovative Pharmaceutical [Member] | Other Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	469		540		332
Global Established Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	25,149		27,619		31,678
Global Established Pharmaceutical [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues	2,699		2,918		2,719
Global Established Pharmaceutical [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues	2,061		2,315		3,948
Global Established Pharmaceutical [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues	1,352		1,353		1,345
Global Established Pharmaceutical [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues	1,112		1,229		1,349
Global Established Pharmaceutical [Member] | Premarin Family [Member]
Revenue from External Customer [Line Items]
Revenues	1,076		1,092		1,073
Global Established Pharmaceutical [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues	756		775		754
Global Established Pharmaceutical [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues	737		698		630
Global Established Pharmaceutical [Member] | Xalatan Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues	495		589		806
Global Established Pharmaceutical [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	443		464		523
Global Established Pharmaceutical [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues					123
Global Established Pharmaceutical [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues	423		469		541
Global Established Pharmaceutical [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues	382		359		368
Global Established Pharmaceutical [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues	364		359		381
Global Established Pharmaceutical [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues	354		309		262
Global Established Pharmaceutical [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues	323		358		335
Global Established Pharmaceutical [Member] | Zithromax Zmax [Member]
Revenue from External Customer [Line Items]
Revenues	314		387		435
Global Established Pharmaceutical [Member] | Zosyn Tazocin [Member]
Revenue from External Customer [Line Items]
Revenues	303		395		484
Global Established Pharmaceutical [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues	294		273		263
Global Established Pharmaceutical [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues	276		307		534
Global Established Pharmaceutical [Member] | Cardura [Member]
Revenue from External Customer [Line Items]
Revenues	263		296		338
Global Established Pharmaceutical [Member] | Xanax/Xanax XR [Member]
Revenue from External Customer [Line Items]
Revenues	253		276		274
Global Established Pharmaceutical [Member] | Inspra [Member]
Revenue from External Customer [Line Items]
Revenues	233		233		214
Global Established Pharmaceutical [Member] | Diflucan [Member]
Revenue from External Customer [Line Items]
Revenues	220		242		259
Global Established Pharmaceutical [Member] | Neurontin [Member]
Revenue from External Customer [Line Items]
Revenues	210		216		235
Global Established Pharmaceutical [Member] | Unasyn [Member]
Revenue from External Customer [Line Items]
Revenues	207		212		228
Global Established Pharmaceutical [Member] | Detrol Detrol LA [Member]
Revenue from External Customer [Line Items]
Revenues	201		562		761
Global Established Pharmaceutical [Member] | Depo-Provera [Member]
Revenue from External Customer [Line Items]
Revenues	201		191		148
Global Established Pharmaceutical [Member] | Protonix / Pantoprazole [Member]
Revenue from External Customer [Line Items]
Revenues	198		185		188
Global Established Pharmaceutical [Member] | Dalacin / Cleocin [Member]
Revenue from External Customer [Line Items]
Revenues	184		199		232
Global Established Pharmaceutical [Member] | Caduet [Member]
Revenue from External Customer [Line Items]
Revenues	180		223		258
Global Established Pharmaceutical [Member] | Other Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	6,175		6,614		7,442
Global Vaccines, Oncology and Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	10,144		9,285		8,991
Global Vaccines, Oncology and Consumer Healthcare [Member] | Prevenar Family [Member]
Revenue from External Customer [Line Items]
Revenues	4,464		3,974		4,117
Global Vaccines, Oncology and Consumer Healthcare [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues	1,174		1,204		1,236
Global Vaccines, Oncology and Consumer Healthcare [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues	438		282
Global Vaccines, Oncology and Consumer Healthcare [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues	410		319		100
Global Vaccines, Oncology and Consumer Healthcare [Member] | Other Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	211		164		236
Global Vaccines, Oncology and Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	$3,446		$3,342		$3,212
[1]	Amounts may not add due to rounding.
[2]	Other primarily includes revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and also includes the revenues related to our transitional manufacturing and supply agreements with Zoetis.
[3]	Lyrica revenues from all of Europe are included in GEP. All other Lyrica revenues are included in GIP.
[4]	Viagra revenues from the U.S. and Canada are included in GIP. All other Viagra revenues are included in GEP.
[5]	Includes Enbrel (GIP, in the U.S. and Canada through October 31, 2013), Spiriva (GEP), Rebif (GIP), Aricept (GEP) and Eliquis (GIP).

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

6 Months Ended

Share data in Millions, except Per Share data, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Feb. 11, 2015

Feb. 27, 2015

Dec. 01, 2014

Dec. 31, 2015

Oct. 23, 2014

Jun. 27, 2013

Nov. 01, 2012

Dec. 12, 2011

Feb. 09, 2015

Subsequent Event [Line Items]

Accelerated share repurchases, authorized amount

$11,000,000,000

$10,000,000,000

$10,000,000,000

$10,000,000,000

Shares repurchased

165

563

349

Collaborative Arrangement [Member]

Subsequent Event [Line Items]

Upfront payments and milestone payments

1,189,000,000

67,000,000

44,000,000

Subsequent Event [Member] | February 9, 2015 Through June 28, 2015 [Member]

Subsequent Event [Line Items]

Accelerated share repurchases, authorized amount

5,000,000,000

Shares repurchased

150

Accelerated share repurchases, cash paid

5,000,000,000

Subsequent Event [Member] | Collaborative Arrangement [Member] | OPKO Health, Inc. [Member]

Subsequent Event [Line Items]

Upfront payments and milestone payments

295,000,000

Potential milestone payments

275,000,000

Baxter International Inc. [Member]

Subsequent Event [Line Items]

Total consideration transferred

635,000,000

Forecast [Member] | Hospira [Member]

Subsequent Event [Line Items]

Business acquisition, per share in cash

$90

Percentage of transaction financed, cash

66.67%

Percentage of transaction financed, debt

33.34%

Total consideration transferred

$17,000,000,000